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Abstract 
Glucocorticoid production by the adrenal gland is regulated by hypothalamic-
pituitary-adrenal (HPA) axis activity. Within cells, glucocorticoid levels are 
modulated by 11β-hydroxysteroid dehydrogenase (11β-HSD), which interconverts 
active and intrinsically inert glucocorticoids. Glucocorticoids have widespread 
physiological effects and, in the cardiovascular system, they play a crucial role in 
heart development and maturation, blood pressure control, and myocardial calcium 
cycling. Mice which are unable to regenerate the physiological glucocorticoid, 
corticosterone, from 11-dehydrocorticosterone due to deletion of the type 1 11β-HSD 
isozyme (11β-HSD1) have previously been shown to have smaller, lighter hearts but 
unaltered systolic function. Moreover, a single nucleotide polymorphism (SNP) in 
the Hsd11b1 gene has been associated with reduced left ventricular mass in humans, 
suggesting a role for 11β-HSD1 in regulating cardiac size. After myocardial 
infarction (MI), 11β-HSD1 deficient mice have an augmented inflammatory 
response, increased numbers of pro-reparative alternatively-activated macrophages in 
the heart, enhanced peri-infarct angiogenesis and improved cardiac function 
compared to C57BL/6 controls. However, the role of ‘cardiovascular’ 11β-HSD1 in 
the development of these phenotypes, both basally and after MI, is unknown. It was 
hypothesised that ‘cardiovascular’ 11β-HSD1 deficiency would result in smaller 
hearts, and that this selective deletion would lead to altered calcium handling protein 
expression and diastolic abnormalities. Furthermore, it was hypothesised that 
‘cardiovascular’ 11β-HSD1 deletion would reproduce the beneficial post-MI 
phenotype previously seen in global 11β-HSD1 deficient mice.  
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The first aim was to characterise the cardiac phenotype of mice with global deletion 
of 11β-HSD1 (DelI mice), and mice in which deletion is restricted to cardiomyocytes 
and vascular smooth muscle cells (SMAC mice). SMAC mice have ‘floxed’ 11β-
HSD1 alleles and a Cre recombinase transgene inserted into the Sm22α gene. Sm22α 
is expressed in vascular smooth muscle cells, and transiently in cardiomyocytes 
during development. Thus, Cre expression in these cells results in deletion of exon 
three of the Hsd11b1 gene and gives rise to a non-functional protein. Controls for 
DelI mice were C57BL/6 mice, and controls for SMAC mice were their Cre
-
 
littermates. DelI, but not SMAC, mice have smaller, lighter hearts, which may be 
explained by their shorter cardiomyocytes measured following isolation using a 
Langendorff preparation. Cardiomyocyte cross-sectional area is unchanged. In vivo 
measurement of cardiac function using ultrasound imaging showed systolic function 
is comparable between DelI mice and SMAC mice and their respective controls. 
However, there is mild diastolic dysfunction in both DelI and SMAC mice, 
characterised by reduced E wave deceleration and an increased mitral valve 
deceleration time. This phenotype occurred following pharmacological inhibition of 
11β-HSD1, by administration of UE2316, a selective 11β-HSD1 inhibitor, to adult 
C57BL6/SJL mice. While ventricular collagen content is unaltered in DelI, SMAC 
and UE2316-treated mice compared to their respective controls, expression of 
sarcoplasmic reticulum Ca
2+
 ATPase (SERCA) is reduced, suggesting that altered 
calcium handling, rather than changes in stiffness, may underlie this phenotype. 
The second aim was to determine whether the beneficial acute outcomes seen 
previously in 11β-HSD1 deficient mice after MI could be reproduced by selective 




littermate controls, SMAC mice have similar peri-infarct angiogenesis, total 
macrophage and alternatively-activated macrophage infiltration into the heart, infarct 
size, ventricular dilatation and systolic function. This suggests 11β-HSD1 deletion in 
another cell type, or types, is responsible for the phenotype seen in global 11β-HSD1 
deficient mice. 
The final aim was to assess the impact of global 11β-HSD1 deficiency and 
‘cardiovascular’ 11β-HSD1 deletion on the development of heart failure, using 
magnetic resonance imaging to determine structure and function. Eight weeks after 
MI, mice globally deficient in 11β-HSD1 have attenuated expression of ANP and β-
MHC, RNA markers of heart failure, and show attenuated pulmonary oedema, 
reduced chamber dilatation, preserved systolic function and smaller infarcts 
compared to control. None of these parameters are altered in SMAC mice relative to 
control. 
In conclusion, the data presented in this thesis shows that cardiovascular 11β-HSD1 
influences physiological cardiac function, potentially through regulation of calcium 
handling. 11β-HSD1 in other cells influences cardiomyocyte length, resulting in 
smaller hearts in its absence. Despite this, global 11β-HSD1 deficiency prevents 
heart failure development after MI, suggesting that pharmacological inhibition of 
11β-HSD1 may be of benefit in treating this condition. Cardiovascular 11β-HSD1 
does not, however, account for the changes in infarct healing or remodelling 
associated with this beneficial outcome, therefore these effects must be related to 
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Cardiovascular disease remains the primary cause of mortality worldwide, 
accounting for one third of all deaths. In the United Kingdom, cardiovascular disease 
is responsible for around 180, 000 deaths annually with the majority due to 
cerebrovascular disease, coronary heart disease, and heart failure  (Scarborough, et 
al., 2010; Townsend, et al., 2012). Myocardial infarction (MI) is the leading cause of 
heart failure, a condition characterised by loss of cardiac function to such an extent 
that myocardial performance cannot meet the demands of the body. Drug treatments 
which aim to reduce the load on the heart and manage this condition include 
angiotensin converting enzyme (ACE) inhibitors, β-adrenoceptor antagonsists (β 
blockers), loop diuretics, statins and nitrates. While these can improve quality of life 
they have had limited success in prolonging life. Sixty percent of heart failure 
patients die within five years of diagnosis (Tribouilloy, et al., 2008). Because of this 
poor prognosis, further research into MI, the principal cause of heart failure, is key to 
facilitating the development of new therapeutic agents and the identification of novel 
targets. 
Previous work in our laboratory has suggested that targeting local glucocorticoid 
synthesis may provide a novel method of preventing the development of heart failure 
after MI. The focus of this thesis is to understand the physiological role of 
glucocorticoid metabolism in cardiovascular tissue, and whether manipulation of 
glucocorticoid metabolism in the cardiovascular system prevents the progression of 
heart failure after infarction. 
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1.1 Glucocorticoids 
1.1.1 Glucocorticoid synthesis and secretion 
Glucocorticoids are a class of steroid hormones produced in, and secreted by the 
zona fasciculata of the adrenal gland (Buckingham, 2006). Endogenous circulating 
glucocorticoid levels are regulated by the hypothalamic-pituitary-adrenal (HPA) axis 
(see Figure 1.1). In response to physical or psychological stressful stimuli, such as 
pain, trauma, infection, or elevated temperature, corticotropin-releasing factor (CRF) 
and arginine vasopressin (AVP) are released from the paraventricular nucleus in the 
hypothalamus (Jacobson, 2005). This causes cleavage of pro-opiomelanocortin 
(POMC) in the anterior pituitary gland resulting in production of adrenocorticotropic 
hormone (ACTH) (Aguilera, et al., 2001; Jacobson, 2005; Buckingham, 2006). 
ACTH is released into the systemic circulation and acts in the adrenal gland to 
stimulate glucocorticoid synthesis (Axelrod & Reisine, 1984). In addition, ACTH 
also induces production of mineralocorticoids and androgen precursors. 
Glucocorticoids exert a negative feedback effect over their own synthesis, whereby 
they inhibit production of CRF and ACTH (Gagner & Drouin, 1985; Ma, et al., 
2001; Jacobson, 2005; Buckingham, 2006). 
The primary active glucocorticoid in humans is cortisol, whereas in rodents it is 
corticosterone (Lin & Achermann, 2004). This is due to rodents lacking the 17α-
hydroxylase enzyme (Lin & Achermann, 2004). Glucocortcoids display a diurnal 
circadian rhythm, with levels in humans peaking early in the morning and declining 
to a nadir in the evening (Lupien, et al., 1998; Jacobson, 2005). This is reversed in 














Figure 1.1 The hypothalamic-pituitary-adrenal axis 
In response to physical or psychological stressful stimuli, corticotropin-releasing factor 
(CRF) is released from the paraventricular nucleus in the hypothalamus. This acts in the 
anterior pituitary gland to produce adrenocorticotropic hormone (ACTH). ACTH is released 
into the systemic circulation and acts in the adrenal gland to stimulate glucocorticoid 
synthesis. Glucocorticoids exert a negative feedback effect over their own synthesis, 










Once in the circulation, approximately 95% of cortisol is sequestered by plasma 
proteins, namely corticosteroid-binding globulin (CBG) and albumin (Dunn, et al., 
1981; Lewis, et al., 2005). This generally renders them inactive and prevents them 
from entering cells and binding to cytosolic glucocorticoid receptors (GR) and 
mineralocorticoid receptors (MR). Glucocorticoids which do cross the cell 
membrane and enter the cytosol are subject to pre-receptor metabolism by the two 
isozymes of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD). 
 
1.1.2 11β-HSDs 
Glucocorticoids exist in both ‘active’ and ‘inactive’ forms, and are interconverted 
between these two states by 11β-HSD type 1 (11β-HSD1) and 11β-HSD type 2 (11β-
HSD2) (Tomlinson & Stewart, 2005) (see Figure 1.2). 11β-HSD1 regenerates 
glucocorticoids, converting inactive cortisone (11-dehydrocorticosterone in rodents) 
to its active form, cortisol (corticosterone in rodents). 11β-HSD2 catalyses the 
reverse reaction, essentially inactivating glucocorticoids in the cytosol and 







Figure 1.2 The intracellular action of the 11β-HSD isozymes 
11β-HSD1 regenerates glucocorticoids, converting inactive cortisone (11-
dehydrocorticosterone in rodents) to its active form, cortisol (corticosterone in rodents). 11β-











11β-HSD1 is a bidirectional enzyme with the ability to function as both a reductase 
enzyme and a dehydrogenase enzyme. In cell homogenates it has been shown to 
elicit both actions, and in primary cell cultures of human omental adipose stromal 
cells it has been shown to act as a dehydrogenase (Bujalska, et al., 2005), however 
only reductase activity has been reported in intact cells (Gao, et al., 1997; Seckl, 
2004). This reductase action appears to be regulated by the enzyme hexose-6-
phosphate dehydrogenase (H6PDH) which catalyses the conversion of glucose-6-
phosphate to 6-phosphogluconolactonate resulting in the concomitant reduction of 
nicotinamide adenine disphosphonucleotide (NADPH) from its oxidised form 
NADP
+
 (Bujalska, et al., 2005; Morton, 2010). NADPH is a crucial cofactor required 
by 11β-HSD1 in order for it to function as a reductase, as experiments using H6PDH 
knock-out (KO) mice, which lack NADPH, result in 11β-HSD1 acting as a 
dehydrogenase (Lavery, et al., 2006). Furthermore, humans with mutations which 
inactivate H6PDH have ‘apparent cortisone reductase deficiency’, and mutations in 
the 11β-HSD1 gene (Hsd11b1) itself give rise to ‘cortisone reductase deficiency’ 
(Tomlinson & Stewart, 2005; Lavery, et al., 2006; Lawson, et al., 2011). Inactivating 
mutations in H6PDH can lead to increased activation of the HPA axis, as a 
compensatory mechanism for reduced cortisol signalling, which also results in 
increased production of androgens (Tomlinson & Stewart, 2005). Inhibition of 
androgen synthesis in this setting can be achieved by treatment with the synthetic 
glucocorticoid dexamethasone (Tomlinson & Stewart, 2005). 
Both 11β-HSD1 and H6PDH are localised at the lumen of the endoplasmic reticulum 
(ER). The N terminus of the 11β-HSD1 protein is attached to the ER membrane and 
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the C terminus resides in the ER lumen (Ozols, 1998; Odermatt, et al., 1999). 11β-
HSD1 is widely expressed in various tissues and distribution has been found to be 
similar in rodents and humans, with highest expression in the liver (Moisan, et al., 
1990). 11β-HSD1 has also been found in lung, skeletal muscle, brain, adipose, 
gonads and the gastrointestinal tract (Walker & Seckl, 2003; Tomlinson & Stewart, 
2005). 11β-HSD1 has also been detected in inflammatory cells, with expression 
induced in monocytes after stimulation with proinflammatory cytokines such as 
interleukin (IL)-4 or IL-13 (Thieringer, et al., 2001). It is also induced in 
macrophages after differentiation from monocytes, and expression has been shown to 
be further increased in vitro after treatment with lipopolysaccharide (LPS) 
(Thieringer, et al., 2001). In vivo, 11β-HSD1 is present in neutrophils during 
inflammation as well as in mast cells (Kardon, et al., 2008; Coutinho, 2009). In the 
cardiovascular system, 11β-HSD1 is found in cardiomyocytes, vascular smooth 
muscle cells, fibroblasts and the vascular wall (Hadoke, et al., 2001; Christy, et al., 
2003; Klusonova, et al., 2009; McSweeney, 2010). During development it has been 
shown to be present in lung and liver, as well as in neonatal heart (Sheppard & 
Autelitano, 2002; Speirs, et al., 2004). 
The in vivo role of 11β-HSD1 has largely been investigated using the 11β-HSD1 
deficient mouse (Kotelevtsev, et al., 1997). Originally, this mouse was described as a 
knock-out mouse, however it has since been found to be hypomorphic for 11β-
HSD1, and is now referred to as ‘deficient’ for 11β-HSD1 (see Section 2.1.2 for full 
details). Nevertheless, in most tissues, including the liver, 11β-HSD1 deficient mice 
are unable to regenerate 11-dehydrocorticosterone to corticosterone intracellularly, 
confirming that 11β-HSD1 is the only 11β-reductase enzyme present in rodents 
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(Kotelevtsev, et al., 1997). On the C57BL/6 background, 11β-HSD1 deficient mice 
show increased insulin sensitivity in both liver and adipose tissue and show 
resistance to diet-induced central obesity when fed a high fat diet (Kotelevtsev, et al., 
1997; Morton, et al., 2001; Morton, et al., 2004). Age-related cognitive decline is 
also attenuated in these mice (Yau, et al., 2001; Yau, et al., 2007). In addition, mice 
with genetic overexpression of 11β-HSD1 in adipose have increased adipose levels 
of corticosterone and increased fat mass, whereas overexpression of 11β-HSD1 in 
liver leads to insulin resistance, dyslipidaemia, and fatty deposits in this tissue 
(Masuzaki, et al., 2001; Paterson, et al., 2005). 
 
1.1.2.1.1 11β-HSD1 and the vasculature 
In the cardiovascular system, the role of 11β-HSD1 has also been investigated using 
the 11β-HSD1 deficient mouse. The expression of 11β-HSD1 in VSMCs indicates 
that it may play a role in vasoconstriction, but ex vivo aortic ring myography 
preparations from 11β-HSD1 deficient mice revealed vessel contraction after 
norepinephrine treatment was similar to control (Hadoke, et al., 2001).  
Apolipoprotein E (ApoE) KO mice are atherosclerosis-prone (Meir & Leitersdorf, 
2004; Kolovou, et al., 2008). ‘Double KO’ mice created by crossing ApoE KO mice 
with 11β-HSD1 deficient mice, have reduced atherosclerosis and decreased 
macrophage recruitment into atherosclerotic plaques (Kipari, et al., 2013). This may 
be due to the decreased expression of vascular cell adhesion protein (VCAM)-1 seen 
in these ‘double KO’ mice (Kipari, et al., 2013). Further investigation has revealed a 
role for 11β-HSD1 in myeloid cells in this setting (Kipari, et al., 2013). Irradiated 
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ApoE KO mice which received 11β-HSD1 deficient bone marrow also exhibited an 
atheroprotective phenotype, suggesting 11β-HSD1 in myeloid cells is key (Kipari, et 
al., 2013). 
11β-HSD1 has been shown to play a key role in angiogenesis and vascular 
remodelling (Small, et al., 2005; Hadoke, et al., 2006; McSweeney, et al., 2010). 
Glucocorticoids are known to inhibit angiogenesis and neointimal proliferation (Van 
Put, et al., 1995). In agreement with this, 11β-HSD1 deficiency has been shown to 
result in enhanced angiogenesis in aortic ring preparations in vitro and in implanted 
subcutaneous sponges in vivo (Small, et al., 2005). Furthermore, 11β-HSD1 
deficiency results in increased angiogenesis in vivo in the peri-infarct region of the 
heart 7d after myocardial infarction (MI) (Small, et al., 2005; McSweeney, et al., 
2010). However, it is unclear whether this increase in angiogenesis is due to direct 
effects of 11β-HSD1 deficiency in the vasculature, or secondary to changes in pro-
angiogenic signalling elsewhere. For example, in the healing myocardial infarct, 
expression of IL-8, a potent pro-angiogenic cytokine, is increased (Matsukawa, et al., 
1999; McSweeney, et al., 2010; Balamayooran, et al., 2011). The inflammatory 
response is also altered in these mice, with increased neutrophils seen in the heart 
48h after MI which may be a result of increased monocyte chemoattractant protein 
(MCP)-1 expression (McSweeney, et al., 2010). Moreover, increased numbers of 
pro-reparative, pro-angiogenic, alternatively-activated macrophages are also seen in 





1.1.2.1.2 11β-HSD1 and the myocardium 
11β-HSD1 has also been shown to regulate heart size, with a single nucleotide 
polymorphism in the Hsd11b1 gene, which encodes the 11β-HSD1 protein, 
associating with reduced left ventricular mass in a human population study (Rahman, 
et al., 2011). 11β-HSD1 deficient mice also exhibit a reduced heart size and weight 
at 12w of age, but systolic function appears to be maintained (McSweeney, 2010). 




11β-HSD2 is a NADP
+
-dependent enzyme which functions solely as a 
dehydrogenase, and oxidises active glucocorticoids to their inert 11-keto metabolites 
(Albiston, et al., 1994). Like 11β-HSD1, 11β-HSD2 is similarly localised to the ER, 
however the catalytic domain faces the cytosol rather than the ER lumen (Odermatt, 
et al., 1999). 11β-HSD2 functions to confer specificity for MR by preventing 
glucocorticoids from illicitly activating these receptors, and allowing occupation by 
the mineralocorticoid, aldosterone. Aldosterone is not a substrate for 11β-HSD2 
(Funder, 1997). The concentration of circulating glucocorticoids is approximately 
100 fold higher than that of aldosterone  (Krozowski & Funder, 1983; Chapman, et 
al., 2013). MR have a relatively higher affinity for aldosterone, corticosterone and 
cortisol (KD = 0.5-2nM) whereas GR have a lower binding affinity for 
glucocorticoids (KD = 10-20nM) and show virtually no binding of aldosterone  
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(Krozowski & Funder, 1983; Hollenberg, et al., 1985; Arriza, et al., 1987; Sheppard 
& Funder, 1987; Buckingham, 2006; Nishi & Kawata, 2007). 
11β-HSD2 is present in the collecting ducts and medulla of the kidneys, where it 
protects MR from glucocorticoid activation (Edwards, et al., 1988; Brown, et al., 
1996). This is crucial because glucocorticoid-mediated MR activation in this tissue 
leads to increased water and sodium retention and potassium excretion, resulting in 
hypertension (Morton & Seckl, 2008). 11β-HSD2 is also found in the colon, adrenal 
cortex, salivary glands and placenta (Edwards, et al., 1988; Brown, et al., 1996; 
Walker & Stewart, 2003). There is some debate as to whether 11β-HSD2 is present 
in the vasculature, since 11β-HSD2 KO mice exhibit altered vascular function 
suggesting a functional role for 11β-HSD2 in this tissue (Hadoke, et al., 2001; 
Christy, et al., 2003). For example, aortic preparations from these mice exhibit 
enhanced contraction after norepinephrine treatment, and impaired vessel relaxation. 
Importantly, there is no evidence for 11β-HSD2 in cardiomyocytes (Christy, et al., 
2003), but it is expressed, albeit at relatively modest levels, in the vascular 
endothelium (Brem, et al., 1998). Therefore in the heart, GR and MR are both 
primarily activated by cortisol/corticosterone (Esteban, et al., 1991; Funder, 1997). 
Approximately 50% of 11β-HSD2 KO mice die within 48h of birth, with survivors 
displaying renal hypertrophy, hypokalaemia and hypertension, in addition to the 
impaired vascular function described above (Kotelevtsev, et al., 1999). Human 
mutations in the 11β-HSD2 gene (Hsd11b2) can lead to the Syndrome of Apparent 




1.1.2.3 11β-HSD1 inhibitors 
Glucocorticoids were first reported to possess anti-inflammatory properties in the 
1940s and have been used to treat a wide variety of inflammatory diseases ever since, 
including asthma and rheumatoid arthritis (Hench & Slocumb, 1949). However, in 
humans with chronically elevated plasma glucocorticoid levels (Cushing’s 
Syndrome), elevated cortisol gives rise to the characteristic hypertension and central 
obesity observed in these patients (De Bosscher, et al., 2003; Souverein, et al., 
2004). Leptin-resistant obese Zucker rats exhibit glucocorticoid-dependent obesity 
and elevated 11β-HSD1 expression in adipose tissue (Livingstone, et al., 2000). 
Furthermore, pharmacological doses of glucocorticoids administered to combat 
inflammatory diseases can have severe adverse side effects, such as type 2 diabetes 
mellitus and cardiovascular disease. 
As previously described, 11β-HSD1 deficient mice show increased insulin sensitivity 
and resistance to diet-induced central obesity when fed a high fat diet (Kotelevtsev, 
et al., 1997; Morton, et al., 2001; Morton, et al., 2004), attenuated age-related 
cognitive decline (Yau, et al., 2001; Yau, et al., 2007), as well as reduced 
atherosclerosis on the ApoE KO background (Kipari, et al., 2013). As such, 
inhibition of 11β-HSD1 has been investigated as a possible therapeutic target. 
Selective 11β-HSD1 inhibitors have been developed by several pharmaceutical 
companies such as Merck, Biovitrum and Amgen. In animals models of obesity they 
have been shown to lower body weight, fasting glucose levels, and plasma 
cholesterol and triglycerides (Hermanowski-Vosatka, et al., 2005). 11β-HSD1 
inhibitors have also been shown to improve glucose tolerance and insulin sensitivity 
in a model of diabetes mellitus (Hermanowski-Vosatka, et al., 2005). In 
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atherosclerosis-prone ApoE KO mice, administration of an 11β-HSD1 inhibitor 
attenuates plaque development (Hermanowski-Vosatka, et al., 2005). More recently, 
a selective 11β-HSD1 inhibitor developed in our centre has demonstrated efficacy in 
experimental models of aging and cognitive impairment (Sooy, et al., 2010; Yau, et 
al., 2011). Further development of pharmacological 11β-HSD1 inhibitors therefore 
remains a promising area of pharmaceutical research with widespread clinical 
applications. 
 
1.1.3 Glucocorticoid signalling 
Glucocorticoid action is largely mediated by binding to two intracellular nuclear 
receptors, GR and MR. GR are ubiquitously expressed in almost all tissues and are 
chiefly responsible for the physiological effects of glucocorticoids. MR, on the other 
hand, have a more specific expression pattern and are co-localised with 11β-HSD2 to 
prevent inappropriate activation by glucocorticoids. MR are found in 
mineralocorticoid target tissues such as the distal tubule of the kidney, the colon, the 
brain and the salivary glands as well as the heart and vasculature (reviewed in 
Chapman, et al., 2013). 
When GR are not occupied by glucocorticoids they are sequestered in the cytosol by 
a 300kDa chaperone complex which consists of Hsp70 and Hsp90 as well as 
stabilising proteins including p23, CyP-40, FKBP51 and FKBP52 (Pratt, et al., 2004; 
Newton & Holden, 2007). When glucocorticoids bind to GR this complex dissociates 
and allows GR to dimerise and translocate to the nucleus where they regulate gene 
transcription (Bledsoe, et al., 2004; Grad & Picard, 2007). Activated GR bind to 
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glucocorticoid response elements (GRE) in the DNA which lie upstream of the 
promoter regions of target genes (Smoak & Cidlowski, 2004). GREs consist of two 
hexameric half sites which each bind one activated GR (Barnes, 1998). These half 
sites are imperfect palindromic sequences (5’-GGTACAxxxTGTTCT-3’) which are 
separated by three nucleotides (denoted ‘x’) (Barnes, 1998). It is primarily through 
this mechanism that GR promote gene expression, however a non-genomic role for 
GR transcriptional regulation has been described, with GR monomers binding to 
other transcription factors (TF), such as signal transducer and activator of 
transcription 3 (STAT3), which promotes expression of IL-10 (Beck, et al., 2009). 
GR-mediated repression of gene expression has also been reported, although the 
mechanism behind this is not completely understood. However, it has been proposed 
that GR binding to AP-1 or nuclear factor-κB (NFκB) may prevent these pro-
inflammatory TFs from interacting with DNA binding sites and initiating pro-
inflammatory gene transcription (McKay & Cidlowski, 1999; Liberman, et al., 
2007). 
 
1.1.4 Glucocorticoids and the cardiovascular system 
Despite the therapeutic anti-inflammatory properties of glucocorticoids providing 
effective treatment against several inflammatory diseases, prolonged glucocorticoid 
administration can lead to adverse cardiovascular side effects, including diabetes 
mellitus, central obesity and hypertension. In the cardiovascular system, GR and MR 
are expressed in VSMCs, endothelial cells (EC), cardiomyocytes and fibroblasts, 
although MR expression in cardiomyocytes is relatively low compared to that of GR 
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(Walker, et al., 1991; Ullian, 1999; Yang & Zhang, 2004; Hadoke, et al., 2006; 
Takeda, et al., 2007; Lother, et al., 2011). 
 
1.1.4.1 Blood pressure, vascular function and cardiac size 
Physiologically, glucocorticoids regulate blood pressure by acting in the kidney, the 
heart and the vasculature (Connell, et al., 1987; Fraser, et al., 1999; Masuzaki, et al., 
2003; Van Raalte, et al., 2013). The importance of glucocorticoids in blood pressure 
control is highlighted by the human conditions Cushing’s Syndrome and Addison’s 
Disease, whereby glucocorticoid excess (Cushing’s Syndrome) leads to hypertension 
and, correspondingly, glucocorticoid deficiency (Addison’s Disease) leads to 
hypotension (De Bosscher, et al., 2003; Chrousos, 2004; Souverein, et al., 2004). 
Blood pressure and circulating cortisol are both known to increase with age, and both 
have been shown to enhance the development of cardiac hypertrophy (Landahl, et 
al., 1986; Van Cauter, et al., 1996; Walker, 2007a; De, et al., 2011; Drazner, 2011). 
Furthermore, epidemiological studies have shown a clear link between circulating 
cortisol and cardiovascular disease. For example, increased HPA axis activity 
associates with insulin resistance in men (Phillips, et al., 1998), and in a cohort of 
patients with type 2 diabetes mellitus, elevated circulating cortisol was associated 
with the prevalence of ischaemic heart disease (Reynolds, et al., 2010a) 
In the kidney GR- and MR-mediated glucocorticoid action results in water and 
sodium retention which increases blood volume and, therefore, blood pressure 
(Morton & Seckl, 2008). 11β-HSD2 is highly expressed in the kidney and may serve 
to regulate glucocorticoid action through MR, since 11β-HSD2 deficiency results in 
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hypertension (Kotelevtsev, et al., 1999; Draper & Stewart, 2005). Within the kidney 
itself, glucocorticoids can induce vasodilatation of afferent and efferent arterioles by 
promoting expression of nitric oxide (NO), a potent vasodilator (De Matteo & May, 
1997; Whitworth, et al., 2000). 
In the systemic circulation, glucocorticoids increase vascular tone and peripheral 
resistance, and facilitate vasoconstriction in a GR-mediated manner (Walker & 
Williams, 1992). Glucocorticoids reduce expression of the calcium-activated 
potassium channel in VSMCs (Brem, 2001). This channel extrudes potassium from 
the cell which aides cellular relaxation (Brem, 2001). Glucocorticoids also stimulate 
the renin-angiotensin-aldosterone system (RAAS) by upregulating production of 
angiotensinogen and angiotensin-converting enzyme (ACE) (Sato, et al., 1994). This 
leads to increased angiotensin-mediated vasoconstriction (Sato, et al., 1994). 
Additionally, glucocorticoids inhibit several vasodilators, namely prostacyclin 
(Walker & Williams, 1992) and prostaglandin I2 (Falardeau & Martineau, 1989), as 
well as endothelial nitric oxide synthase (eNOS) and inducible nitric oxide synthase 
(iNOS), which reduces NO bioavailability (Mitchell & Webb, 2002). 
Glucocorticoids also enhance the effect of vasoconstrictors, including endothelin, 
and catecholamines such as noradrenaline (Ullian, 1999; Hadoke, et al., 2006; 
Goodwin, et al., 2011).  
Blood pressure and blood volume both affect preload, a term used to describe the 
pressure exerted on the left ventricle at the end of diastole. A reduced blood volume 
decreases the end diastolic filling pressure and results in a smaller left ventricular end 
diastolic volume (De Simone, 2003). This is because the pressure experienced by the 
cardiomyocytes in the left ventricular wall is reduced and so cardiomyocyte diastolic 
 47 
length is reduced (Hanft, et al., 2008). As such, hypotensive Addison’s Disease 
patients exhibit reduced heart size (Fallo, et al., 1999; Oakley, et al., 2013), whereas 
hypertensive Cushing’s Syndrome patients exhibit cardiac hypertrophy and dilated 
cardiomyopathy (Petramala, et al., 2007; Hey, et al., 2013; Kim, et al., 2014). 
The effect of glucocorticoids on heart size has recently come to light, with 11β-
HSD1 deficient mice exhibiting reduced heart size and weight (McSweeney, 2010). 
However, the mechanism for this remains unknown. Moreover, a single nucleotide 
polymorphism in the Hsd11b1 gene, which encodes the 11β-HSD1 protein, has been 
associated with reduced left ventricular mass in a human population study (Rahman, 
et al., 2011). Studies using the GR KO mouse have shown a crucial role for 
glucocorticoids in heart maturation. GR KO mice die at birth due to underdeveloped 
lungs (Cole, et al., 1995), however a number of these mice die prenatally, prior to 
lung function being required. It is suggested that this is due to diastolic dysfunction, 
disorganised myofibrils within cardiomyocytes, and impaired calcium-induced 
calcium release (Rog-Zielinska, et al., 2013). 
 
1.1.4.2 Glucocorticoids and angiogenesis 
The anti-angiogenic properties of glucocorticoids have been established for a number 
of years (Folkman, et al., 1983) and, more recently, 11β-HSD1 deficiency has been 
shown to enhance angiogenesis in subcutaneous sponge implants (Small, et al., 
2005), suggesting that endogenous, as well as exogenous, glucocorticoids play a role 
in angiogenesis. Furthermore, in 11β-HSD1 deficient mice, implantation of sponges 
impregnated with cortisol abolished this increase in angiogenesis (Small, et al., 
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2005). However, implantation of sponges impregnated with the cortisol precursor 
cortisone did not attenuate this increased angiogenesis, confirming a key role for 
11β-HSD1 in this phenotype (Small, et al., 2005). This anti-angiogenic effect of 
glucocorticoids seems to be GR-mediated, as administration of RU486, a GR 
antagonist, also enhances angiogenesis (Small, et al., 2005). This is in agreement 
with in vitro experiments which showed that angiogenesis is attenuated in cultured 
VSMCs and ECs treated with dexamethasone, but not aldosterone, suggesting this 
anti-angiogenic influence is GR-mediated (Longenecker, et al., 1982; Longenecker, 
et al., 1984). 
Hypoxia in adipose tissue is seen in obesity (Hosogai, et al., 2007). Deficiency of 
11β-HSD1 in this tissue attenuates hypoxia and results in increased angiogenesis, 
possibly due to upregulation of hypoxia-inducible factor-1α (HIF-1α) and reduced 
fibrosis in this tissue (Michailidou, et al., 2012). HIF-1α is a transcription factor 
which, under normoxic conditions, is cytosolically sequestered by ubiquitination and 
subsequent proteosomal degradation (Ke & Costa, 2006). However, at low oxygen 
tension HIF-1α translocates to the nucleus where it transcribes genes involved in 
metabolism, erythropoiesis and angiogenesis, such as vascular endothelial growth 
factor (VEGF), transforming growth factor β (TGFβ), angiopoetin-1 (Ang-1), 
angiopoetin-1 (Ang-2) and platelet derived growth factor B (PDGFB) (Kelly, et al., 
2003). VEGF binds to the VEGF receptor 2 (VEGFR2), a tyrosine kinase receptor, 
on endothelial cells to initiate a signalling cascade which results in production of 
eNOS (Kroll & Waltenberger, 1998). This enzyme catalyses the conversion of L-
arginine to NO which increases vascular permeability and has been shown to mediate 
VEGF-mediated angiogenesis; administration of eNOS inhibitors attenuates 
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angiogenesis in vitro and in vivo (Palmer, et al., 1988; Ziche, et al., 1997; Fukumara, 
et al., 2001). VEGF signalling also stimulates fibroblast growth factor (FGF), which 
is involved in proliferation and survival of ECs and VSMCs (Sunderkotter, et al., 
1994).  
The role of HIF-1α and VEGF in inhibition of angiogenesis by glucocorticoids has 
been shown by experiments in which osteoblasts and osteocytes transgenically 
express 11β-HSD2 (Weinstein, et al., 2010). 11β-HSD2 expression in these cells 
attenuates the decline in bone strength and mass usually seen in aging by enhancing 
angiogenesis, possibly by diminishing the inhibition of HIF-1α and VEGF 
(Weinstein, et al., 2010). In humans, Cushing’s Syndrome patients have elevated 
glucocorticoid levels and display impaired wound healing, potentially through 
reduced VEGF signalling (Gordon, et al., 1994; Stojadinovic, et al., 2007). 
 
1.1.5 Cardiac function 
Calcium handling is an important regulator of cardiomyocyte contraction and 
relaxation. Contraction is regulated by a process called excitation-contraction 
coupling, which is a term used to describe the conversion of an electrical stimulus, 
such as an action potential, into a cellular response. As an action potential propagates 
along a cardiomyocyte and depolarises the cell membrane, calcium flows into the 
cell from the extracellular space predominantly through L-type calcium channels, 
which are primarily located on the t-tubules (Sham, et al., 1995; Cannell & Soeller, 
1997), although the sodium calcium exchanger (NCX) also contributes to calcium 
entry (Weisser-Thomas, et al., 2003) (see Figure 1.3). Upon entering the cell, 
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calcium binds to ryanodine receptors (RyR) which are present on the surface of the 
sarcoplasmic reticulum (SR) (Fabiato & Fabiato, 1972; Sham, et al., 1995; Cannell 
& Soeller, 1997). This activates ryanodine receptors and allows further calcium to 
enter the cytosol from the SR (Fabiato & Fabiato, 1972; Sham, et al., 1995; Cannell 
& Soeller, 1997). These small releases of calcium from one RyR, or from a cluster of 
RyRs, comprise the basic events of excitation-contraction coupling and are called 
calcium sparks (Cheng, et al., 1993). The summation of several thousand calcium 
sparks gives rise to the calcium transient, which ultimately increases the 
concentration of intracellular calcium (Lopez-Lopez, et al., 1995). This process is 
called calcium-induced calcium release (CICR), which is one of the key mechanisms 
involved in excitation-contraction coupling in cardiac muscle. The rise in 
intracellular calcium concentration causes calcium to bind to troponin C, which is 
part of the myofilament complex (Haikala, et al., 1995; Spyracopoulos, et al., 1997). 
Upon calcium binding, troponin C undergoes a conformational change which 
ultimately allows the myosin heads access to the actin filament, resulting in cellular 
contraction (Spyracopoulos, et al., 1997). 
Following contraction, calcium is removed from the cytosol via a number of 
mechanisms. Calcium is either taken back up into the SR through the action of the 
sarcoplasmic reticulum Ca
2+
 ATPase (SERCA), or extruded from the cell by NCX 
(Reeves & Hale, 1984; Periasamy & Kalyanasundaram, 2007). The sarcolemmal 
Ca
2+
 ATPase also contributes to calcium extrusion from the cell but only accounts 
for approximately 2-3% of calcium removal (Bassani, et al., 1992). Efficient removal 













Figure 1.3 The mechanism of excitation-contraction coupling in cardiomyocytes 
(1) An action potential is sensed by the L-type calcium channel, which opens and allows 
extracellular calcium to enter the cell. (2) This calcium binds to RyR on the surface of the 
SR, causing high levels of calcium to be released from the SR into the cytosol which raises 
the intracellular calcium concentration. (3) Calcium then binds to the troponin complex on 
the sarcomeres causing contraction. (4) Calcium is then removed from the cytosol either by 



























In rodents, re-uptake of calcium back into the SR by SERCA is the dominant 
mechanism, accounting for over 90% of calcium removal from the cytosol (Bers, 
2001). This is in contrast with humans, where SERCA is only responsible for 
removing approximately two thirds of calcium from the cytosol (Haghighi, et al., 
2003). SERCA is also important for appropriate systolic function, as mice 
heterozygous for the gene encoding SERCA, Atp2a2, show a reduction in contractile 
capacity (Schultz, et al., 2004). SERCA KO mice show reduced contractility 
possibly due to reduced SR calcium stores and therefore reduced calcium release 
during excitation-contraction coupling (Ji, et al., 2000). Furthermore, overexpression 
of SERCA results in an enhanced rate of contractility, due to a doubling of the 
calcium transient amplitude, as well as relaxation (Baker, et al., 1998; Vetter, et al., 
2002). 
SERCA activity is regulated by phospholamban (PLN) (MacLennan, et al., 2003). 
When PLN is phosphorylated, it is unable to interact with SERCA and so SERCA 
can transport calcium into the SR (MacLennan, et al., 2003). When PLN is not 
phosphorylated, it inhibits SERCA activity (MacLennan, et al., 2003). PLN 
phosphorylation at Serine 16 (Ser16) and Threonine 17 (Thr17), by protein kinase A 
(PKA) and Ca
2+
/calmodulin dependent protein kinase II (CamKII), respectively, is 
key to relieving inhibition of SERCA (McIvor, et al., 1988; Picht, et al., 2007). NCX 
is the primary mechanism by which calcium is extruded from the cell and is inhibited 
by phospholemman (Cheung, et al., 2007). This inhibition is lifted by PKA-mediated 
phosphorylation of phospholemman (Cheung, et al., 2007). 
There is clear interplay between these two mechanisms of calcium removal from the 
cytosol, as they can be thought of as ‘competing’ for the same pool of intracellular 
 53 
calcium. For example, in the SERCA KO mouse, there is a 2.5 fold increase in 
calcium extrusion by NCX, which is possibly to compensate for the lack of calcium 
reuptake into the SR (Li, et al., 2011). In heart failure, several clinical studies have 
reported reduced SERCA mRNA levels and protein expression (Mercadier, et al., 
1990; Takahashi, et al., 1992) and a subsequent increase in NCX mRNA and protein 
expression (Studer, et al., 1994; Flesch, et al., 1996). Global NCX KO is embryonic 
lethal (Cho, et al., 2000), but cardiomyocyte-specific NCX KO mice survive through 
to adulthood (Henderson, et al., 2004). These mice appear to compensate for lack of 
NCX by increasing activity of the sarcolemmal calcium pump (Henderson, et al., 
2004). L-type calcium channel current is reduced by approximately 50% and so these 
mice avoid intracellular calcium overload by limiting calcium entry into the cell 
(Henderson, et al., 2004). 
 
1.1.5.1 Glucocorticoids and cardiac function 
The role of glucocorticoids on cardiac function has also been investigated, primarily 
through the use of genetically modified animals. GR overexpression studies have 
shown the importance of glucocorticoids in maintaining cardiac homeostasis with 
tissue-specific myocardial overexpression of GR contributing to bradycardia, atrio-
ventricular block, and altered calcium cycling (Sainte-Marie, et al., 2007). For 
example, isolated ventricular cardiomyocytes from these mice have increased 
calcium transients and increased SR calcium load (Sainte-Marie, et al., 2007). 
Glucocorticoids have been shown to play a role in SERCA expression 
developmentally, in adulthood, and after an ischaemic insult. In late gestation an 
increase in SERCA mRNA is normally seen, however this is attenuated in GR KO 
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mice suggesting immature excitation-contraction coupling, as well as calcium-
induced calcium release, in these mice (Rog-Zielinska, et al., 2013). In a setting of 
myocardial ischaemia in piglets, methylprednisolone treatment after cardio-
pulmonary graft prevents loss of SERCA protein and maintains the calcium transient 
in cardiomyocytes (Pearl, et al., 2011). Furthermore, hexose-6-phosphate 
dehydrogenase (H6PDH) KO mice have reduced SERCA protein expression in 
skeletal muscle (Lavery, et al., 2008) 
Glucocorticoids have been known for a long time to be implicated in contractile 
function, as adrenalectomy in rats decreased papillary muscle contractile force 
(Lefer, 1968). This phenotype can be reversed by dexamethasone administration 
(Lefer, 1968). Experimental investigation of MR has also provided insights into the 
role of these receptors in cardiac function. MR cardiac deletion and cardiac 
overexpression studies have found that both these genetic manipulations lead to 
premature death (Beggah, et al., 2002; Ouvrard-Pascaud, et al., 2005). Furthermore, 
surviving mice with cardiac overexpression of MR have arrhythmias (Ouvrard-
Pascaud, et al., 2005). Cardiac overexpression of 11β-HSD2 has been shown to 
enhance cardiac fibrosis and lead to hypertrophy and heart failure (Qin, et al., 2003). 
With regard to intracellular glucocorticoid amplification, 11β-HSD1 deficiency does 
not seem to impact upon systolic function (McSweeney, 2010), however diastolic 
function in this setting remains unknown. Considering all the above literature, this 




1.1.6 Glucocorticoids and inflammation 
Historically, glucocorticoids have been viewed as anti-inflammatory, however their 
role is best described as immunomodulatory (Sapolsky, et al., 2000). Glucocorticoids 
inhibit production of the pro-inflammatory cytokines and chemokines IL-1β, IL-6, 
IL-8, tumour necrosis factor α (TNFα) and MCP-1, as well as increasing expression 
of anti-inflammatory molecules such as IL-4 and IL-10 (Barnes, 1998; Tuckermann, 
et al., 2007). Due to a lack of GREs in the promoter regions of some of these genes, 
and due to the relatively short timescale in which these glucocorticoid-mediated 
effects are seen (minutes rather than hours), it is thought these actions are achieved 
via non-genomic mechanisms. For example, macrophage phagocytosis is inhibited in 
vitro within 30min of corticosterone administration, and neutrophil degranulation is 
suppressed in vitro within 5min of 6α-methylprednisolone administration (Liu, et al., 
2005; Long, et al., 2005). Furthermore, mice with a mutation in the GR DNA binding 
domain, which prevents activated GR from dimerising and binding to GREs, still 
exhibit anti-inflammatory properties by suppressing the action of NFκB and AP-1 
(Reichardt, et al., 1998). Activated GR also stimulate production of inhibitor of κB 
(IκB) (Barnes, 1998). IκB is a regulatory subunit which sequesters NFκB in the 
cytosol and prevents it from translocating to the nucleus. 
Recently, glucocorticoids have also been shown to possess pro-inflammatory actions. 
Following LPS exposure, administration of glucocorticoids has been shown to 
suppress production of the pro-inflammatory mediators TNFα, IL-1β and IL-6 in 
rodents in vivo, whereas administration of glucocorticoids prior to LPS treatment 
enhances the expression of these molecules (Frank, et al., 2010). Endogenous 
glucocorticoids have also been demonstrated to mobilise neutrophils from the bone 
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marrow in a GR-dependent manner (Cavalcanti, et al., 2007). Administration of 
granulocyte colony-stimulating factor (G-CSF) has been shown to increase 
circulating neutrophil numbers, an effect which is potentiated by administration of 
the exogenous glucocorticoid, dexamethasone (Liles, et al., 1997). 
Intracellular glucocorticoid regeneration by 11β-HSD1 has implicated a further role 
for glucocorticoids in modulating the inflammatory response. For example, 11β-
HSD1 mRNA levels are known to increase once monocytes differentiate into 
macrophages (Thieringer, et al., 2001) and 11β-HSD1 activity in macrophages is 
potentiated in a model of sterile peritonitis (Gilmour, et al., 2006). Furthermore, 
administration of an 11β-HSD1 inhibitor following LPS treatment attenuates pro-
inflammatory cytokine production (Ishii, et al., 2007). 
The role of 11β-HSD1 in modulating the inflammatory response and regulating 
angiogenesis has therefore led to speculation that 11β-HSD1 may be a suitable target 
for beneficially modifying the post-MI response. 
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1.2 Myocardial infarction 
Myocardial infarction results from an occlusion in one of the coronary arteries which 
perfuse the myocardium. This occlusion is usually due to the rupture of an 
atherosclerotic plaque and subsequent thrombus formation. In the past ten years, 
there has been a three fold rise in percutaneous coronary interventions, a procedure 
used to unblock stenosed coronary arteries (Townsend, et al., 2012). As such, 
investigation into preventing and treating MI, as well as attenuating the post-MI 
progression to heart failure remains a key area of medical research. 
 
1.2.1 Cardiomyocyte necrosis 
Tissue distal to the point of occlusion in the the coronary artery becomes ischaemic 
leading to necrotic and apoptotic cell death (Mani, 2008), which triggers an 
inflammatory response and ultimately results in formation of a collagen scar, as the 
myocardium is unable to efficiently regenerate in order to replace the damaged 
tissue. Intracellular hallmarks of necrosis include calcium accumulation, increased 
levels of reactive oxygen species (ROS), such as superoxide and peroxynitrite, and 
mitochondrial dysfunction, resulting in reduced anaerobic respiration (Niehaus Jr, 
1978; Mani, 2008). In a normal physiological environment, ROS are essential for cell 
signalling and are regulated by antioxidants (Thannickal & Fanburg, 2000). 
However, high levels of ROS, such as those seen after MI, can escape this regulatory 
mechanism and lead to cell injury; they reduce cardiomyocyte cell membrane 
integrity by peroxidising membrane lipids and therefore contribute to the spilling of 
cytosolic contents into the extracellular matrix (ECM) (Thollon, et al., 1995; Von 
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Harsdorf, et al., 1999). Spillage of mitochondrial proteins, such as cardiolipin, from 
necrotic cardiomyocytes triggers the sequential serine protease reactions of the 
complement cascade (Rossen, et al., 1994).  
Necrosis of cardiomyocytes is a powerful inflammatory stimulus which activates 
toll-like receptors (TLRs) and the complement cascade through the release of 
damage-associated molecular patterns (DAMPs) from cardiomyocytes (De Haan, et 
al., 2013). ROS, TNFα, and DNA and RNA spilled into the ECM by necrotic 
cardiomyocytes activates TLRs, specifically TLR2, and other pathways leading to 
the dissociation of NFκB from its regulatory subunit IκB, allowing NFκB to 
translocate to the nucleus (Kin, et al., 2006). Once in the nucleus, it initiates the 
transcription of genes involved in the inflammatory response, as well as cell 
proliferation and survival (Kin, et al., 2006). These include IL-1β, IL-6, IL-8, MCP-1 
and macrophage inflammatory protein-2 (MIP-2) (Li, et al., 2001; Zhou, et al., 
2003), which are involved in neutrophil and macrophage recruitment to the site of 
injury. The importance of TLR2 has been shown using the TLR2 KO mouse, which 
exhibits reduced fibrosis and preserved ejection fraction after MI (Shishido, et al., 
2003). 
 
1.2.2 Cardiomyocyte apoptosis 
Cardiomyocyte apoptosis occurs in areas of low oxygen tension, primarily around 
the infarct border, and is characterised by shrinkage of the cell, chromatin 
condensation and DNA fragmentation (Shih, et al., 2011). Hypoxia can activate the 
B-cell lymphoma-2 (BCL-2) family which increases the mitochondrial outer 
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membrane permeability (MOMP) (Youle & Strasser, 2008). This results in 
cytochrome-C entering the cytosol and activating caspases, namely caspase-9 and 
caspase-3 (Youle & Strasser, 2008). These caspases stimulate nuclear lamins and 
nuclear inhibitor of caspase-activated deoxyribonuclease/DNA fragmentation factor-
45 (ICAD/DEF45) leading to DNA fragmentation (Henkart, 1996; Sakahira, et al., 
1998). Alternatively, activation of death receptors by TNFα or Fas ligand can 
activate bax which in turn modifies MOMP and results in caspase activation (Chao, 
et al., 2002). Compared to necrosis, apoptosis does not elicit an inflammatory 
response, and apoptotic cells can even promote expression of anti-inflammatory 
molecules, such as TGFβ, from macrophages (Huynh, et al., 2002). 
Several studies, going back to the 1970s, have investigated the therapeutic capacity 
of administering glucocorticoids after MI (Libby, et al., 1973; Hoffstein, et al., 
1976). In a canine model, glucocorticoids given immediately after infarction were 
found to be initially protective, by reducing ischaemic cell death, and therefore 
limiting infarct size (Libby, et al., 1973), possibly by preserving the integrity of 
lysosomal membranes and thus preventing the spillage of lysozymes into the cytosol 
(Hoffstein, et al., 1976). This led to studies in humans which showed that 
administration of glucocorticoids within 48h of infarction reduced mortality and 
infarct size (Barzilai, et al., 1972; Morrison, et al., 1976). However, chronic 
glucocorticoid treatment increases infarct size and the prevalence of arrhythmias 
(Roberts, et al., 1976), as well as increasing the likelihood of left ventricular rupture 
(Hammerman, et al., 1983). In a rat model of MI, long term corticosteroid 
administration has been shown to increase infarct size (Scheuer & Mifflin, 1997) 
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1.2.3 Neutrophil recruitment 
Induction of proinflammatory cytokines and chemokines by necrosis after MI, such 
as IL-6, IL-8 and TNFα leads, firstly, to neutrophil infiltration and then shortly 
thereafter to macrophage infiltration (Li, et al., 2001; Zhou, et al., 2003). Neutrophils 
appear early after MI, with levels peaking at 24-48 hours after infarction, and are 
responsible for removing necrotic cells, which are mainly cardiomyocytes, from the 
site of injury (Nahrendorf, et al., 2007). Neutrophils are very important to the post-
MI inflammatory response, since they play a key role in clearing cell debris from the 
site of injury. Furthermore, they secrete IL-4  which contributes to regulation of the 
pro-reparative phase of infarct healing (Brandt, et al., 2000). In normal conditions, 
they remain in the systemic circulation, but migrate towards the heart after MI in 
response to pro-inflammatory stimuli and interact with the vessel wall 
(Frangogiannis, et al., 2002). Upregulation of adhesion molecules on ECs, such as P-
selectin, intercellular adhesion molecule-1 (ICAM-1), and platelet endothelial cell 
adhesion molecule-1 (PECAM-1, also called CD31) allows neutrophils to adhere to 
and then roll along the vessel wall (Briaud, et al., 2001; Thompson, et al., 2001). β2-
integrins and L-selectin on the cell surface of neutrophils facilitates tethering to ECs 
and subsequent transmigration into tissues (Frangogiannis, et al., 2002). 
IL-6 and IL-8 are key pro-inflammatory molecules involved in neutrophil 
recruitment to the site of injury (Frangogiannis, et al., 2002). After splanchnic artery 
occlusion shock, IL-6 KO mice have reduced P-selectin and ICAM-1 expression in 
the ileum and attenuated neutrophil infiltration into the reperfused intestine 
(Cuzzocrea, et al., 1999). IL-8 deficiency, or antagonism of its receptor CXCR2, has 
been shown to impair neutrophil infiltration into the heart after MI and into the 
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synovial vasculature in another inflammatory model; monarticular antigen-induced 
arthritis (Kukielka, et al., 1995; Coelho, et al., 2008). 
As has been described in Section 1.1.6, endogenous glucocorticoids play a role in 
mobilising neutrophils from the bone marrow in a GR-dependent manner 
(Cavalcanti, et al., 2007). Furthermore, the increase in circulating neutrophils in 
response to G-CSF treatment is potentiated by administration of the exogenous 
glucocorticoid, dexamethasone (Liles, et al., 1997). ACTH administration has also 
been shown to augment neutrophil liberation from the bone marrow (Roth, et al., 
1982), which may provide a mechanism for the well-established increase in recruited 
neutrophils seen in the heart after MI (Frangogiannis, 2008), since circulating 
cortisol is also known to increase after infarction (Nito, et al., 2004). Although 
glucocorticoids have been shown to prolong neutrophil survival in vitro (Ruiz, et al., 
2002), they do not inhibit neutrophil apoptosis in hypoxic conditions (Marwick, et 
al., 2013), which are similar to those found in the heart after MI. Moreover, primary 
cultured endothelial cells from adrenalectomised rats, which are glucocorticoid 
deficient, have increased expression of ICAM-1, VCAM-1 and L-selectin 
(Cavalcanti, et al., 2007). These genes are involved in cellular adhesion, and 
neutrophil tethering and extravasation (Cavalcanti, et al., 2007). In agreement with 
these findings are experiments which show dexamethasone treatment inhibits the 
increase in expression of endothelial-leukocyte adhesion molecule-1 (ELAM-1) and 
ICAM-1 on LPS-stimulated human umbilical vein endothelial cells (HUVECs) 
(Cronstein, et al., 1992). Dexamethasone treatment has also been shown to reduce 
expression of L-selectin and β2 integrins on circulating neutrophils and lymphocytes 
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(Burton, et al., 1995; Jilma, et al., 1997; Briaud, et al., 2001). These genes are 
required for neutrophil adhesion and transmigration into tissues. 
 
1.2.4 Macrophage infiltration 
In the bone marrow, CD34
+
 macrophage and dendritic cell progenitor cells give rise 
to monocytes, which circulate in the blood and enter tissues in response to pro-
inflammatory stimuli  (Van Furth & Cohn, 1968; Auffray, et al., 2009; Geissmann, et 
al., 2010). After MI, they are one of the first cell types to enter the heart where they 
differentiate into macrophages (Jung, et al., 2013). In mice, as in humans, there are 
two distinct monocyte subsets, which are characterised by their relative expression of 
lymphocyte antigen 6C (Ly6C) (Geissmann, et al., 2003). Ly6C
hi
 monocytes are 
potent proinflammatory mediators, whereas Ly6C
lo
 monocytes play a key role in the 
resolution of inflammation and are thus regarded as anti-inflammatory (Geissmann, 
et al., 2003; Nahrendorf, et al., 2007). Macrophage differentiation from monocytes is 
stimulated by macrophage colony-stimulating factor (M-CSF) (Frangogiannis, et al., 
2002), and macrophages have been shown to be crucial for appropriate healing of the 
myocardium after MI, since macrophage depletion using anti-macrophage serum 
impairs wound healing (Cohen, et al., 1987). Furthermore, inhibition of macrophage 
function by administration of clodronate-containing liposomes results in impaired 
angiogenesis in the infarct border in vivo, as well as reduced vessel sprouting in an ex 
vivo aortic ring preparation (Gelati, et al., 2008; Van Amerongen, et al., 2008). This 
phenotype may be rescued following treatment with bone marrow-derived 
macrophages which highlights the important role of macrophages in the induction of 
angiogenesis (Gelati, et al., 2008). Moreover, injection of macrophages into the heart 
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in an experimental model of MI leads to preserved systolic function and attenuated 
left ventricular remodelling (Leor, et al., 2006). 
In the first 3 to 4 days after MI, Ly6C
hi
 monocytes are the dominant subset in the 
myocardium, where they are attracted to the site of injury by MCP-1 and 
differentiate into ‘classically-activated’ macrophages, also called M1 macrophages  
(Kakio, et al., 2000; Nahrendorf, et al., 2007). These cells digest infarcted tissue, and 
remove apoptotic neutrophils and necrotic cardiomyocytes. Furthermore, these cells 
produce the pro-inflammatory mediators IL-1, IL-6 and IL-23, thus augmenting the 
inflammatory response  (Sunderkotter, et al., 1994). M1 macrophages are also 
involved in regulating ECM remodelling by expressing matrix metalloproteinases 
(MMP), such as MMP-9 (Schmidt, et al., 2006). MCP-1 has been shown to be a key 
promoter of Ly6C
hi
 monocyte recruitment to sites of injury, for example in 
atherosclerosis and rheumatoid arthritis (Nelken, et al., 1991; Koch, et al., 1992). 
MCP-1 is known to enhance angiogenesis and maintain systolic function after MI 
(Morimoto, et al., 2006), possibly via its effect on macrophages. This is because 
disruption of the MCP-1 gene results in abnormal macrophage polarisation and 
delayed macrophage infiltration into the heart after MI (Dewald, et al., 2005). This is 
hypothesised to be due to the decreased expression of IL-1β, IL-10, TNFα and 
TGFβ, which are cytokines necessary for differentiation into the pro-reparative 
alternatively-activated state (Dewald, et al., 2005). 
From day four after MI, more ‘alternatively-activated’ Ym1
+
 macrophages are seen 
in the heart, where they play a crucial role in scar resolution and infarct healing 
(Nahrendorf, et al., 2007; McSweeney, et al., 2010). Induction of this M2 phenotype 
is primarily mediated by IL-4 and IL-13 (Gordon, 2003). These cells secrete the anti-
 64 
inflammatory cytokines IL-10 and TGFβ (Nahrendorf, et al., 2007;  Lambert, et al., 
2008; Van Amerongen, et al., 2008) and are involved in induction of post-MI 
angiogenesis, particularly in the peri-infarct region, by releasing basic FGF, insulin-
like growth factor-1 (IGF-1) and VEGF (Berse, et al., 1992; Henke, et al., 1993; 
Nahrendorf, et al., 2007; Dobrucki, et al., 2010). Depletion of macrophages via 
administration of diphtheria toxin to mice expressing the diphtheria toxin receptor 
under the control of the CD11b promoter leads to impaired wound healing (Mirza, et 
al., 2009). Reduced granulation tissue formation and scar deposition, as well as 
increased haemorrhage and apoptosis of neovascular ECs, were seen in these mice in 
response to excisional skin wounding thus showing an essential role for macrophages 
in wound repair (Lucas, et al., 2010). 
The pro-angiogenic factor, IL-8, is secreted by macrophages and endothelial cells, 
and its action is mediated by it binding to its receptor, CXCR2 (Koch, et al., 1992; 
Heidemann, et al., 2003; Li, et al., 2003). IGF-1 is also secreted by macrophages 
(Dobrucki, et al., 2010), and has been shown to upregulate IL-8 expression and 
enhance angiogenesis after isoproterenol-induced MI in rats (Haleagrahara, et al., 
2011). M2 macrophages are also involved in ECM remodelling and scar resolution 
by activating myofibroblasts, which serves to initiate collagen, laminin, and 
fibronectin deposition (Weber & Brilla, 1991).  
The effects of glucocorticoids on modulating the inflammatory response has been 
extensively investigated (reviewed in Walker, 2007a; Chapman, et al., 2009; Cooper 
& Stewart, 2009; Hadoke, et al., 2009). Evidence from clinical trials has shown the 
importance of the post-MI inflammatory response, and the modulatory effect of 
glucocorticoids, with administration of methylprednisolone in MI patients resulting 
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in increased mortality due to left ventricular rupture (Hammerman, et al., 1983). MR 
blockade has been shown to result in a modified inflammatory response, with an 
increase in alternatively-activated macrophages, and enhanced neovascularisation in 
a rat model of MI (Fraccarollo, et al., 2008). Moreover, MR deletion in myeloid cells 
leads to enhanced M2 polarisation, with concomitant protection against hypertrophy 
and fibrosis in response to L-N
G
-nitroarginine methyl ester (L-NAME) and 
angiotensin II treatment (Usher, et al., 2010). 
The role of 11β-HSD1 in modifying inflammation after infarction has also been 
investigated. Mice globally deficient in 11β-HSD1 have an augmented inflammatory 
response, associated with increased representation of pro-reparative alternatively-
activated macrophages 7d post-MI (McSweeney, et al., 2010). 
 
1.2.5 Post-MI angiogenesis 
Angiogenesis, the formation and growth of new vessels from existing capillaries, is a 
complex process and can be induced by several mechanisms including hypoxia 
(Wang, et al., 2006), nitric oxide (Papapetropoulos, et al., 1997; Matsunaga, et al., 
2000), chemokines such as IL-8 (Li, et al., 2003; McSweeney, et al., 2010) and pro-
angiogenic growth factors such as nerve growth factor (NGF) (Meloni, et al., 2010), 
FGF (Giordano, et al., 1996), IGF-1 (Dobrucki, et al., 2010) and VEGF (Pearlman, 
et al., 1995; Ziche, et al., 1997; Schwarz, et al., 2000). These signals activate 
quiescent endothelial cells, which causes an increase in vascular permeability and 
allows endothelial cell migration and proliferation. Following endothelial sprouting, 
the primitive vessel system is pruned and organised into an efficient network 
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(Bergers & Song, 2005). Upon pericyte coating, these vessels mature and provide a 
long term blood supply to the surrounding tissue (Bergers & Song, 2005).  
The induction of HIF-1α expression in ischaemic conditions leads to the upregulation 
of several pro-angiogenic factors, such as VEGF, TGFβ, Ang-1, Ang-2 and PDGFB 
(Kelly, et al., 2003). VEGF-induced angiogenesis is stimulated by eNOS-mediated 
NO production (Ziche, et al., 1997), and experimental data has shown VEGF gene 
therapy increases neovascularisation and improves ejection fraction in rat (Hao, et 
al., 2007) and rabbit (Bull, et al., 2003) models of MI. Moreover, genetic 
manipulation of HIF-1α has confirmed the key role of this protein in mediating 
angiogenesis. Deletion results in impaired vascular development, whereas over-
expression leads to increased angiogenesis and reduced infarct size after MI (Kido, et 
al., 2005; Shohet & Garcia, 2007). 
Stimulation of angiogenesis through the use of growth factors has had limited 
success, (Losordo, et al., 1998; Simons, 2005; Ellis, et al., 2006), as this leads to the 
formation of a disorganised network of leaky vasculature (Korpisalo, et al., 2008). 
Gene therapy studies aimed at enhancing post-MI angiogenesis have included using 
VEGF. VEGF gene therapy in this setting is probably the most extensively 
investigated of all growth factors, and therapy using the VEGF-165 isoform has been 
shown to enhance angiogenesis, leading to improved ejection fraction and increased 
myocardial viability  (Zhang, et al., 2002; Ferrarini, et al., 2006; Rissanen & Yla-
Herttuala, 2007). However, unregulated expression or chronic overexpression of 
VEGF has been shown to accelerate atherosclerosis and lead to the formation of 
intramural vascular tumours (Lee, et al., 2000; Celletti, et al., 2001). Furthermore, 
clinical trials, such as the EUROINJECT and NORTHERN trials, were unable to 
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demonstrate a clear benefit of VEGF therapy (Kastrup, et al., 2005; Stewart, et al., 
2009). As such, the identification of an alternative means of promoting angiogenesis 
after MI is required. 
The role of cardiac fibroblasts in regulating angiogenesis is now also well 
recognised, with several fibroblast-derived proteins, such as collagen I, procollagen 
C endopeptidase enhancer, osteonectin, TGF β-induced protein ig-h3 and IGF-
binding protein 7, having been shown to be critical for lumen formation and EC 
sprouting (Newman, et al., 2011). 
The anti-angiogenic properties of glucocorticoids have been established for a number 
of years (Folkman, et al., 1983). Administration of physiological levels of either 
dexamethasone or cortisol to cultured HUVECs and human aortic endothelial cells 
(HAoECs) results in inhibition of endothelial cell sprouting and therefore decreased 
formation of tube-like structures in vitro (Logie, et al., 2010). This effect is GR-
mediated since the phenotype is reversed by addition of RU486, a GR antagonist 
(Logie, et al., 2010). Furthermore, in vivo experiments have shown exogenous 
glucocorticoid administration suppresses angiogenesis in murine bone, a phenotype 
which is attenuated by overexpression of 11β-HSD2 (Weinstein, et al., 2010). The 
anti-angiogenic properties of glucocorticoids in this setting appear to be due to their 
inhibition of HIF1α and VEGF expression in murine osteoblasts and osteocytes 
(Weinstein, et al., 2010). In a pathophysiological setting of cancer, administration of 
glucocorticoids to renal cell carcinoma cells inhibit VEGF mRNA production and 
protein expression in vitro (Iwai, et al., 2004). Moreover, mice with a DU145 cell 
line (prostate cancer cell line) xenograft show reduced VEGF and IL-8 expression in 
response to dexamethasone treatment in vivo (Yano, et al., 2006).  
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After infarction, 11β-HSD1 deficient mice have also been shown to have increased 
angiogenesis in the peri-infarct region which is associated with maintained ejection 
fraction (Small, et al., 2005; McSweeney, et al., 2010). In the long term, 
maintenance of peri-infarct angiogenesis is crucial to prevent infarct expansion (Liu, 
et al., 2007). For example, in humans, capillary density in infarcted hearts correlates 
with reduced infarct size (Prech, et al., 2006). 
 
1.2.6 Scar formation 
Following the inflammatory phase after infarction, necrotic cardiomyocytes are 
replaced with non-contractile, fibrotic tissue resulting in the formation of a collagen-
rich scar (Frangogiannis, et al., 2002), which is necessary to maintain the structural 
integrity of the left ventricular wall, and to prevent cardiac rupture (Porter & Turner, 
2009). Deposition of collagen type I and type III, and other molecules necessary for 
appropriate ECM remodelling, such as fibronectin and proteoglycans, is primarily 
performed by myofibroblasts; cells which have differentiated from cardiac 
fibroblasts and assume phenotypic characteristics similar to smooth muscle cells 
(Gabbiani, 1998). Expression of pro-inflammatory and pro-fibrotic cytokines, such 
as IL-1β, IL-6, TNFα and TGFβ are all increased in patients following infarction 
(Nian, et al., 2004).  
IL-6, along with TNFα, has been shown to enhance fibroblast proliferation (Siwik, et 
al., 2000; Hellkvist, et al., 2002), with TGFβ known to stimulate fibroblast 
differentiation into myofibroblasts (Hao, et al., 2008). IL-1β and IL-6 have been 
shown to degrade the ECM, primarily through expression of MMPs, such as MMP-2, 
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MMP-9, and MMP-13 (Siwik, et al., 2000). TGFβ also plays a crucial role in 
stimulating collagen, fibronectin and proteoglycan deposition from myofibroblasts 
(Eghbali, et al., 1991; Heimer, et al., 1995; Villarreal, et al., 1996). Atrial natriuretic 
peptide (ANP), which is released from cardiomyocytes in heart failure, performs a 
contrasting role; it inhibits fibroblast proliferation, differentiation into 
myofibroblasts, and collagen synthesis (Li, et al., 2008). 
Fibrillar collagen type I is the most abundant type of collagen present in the heart, 
accounting for approximately 80% of total myocardial collagen, with collagen type 
III comprising approximately 11% (De Souza, 2002). Collagen accumulation is 
associated with reduced compliance and can lead to cardiac pathology (Pauschinger, 
et al., 1999), such as diastolic dysfunction (Kass, et al., 2004; Moreo et al., 2009). 
Collagen type I is stiffer than the more elastic collagen type III, and in infarct scars 
an increase in the relative proportion of collagen type I to collagen type III in seen 
(Pauschinger, et al., 1999). This increase in relative expression, as well as collagen 
cross-linking, may contribute to maintaining the structural integrity of the ventricle 
after MI (Pauschinger, et al., 1999; Dean, et al., 2005). Enhancing collagen 
deposition, by injecting collagen into the heart immediately following MI in rats, has 
been shown to reduce infarct expansion and preserve cardiac function up to six 
weeks after occlusion (Dai, et al., 2005). Administration of physiological levels of 
glucocorticoids have recently been shown to inhibit cardiac fibroblast proliferation in 
vitro (He, et al., 2011). These effects were abrogated by the addition of the GR 
antagonist RU486 showing these effects were GR-mediated (He, et al., 2011). In an 
inflammatory setting, 11β-HSD1 deficient mice display increased collagen in the 
lung following bleomycin treatment (Yang, et al., 2009) and an attenuated response 
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to the age-induced reduction in skin collagen density (Tiganescu, et al., 2013). 
Moreover, 11β-HSD1 deficiency on the ApoE KO background leads to increased 
fibrosis in atherosclerotic plaques following administration of a cholesterol rich diet 
(Kipari, et al., 2013). However, 11β-HSD1 deficient mice fed a high fat diet have 
reduced collagen deposition in adipose tissue, which is hypothesised to be due to the 
increased angiogenesis seen in this tissue (Michailidou, et al., 2012).  
 
1.2.7 Hypertrophy, remodelling and heart failure 
Cardiac remodeling can occur as a result of several diseases or pathological 
conditions, such as MI, chronic hypertension, aortic stenosis, myocarditis and 
idiopathic dilated cardiomyopathy (Cohn, et al., 2000). The extent of remodelling 
which occurs after MI is largely dependent on initial infarct size, and infarct size has 
been shown to negatively correlate with morbidity and mortality (Yang, et al., 2002a; 
Numaguchi, et al., 2006). For example, high levels of ROS released from necrotic 
cells immediately after infarction have been shown to contribute to the pathogenesis 
of heart failure (Dhalla, et al., 1996), and have been shown to play a role in TLR-
mediated vascular dysfunction and arrhythmias (Shishido, et al., 2003). After initial 
collagen deposition, subsequent expansion and thinning of the scar leads to reduced 
cardiac function and left ventricular dilatation (Pfeffer & Braunwald, 1990). Whilst 
hypertrophy may be initially compensatory, it can lead to adverse outcomes in the 
long term and dilatation can become progressively decompensatory (Sabbah & 
Goldstein, 1993). 
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Reduction in cardiac performance, increased wall stress and expression of TNFα, 
TGFβ and endothelin result in cardiomyocytes reverting back to a foetal phenotype, 
whereby they express ANP and β-myosin heavy chain (β-MHC), which are typical 
characteristics of cardiac hypertrophy (Buttrick, et al., 1991; Takahashi, et al., 1992; 
Stanley, et al., 2004; Lu, et al., 2010; Vaz Perez, et al., 2010). 
ANP has been shown to be vital for survival within the first seven days following 
occlusion, and that its action via the guanylyl cyclase-A (GC-A) receptor attenuates 
fibrotic and hypertrophic responses (Nakanishi, et al., 2005). Myocardial and plasma 
ANP levels have been shown to increase after MI, and increasing levels correlate 
with the extent of left ventricular dysfunction (Lu, et al., 2010; Vaz Perez, et al., 
2010). 
β-MHC is upregulated in heart failure (Buttrick, et al., 1991; Takahashi, et al., 1992). 
Cardiac muscle myosin is a hexameric protein which consists of two heavy chain 
subunits, two light chain subunits and two regulatory subunits. The heavy chains 
exist as two isoforms, α and β. In the myocardium of small mammals, such as mice, 
expression of the α isoform predominates (Lompre, et al., 1979) whereas this is 
reversed in humans, with the β isoform accounting for over 90% of the MHC 
subunits (Gorza, et al., 1984). The role of α-MHC in regulating cardiac contractility 
has been shown by genetic manipulation in an experimental model of familial 
hypertrophic cardiomyopathy, with disruption of this gene resulting in cardiac 
dysfunction (Geisterfer-Lowrance, et al., 1996). The ratio of α-MHC:β-MHC has 
been shown to directly correlate with cardiac function in both animals and humans 
(Miyata, et al., 2000; Abraham, et al., 2002; Herron & McDonald, 2002) and can 
thus be used to help determine the extent of heart failure in a model of infarction. 
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As detailed in Section 1.2.4, 11β-HSD1 deficient mice show a beneficial phenotype 
7d post-MI, and this outcome is still apparent 4w post-MI. In these mice, the 
enhanced peri-infarct angiogenesis, increased scar thickness and improved ejection 
fraction are sustained through to 4w after MI, suggesting attenuated development of 
heart failure (McSweeney, et al., 2010). Genetic disruption of the MR gene 
specifically in murine cardiomyocytes results in attenuated adverse remodelling and 
left ventricular dysfunction after MI (Fraccarollo, et al., 2011). Moreover, clinical 
trials, such as RALES and EPHESUS, have demonstrated the beneficial effect of 
early MR inhibition after infarction in humans (Pitt, et al., 1999; Pitt, et al., 2003). In 
these studies, eplerenone treatment and spironolactone treatment was shown to 
reduced morbidity and mortality in acute MI patients, and in patients with severe 
heart failure (Pitt, et al., 1999; Pitt, et al., 2003). Considering the above literature, it 
is clear that glucocorticoids, and 11β-HSD1, play a key role in the post-MI setting 
and in the development of heart failure. 
 73 
1.3 Aims and hypotheses 
Previous work has shown that global 11β-HSD1 deficiency leads to smaller hearts 
(McSweeney, et al., 2010), however the mechanism for this remains unknown. 
Systolic function appears to be maintained but diastolic function and calcium 
regulation have not been studied. In addition, global 11β-HSD1 deficient mice 
exhibit a beneficial phenotype after MI, with an augmented inflammatory response, 
associated with increased representation of pro-reparative alternatively-activated 
macrophages, enhanced peri-infarct angiogenesis and improved cardiac function 
(McSweeney, et al., 2010). However, whether this is due to ‘cardiovascular’ 11β-
HSD1 is unknown. Therefore the work in this thesis addressed the hypotheses that: 
1. Deletion of 11β-HSD1 in cardiomyocytes and VSMCs (SMAC mice) would 
result in smaller, lighter hearts, but would not influence systolic function. 
2. Deletion of 11β-HSD1 in cardiomyocytes and VSMCs would reproduce the 
beneficial post-MI phenotype previously seen in global 11β-HSD1 deficient 
mice. 
The first aim was to characterise the cardiac phenotype of mice globally deficient in 
11β-HSD1 (DelI mice), and mice in which deletion was restricted to cardiomyocytes 
and vascular smooth muscle cells (SMAC mice). 
The second aim was to determine whether the beneficial acute outcomes seen 
previously in 11β-HSD1 deficient mice 7d after MI could be reproduced by selective 
cardiovascular deletion of the enzyme. 
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The final aim was to assess the impact of global 11β-HSD1 deficiency and 





Materials and Methods 
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2.1 Animals and breeding 
2.1.1 Mouse colonies 
Experiments were approved by the University of Edinburgh ethics committee and the 
Home Office (PPL 60/4247, Dr. Gillian Gray) and carried out in strict accordance 
with the Animals (Scientific Procedures) Act (UK) 1986. I performed all techniques 
except where stated. 
 
2.1.2 Mouse lines with 11β-HSD1 deficiency 
2.1.2.1 Global 11β-HSD1 deletion 
Male global 11β-HSD1 knock-out (KO) mice were generated from Hsd11b1 ‘floxed’ 
mice (Hsd11b1
fl/fl
) in which loxP sites flank exon 3 of the Hsd11b1 gene. These mice 
were created by homologous recombination in C57Bl/6 stem cells. Homozygous 
‘floxed’ mice (Hsd11b1
fl/fl
) were crossed with mice in which the Cre recombinase 
enzyme was under control of the hypoxanthine-guanine phosphoribosyltransferase 
promoter. Cre recombination allowed removal of exon three, which encodes the 
binding site for the cofactor NADPH, and also resulted in a frameshift mutation thus 
creating a non-sense transcript.  
Mice were backcrossed with C57BL/6 mice for 7 generations generating 
heterozygous (+/-) mice. Heterozygous mice were then intercrossed to give 
homozygous KO, and this global KO mouse strain is referred to as ‘DelI’ hereafter. 
All of the above work was performed by Karen Chapman and Janet Man (University 
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of Edinburgh). Pairs of DelI mice were then set up for breeding, and in-house male 
C57BL/6 mice were used as controls. 
 
2.1.2.2 Global deficiency of 11β-HSD1 
Male 11β-HSD1 deficient mice, which are hypomorphic for 11β-HSD1, were 
generated in house by Yuri Kotelevtsev (Kotelevtsev, et al., 1997). 11β-HSD1 is 
transcribed from three promoters, with lung mainly using the P1 promoter and most 
other tissues, such as liver, brain and adipose tissue, using the P2 promoter, which 
lies downstream (Bruley, et al., 2006). The Hsd11b1 gene is disrupted in these mice 
by insertion of a neomycin cassette which interferes with, and therefore reduces, 
expression of 11β-HSD1 driven from the P2 promoter. However, there appears to be 
less interference with the more distant P1 promoter. The initial observations after MI 
by Small et al (2005) and McSweeney et al (2010) were made using these mice and 
they were again used for investigating the development of heart failure in this thesis 
(Chapter 5). DelI mice were initially used but all mice (n=16) died between d3 and 
d5 after surgery from cardiac rupture. 11β-HSD1 deficient mice were genotyped by 
Janet Man and in-house male C57BL/6 mice were used as controls. 
 
2.1.2.3 ‘Cardiovascular’ deletion of 11β-HSD1 
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Genotyping of DelI and SMAC animals was performed on ear notch tissue using 
PCR. DNA was extracted using a DNeasy Blood and Tissue Kit (Qiagen). Ear tissue 
was placed into a 1.5ml Eppendorf tube, and 180µl Buffer ATL and 20µl proteinase 
K solution was added. Tubes were vortexed and incubated at 56
o
C for 3h, ensuring 
the tissue was completely lysed. 200µl Buffer AL was added to each sample before 
vortexing again. 200µl 100% ethanol was added to each sample, the tubes were 
vortexed again, and the mixture was transferred to a DNeasy Mini spin column 
which was placed in a 2ml collection tube. The spin column was centrifuged at 8,000 
G for 1min, the flow-through was discarded and 500µl Buffer AW1 was added. Each 
spin column was centrifuged again at 8,000 G for 1min. The flow-through was again 
discarded and 500µl Buffer AW2 was added to each sample. The spin columns were 
centrifuged again at 12,000 G for 3min to dry the DNeasy membrane. The collection 
tube was discarded and the spin column placed in a 1.5ml Eppendorf. 200µl Buffer 
AE was added to each sample, incubated at room temperature for 1min and 





To check the DelI breeding pairs were producing only DelI animals, three custom 
primers (Invitrogen, designed by Janet Man) were used to identify wild type, 
heterozygous and knock-out animals: 
Flox F: 5’-CTTGCATGTGTTTGGTGTTGG-3’ 
Flox R: 5’-AATGTTTCCAAATGCATTGTGGG-3’ 
Del F: 5’-GTGATGTCAGATCTACAGAAGG-3’ 
Two PCR reactions were performed (Figure 2.1). A Del PCR, consisting of DelF and 
FloxR primers, was used to determine whether exon 3 had been deleted (Figure 
2.1a). In the Del PCR, DelI mice produce a 363bp product, whereas control mice 
produce a 1066bp product. A Flox PCR, consisting of FloxF and FloxR primers, was 
used to determine if the floxed allele was present (Figure 2.1b). In the Flox PCR, 
DelI mice generate no product whereas control mice produce a 255bp product. Wild-
type animals produce a 998bp product in the Del PCR and a 221bp product in the 
Flox PCR. This is similar to the products seen for control mice, except each band is 
shorter due to the lack of 34bp loxP sites. 
To identify SMAC and Cre- control animals, two custom primers (Invitrogen, 
designed by Janet Man) were used to detect the presence of Cre recombinase (Guy, 
et al., 2001): 
Cre F: 5’-GACCGTACACCAAAATTTGCCTG-3’ 
Cre R: 5’-TTACGTATATCCTGGCAGCGATC-3’ 
SMAC animals were identified by the presence of a 465bp Cre product, and control 












Figure 2.1 DelI genotyping 
DelI animals have two copies of the Del allele shown in (a), in which exon three has been 
completely excised using the Cre-lox system. Control animals have two copies of the floxed 
allele shown in (b), whereby exon three is present but is flanked by two lox-P sites (red 


































Figure 2.2 PCR gels for selection of DelI and control mice 
Identification of a DelI animal (1 in the gels above) was confirmed by the presence of a 
363bp product from the Del PCR (a), and no product on the Flox PCR (b). A control animal 
(2 in the gels above) was identified by the presence of a 1066bp product from the Del PCR, 
and a 255bp product from the Flox PCR. DNA from known DelI and control animals were 
used for controls. This was to aid the identification of animals of as-yet-unknown genotype 












































































































Figure 2.3 PCR gels for selection of SMAC and control mice 
SMAC mice were identified by the presence of a 465bp Cre product (animals 2 and 4) and 
control animals were identified by its absence (animals 1 and 3). DNA from known SMAC 
and Cre
-
 mice were used as controls. 
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Each reaction mix consisted of 1.3 μl extracted DNA, 2 μl 2.5 μM dNTPs (Promega), 
1 μl 10 pmol/μl forward primer (Flox F or Del F for DelI, Cre F for SMAC), 1 μl 10 
pmol/μl reverse primer (Flox R for DelI, Cre R for SMAC), 0.2 μl Taq DNA 
Polymerase (Invitrogen), 2.25 μl MgCl2, 2.5 μl buffer and 14.75 μl deionised water 
(dH2O). PCR was initiated with a 95 
o
C denaturing step for 10 min followed by 35 
cycles of 30 s at 95 
o
C to denature the DNA, 30 s at 60 
o
C to allow primer annealing 
and 1 min 30 s at 72 
o
C to allow primer extension. The reaction mixtures were then 
heated to 72 
o
C for a further 10 min to allow further extension before being held at 4 
o
C to stop the reaction. 5 μl loading dye was added to each PCR product and 10 μl of 
each product was run on a 1.5 % agarose gel with a 1 kb DNA ladder (New England 
Biolabs), a blank (where 1.3 μl Tris-EDTA (TE) buffer was substituted into the 
reaction mixture instead of DNA), a known wild-type sample and a known knock-out 
sample (obtained from Janet Man). For the DelI animals, this was performed twice; 
one reaction mix contained Flox F and Flox R primers, and the second contained Del 
F and Flox R primers. GelRed (Biotium) was used to visualise the gels in a 
Transilluminator Box to allow identification of wild-type, heterozygous and knock-
out animals. DelI genotyping was performed with help from Kieran McGregor. 
Controls for the floxed mice were not used, and investigation into whether cardiac 
function is altered by insertion of the Cre recombinase was not performed and are 
limitations of the study. This should be investigated in future experiments. 
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2.2 In vivo techniques 
2.2.1 Tail plethysmography 
Blood pressure (BP) was measured by tail cuff plethysmography (Shesely, et al., 
1996) in mice at 12 weeks of age. Calibration of the device was performed by 
Christopher Kenyon. Tail cuff measurement involves the mouse being placed in a 
restrainer and a pulse sensor attached to the tail. The cuff is gradually inflated until 
the pulse stops, indicating the pressure is above systolic BP. The point at which the 
pulse stops is recorded as systolic BP. In order to obtain as accurate a measure of 
systolic BP as possible, mice were preconditioned to the technique for 4 d and BP 
measurement was recorded on the fifth day. Preconditioning was performed as 
follows: mice were placed in a heat box at 38 
o
C for 5 min then restrained in the 
restraining tube for 6-8 min, at the same time of day, for 4 d. Whilst restrained, the 
tail cuff was placed on the mouse’s tail and inflated to 60 mmHg for 5 min. 
Preconditioning was deemed to have been achieved when systolic BP recordings 
were similar on consecutive days and the mice walked into the restraining chamber 
of their own accord, showing no visible signs of stress. On the day of recording the 
mice were weighed, placed in the heat box and restrained before four separate 
measurements of systolic BP were taken. Replicates were averaged and accepted 
providing standard deviation of the values was <3mmHg. The mean of these four 




Echocardiography was performed using a Vevo 770 High Resolution Ultrasound 
Scanner (Visualsonics). Two dimensional echocardiography is based on the 
measurement of the reflection of ultrasound waves, emitted from the end of a probe. 
These waves reflect back on to the probe differently at different tissue boundaries 
due to the change in tissue density. Thus, images based on tissue density can be 
acquired and analysed. Mice were weighed and anaesthesia was induced with 2 % 
isoflurane. The chest was shaved and the mouse was placed in a supine position on a 
heated table to maintain body temperature at 37 
o
C. Temperature was continuously 
monitored by a rectal thermometer. The electrocardiogram was monitored by taping 
the limbs of the mouse down onto contact points on the table, which ensured 
scanning was performed with the heart rate in a range of 500-550 bpm. The 
ultrasound transducer, operating at a frequency of 45 MHz, was placed parasternally 
in order to obtain 2D images of the heart. Long axis views of the heart in ECG-Gated 
Kilohertz Visualisation (EKV) mode (Figure 2.4a) and M-mode (Figure 2.4b) were 
acquired. Mitral valve pulsed-wave Doppler ultrasound (Figure 2.4c) was performed 
to measure blood flow across the mitral valve. B-mode images were also acquired in 
the long axis and the short axis should further analysis be required at a later stage. 
All scanning was performed by Adrian Thomson, Edinburgh Preclinical Imaging. 
Vevo Image Analysis Software (Visualsonics) was used to measure several 
parameters. From the EKV images, cardiac output (CO), stroke volume (SV), 
ejection fraction (EF), left ventricular end diastolic area (LVEDA) and left 
ventricular end systolic area (LVESA) were calculated. Fractional shortening (FS) 
was calculated from M-mode. From the mitral valve pulsed-wave Doppler 
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ultrasound, peak E wave velocity, peak A wave velocity, E/A wave ratio, E wave 
deceleration, and E wave deceleration time were measured. Table 2.1 lists the 
formulae used to calculate parameters derived from the raw measurements. 
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Table 2.1 Ultrasound parameter formulae 
Stroke volume (SV) was calculated by subtracting the end systolic left ventricular volume 
(LV vol;s) from the end diastolic left ventricular volume (LV vol;d). Cardiac output (CO) 
was calculated by multiplying heart rate (HR) by stroke volume (SV). Ejection fraction (EF) 
was calculated by dividing SV LV vol;d and multiplying by 100. Fractional shortening (FS) 
was calculated by subtracting the end systolic left ventricular inner diameter (LVID;s) from 
the end diastolic left ventricular inner diameter (LVID;d) and dividing that by LVID;d then 





















Figure 2.4 Echocardiography traces 
An example EKV-mode image showing the LV endocardial trace (a), an example M-mode 
image showing the LV inner diameters during systole and diastole (b) and an example 
Doppler image (c) showing the E and A waves and measurements of E wave deceleration 







2.2.3 Coronary artery ligation surgery 
Coronary artery ligation surgery was performed using the method described in 
McSweeney et al (2010) but with modifications to the anaesthetic procedure, which 
are described by Takagawa et al (2007). This surgery aims to mimic experimentally 
what happens during MI, namely the occlusion of a coronary artery. By ligating the 
left anterior descending coronary artery in this surgery, tissue which is supplied by 
this artery will become ischaemic and allow for experimental investigation of 
infarction. 
Male mice, aged 10-12 weeks, were anaesthetised using 2 % isoflurane and 
maintained on 2 % isoflurane with oxygen throughout the surgery at a flow rate of 1 
L/min. They were intubated via the mouth for mechanical ventilation (120 
strokes/min, 200 μl stroke volume, HSE-Harvard MiniVent Ventilator) using a 20 
gauge IV cannula. Lacri-lube eye ointment (Allergan) was applied to the eyes to 
prevent dessication. Buprenorphine (0.05 mg/kg) was administered subcutaneously 
before an incision was made at the left upper thorax. The superficial pectoralis 
muscles were blunt-dissected and the chest was opened at the fourth intercostal 
space. This was held open using retractors (Mini-Goldstein, Fine Science Tools) and 
the pericardium was removed from the heart.  
The left anterior descending (LAD) coronary artery was ligated using a 6-0 prolene 
suture (Ethicon) just below the left atrium. Sham surgeries were performed by 
passing the suture underneath the LAD coronary artery, but omitting the ligation. 
The retractors were removed and the chest was closed using a 5-0 mersilk suture 
(Ethicon) ensuring no air remained in the chest cavity, thus avoiding pneumothorax. 
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The skin was closed using 9 mm autoclips (Harvard Apparatus). 1.5 ml 0.9 % sterile 
saline was administered subcutaneously to aid recovery and isoflurane was stopped. 
Mice were returned to their cages which were left on a 37 
o
C heat pad overnight. 1.5 
ml 0.9 % saline and 0.05 mg/kg buprenorphine were administered subcutaneously 24 
h after surgery, and tail blood was taken as described in Section 2.2.4 in order to 
measure plasma cardiac troponin-I levels (Section 2.6.5). 
 
2.2.4 Tail blood collection 
Tail blood was collected 24 h after surgery in order to determine plasma cardiac 
troponin-I levels (Gassenmaier, et al., 2012). Approximately 2 mm of tail was 
removed using surgical scissors and the cut tail was dipped in sodium citrate buffer 
to prevent clotting. Then, approximately 45 μl tail blood was gently milked into the 
lid of a 0.5 ml Eppendorf tube which contained 15 μl sodium citrate buffer. Once the 
blood had been collected (approximately 1 min) the end of the tail was dried using a 
sterile paper towel until bleeding ceased. The mouse was then placed back in its 
cage. 
The blood sample was temporarily stored at 4 
o
C (approximately 10 min) before 
being centrifuged (3,000 G for 5 min) and the supernatant collected and stored at       
-80
o 






2.2.5 CINE magnetic resonance imaging 
Eight weeks after coronary artery ligation surgery, cardiac structure, function and 
infarct size were measured using CINE magnetic resonance imaging (MRI) 
(Marshall, et al., 2013). The basis of MRI revolves around the manipulation of 
protons. Present throughout every tissue, protons are subject to magnetic fields and 
will either align in parallel or anti-parallel with a magnetic field. During MRI image 
acquisition, a magnetic field is applied to the mouse followed by radiofrequency 
(RF) pulses which aim to disturb these protons by the transfer of energy. The time 
taken to ‘relax’ back to their original state is dependent upon the molecule they are 
present in. As such, different tissues will ‘relax’ at different rates allowing images to 
be constructed based on their relative relaxation times. 
Mice were anaesthetised using isoflurane and maintained on 1.5 % isoflurane with 
oxygen throughout the procedure. Respiration rate was maintained at 50-60 
breaths/min using a pressure pad. Needle electrodes (Small Animal Instruments Inc.) 
placed subdermally either side of the heart allowed monitoring of the heart rate from 
ECG traces. Temperature was also monitored via a rectal thermometer and 
maintained at 37 
o
C using an adjustable hot air blower. 
Animals were placed, in a supine position, inside a 7T MRI scanner (Agilent 
Technologies) with a 39 mm quadrature coil. ECG-gating and respiratory-gating 
were used to synchronise images. The short axis of the heart was identified by 
performing several ‘scout’ scans, and short axis cardiac images were acquired using 
a gradient echo ‘CINE’ sequence (TR/TE = 7.3/2.7 ms with a flip angle of 15
o
) with 
gradient and RF spoiling. Nine consecutive 1mm thick slices from 12-13 time frames 
were acquired, which encompassed the entire heart from base to apex. The field of 
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view was 30mm with a 192 x 192 matrix and 4 averages were used. All scanning was 
performed by Maurits Jansen and Ross Lennen. 
ImageJ software (National Institutes of Health) was used to measure a number of 
parameters such as left ventricular end diastolic volume (LVEDV), left ventricular 
end systolic volume (LVESV), and ejection fraction (EF). Infarct length was 
measured by segmenting each short axis image into 20 sections. Any section which 
was thinned and akinetic or dyskinetic over the cardiac cycle was designated as 
infarcted tissue. Grey scale contrast also allowed visual confirmation of infarcted 
tissue. Infarct length was quantified by adding together the endo and epicardial 
circumference of infarcted tissue and dividing this by the sum of the total endo and 













2.3 Ex vivo techniques 
2.3.1 Perfusion fixation 
Perfusion fixation allows the morphology of blood vessel to be preserved as best as 
possible. This is because the vessels are being perfused with fixative via cannulation, 
rather than a tissue simply being submerged in fixative once it has been excised. This 
technique is of particular use when studying changes in vasculature structure and 
morphology. 
Mice culled by retrograde perfusion fixation were anaesthetised (1 mg/kg 
medetomidine and 75 mg/kg ketamine administered intraperitoneally) and an 
incision was made in the abdomen before the abdominal aorta was cannulated below 
the branch of the hepatic vein. An arterial blood sample (approximately 500 μl) was 
drawn up into a syringe containing 15 μl sodium citrate buffer before organs were 
perfused with heparinised phosphate-buffered saline (PBS, 2 min) and 10 % formalin 
in PBS (5 min) at physiological pressure (100 mmHg). Following perfusion with 10 
% formalin in PBS, the inferior vena cava was cut to release the perfusate. Perfusion 
was stopped according to time (a minimum of 5 min) and by using visual cues; 
blanching of the liver and clear fluid running from the inferior vena cava indicated 
satisfactory perfusion. Heart, spleen, aorta and liver were then harvested, placed in 
10 % formalin in PBS for 24 h and transferred to 70 % EtOH before processing and 
paraffin embedding for immunohistological analysis. The processing and paraffin 
embedding was carried out by the Histology Department (Queen’s Medical Research 
Institute, University of Edinburgh). 
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2.3.2 Blood volume 
Calculation of blood volume is performed by injecting a known quantity of dye into 
the mouse and allowing it to circulate. Once dispersed evenly, a blood sample can be 
drawn and the concentration of the dye measured. By scaling up this concentration, 
and by knowing the quantity of dye initially injected, blood volume can be 
determined. Male DelI and control mice, aged 12 weeks, were anaesthetised (1 
mg/kg medetomidine and 75 mg/kg ketamine administered intraperitoneally) and the 
jugular vein was cannulated with a 27 gauge needle. 1 μl/g of body weight Evans 
Blue stock solution (0.5 μg/ml Evans Blue in sterile 0.9 % saline) was injected into 
the jugular vein and left to circulate for 10 min. The abdominal aorta was cannulated 
during this time using a 27 gauge needle and, after 10 min had elapsed, an arterial 
blood sample (approx 500 μl) was drawn up into a heparinised blood collection tube. 
Cannulation was performed by Gill Brooker. Blood from the collection tube was 
drawn up into a capillary tube and haematocrit was measured by centrifuging the 
capillary tube (8,000 G for 5min) and determining the packed cell volume. The 
remaining blood in the collection tube was centrifuged at 3,000 G for 5min. 95 μl of 
the supernatant, which consisted of plasma and Evans Blue solution, and 95 μl of 
each Evans Blue standard (0, 0.05, 0.1, 0.2 and 0.5 μg/ml) were loaded onto a clear 
96 well plate in duplicate. Absorbance was read at 620 nm and blood volume was 
calculated using the following formulae (Greenleaf, et al., 1979; Zhang, et al., 2005): 
𝑃𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 =
𝐼𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝐸𝑣𝑎𝑛𝑠 𝐵𝑙𝑢𝑒  𝜇𝑔 
𝑝𝑙𝑎𝑠𝑚𝑎 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝜇𝑔/𝑚𝑙)
 
𝐵𝑙𝑜𝑜𝑑 𝑣𝑜𝑙𝑢𝑚𝑒 = 𝑃𝑙𝑎𝑠𝑚𝑎 𝑣𝑜𝑙𝑢𝑚𝑒 𝑥 
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2.3.3 Myocardial interstitial fluid volume 
Interstitial fluid volume can be determined by simply calculating the difference in 
heart weight immediately after excision, and once it has been thoroughly desiccated. 
Male DelI and C57BL/6 control mice, aged 12 weeks, were culled by cervical 
dislocation. Hearts were removed immediately below the thymus and massaged in 
ice cold 0.9 % saline to remove any residual blood in the atria and ventricles. The 
hearts were weighed (wet weight) and wrapped in tin foil before being placed in a 
desiccator containing silica. The hearts were weighed daily for 7 d which allowed for 
complete desiccation. The weight on the seventh and final day was taken as the ‘dry 
weight’. Heart wet weight to dry weight ratio was calculated in order to determine if 
there were differences in interstitial fluid between the two groups. 
 
2.3.4 Cardiomyocyte isolation 
The isolation of cardiomyocytes is achieved by excising the heart and perfusing it 
with several solutions using a Langendorff preparation. This preparation allows the 
heart to be artificially perfused and digested, therefore allowing individual 
cardiomyocytes to be analysed. 
Male DelI and C57BL/6 control mice, aged 12 weeks, were injected intraperitoneally 
with 200 μl heparin solution (100 units/ml in sterile 0.9 % saline). After 5 min the 
mice were culled by cervical dislocation and the heart was dissected out just below 
the thymus, ensuring approximately 5 mm of aorta remained attached to the heart. 
The heart was massaged in ice cold Krebs solution to remove any residual blood and 
then transferred to a beaker of fresh, room temperature Krebs solution. A 22 gauge 
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cannula (AD Instruments) was inserted into the aorta and the aorta was tied onto the 
cannula using 5-0 mersilk suture (Ethicon). The heart was then perfused, at a flow 
rate of 4 ml/min, with Krebs solution (40 
o
C for 2 min) before being perfused with 
collagenase solution (25 mg collagenase type 1 (Worthington Biochemical) and 2.5 
mg protease type XIV (Sigma) in 50 ml Krebs solution at 40 
o
C for 12 min). External 
Ca
2+
 concentration was zero. Visual cues were used to determine when a satisfactory 
digestion had been achieved; the heart feeling soft when squeezed gently with 
forceps, the heart appearing translucent, and the vessels being clearly visible on the 
surface of the heart. 
Once successful digestion had been achieved the heart was perfused with bovine 
serum albumin (BSA) Fraction V solution (467 mg BSA in 100 ml Krebs solution at 
40 
o
C for 5 min) before it was removed from the cannula. The aorta, atria and right 
ventricle were carefully removed using a surgical scalpel and forceps, and the 
remaining heart tissue was cut up into small pieces using surgical scissors. These 
pieces of tissue were then transferred to a 15 ml Falcon tube containing 5 ml BSA 
solution. This solution was then agitated using a sterile pastette until the solution 
became cloudy, and one drop of this solution was added to a glass slide. Isolated, 
intact cardiomyocytes were identified and their diastolic length was measured using 
Image Pro 6.2 and a Stereologer Analyser 6 (MediaCybernetics). Only cell length 
was measured due to equipment limitations. 
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2.4 Histology 
Immunohistochemical analysis is performed by excising the tissue in question, then 
dehydrating and fixing it, before microtoming it into sections and allowing it to 
adhere to a microscope slide. The purpose of this is allow a specific antibody to bind 
to its target protein in order to analyse the abundance of this protein. This is done by 
amplifying the signal from the antibody either by using fluorescent secondary and 
tertiary antibodies, or by subjecting a secondary antibody to a reactive dye. Providing 
the antibodies used are specific to the protein in question, the protein can be 
identified and quantified. Histological analysis is performed by subjecting these 
tissue sections to various solutions which will bind and/or react when they bind to a 
particular protein. 
 
2.4.1 Picrosirius Red staining 
Picrosirius Red staining was performed to calculate myocardial collagen content 
(McSweeney, et al., 2010). 4 μm thick sections of paraffin wax-embedded heart were 
cut using a microtome and transferred to glass slides. These sections were allowed to 
adhere to the slide overnight before being deparaffinised and rehydrated using xylene 
(2 x 5 min), 100 % EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH (3 min) and 
finally dH2O (30 s). The slides were submerged in Weigert’s haematoxylin (8 min), 
rinsed under running tap water (10 min) and incubated in Picrosirius Red solution 
(0.5 g Direct Red in 500 ml saturated picric acid) for 1 h. Slides were then washed 
twice in acidified water and dehydrated using 70 % EtOH (1 min), 80 % EtOH (1 
min), 95 % EtOH (1 min), 100 % EtOH (2 x 1 min) and xylene (2 x 1 min) before 
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being mounted in DPX and coverslipped. The staining was performed by the 
Histology Department (Queen’s Medical Research Institute, University of 
Edinburgh). 
Quantification was performed using Image Pro 6.2 and a Stereologer Analyser 6 
(MediaCybernetics). The entire heart section was tiled at 40 x magnification and the 
area of the left ventricle was measured. A colour threshold was set manually so as to 
only select positive pink staining (see Figure 3.18) for collagen. This was done by 
eye to ensure only appropriate, specific, positive staining was included for analysis. 
The area of this positive staining within the left ventricle was calculated 
automatically. Myocardial collagen content was then expressed as percentage of 
positive staining in the left ventricle. 
 
2.4.2 Masson’s Trichrome staining 
4 μm thick sections of paraffin wax-embedded heart were cut using a microtome and 
transferred to glass slides. These sections were taken at the level of the papillary 
muscles to ensure reproducibility, and they were allowed to adhere to the slide 
overnight before being deparaffinised and rehydrated using xylene (2 x 5 min), 100 
% EtOH (2 x 5 min), 90 % EtOH (3 min), 70% EtOH (3 min) and finally dH2O (30 
s). The slides were submerged in Weigert’s haematoxylin (10 min) and rinsed under 
warm running tap water (10 min). Slides were incubated in phosphomolybdic-
phosphotungstic acid solution until the collagen no longer appeared red 
(approximately 15 min). Slides were then incubated with aniline blue solution (10 
min), washed in distilled water and incubated with 1 % acetic acid (3 – 5 min). 
 99 
Following further washing in distilled water the slides were dehydrated using 70 % 
EtOH (1 min), 80 % EtOH (1 min), 95 % EtOH (1 min), 100 % EtOH (2 x 1 min) 
and xylene (2 x 1 min) before being mounted in DPX and coverslipped. This staining 
was performed by the Histology Department (Queen’s Medical Research Institute, 
University of Edinburgh). 
Quantification was performed using Image Pro 6.2 and a Stereologer Analyser 6 
(MediaCybernetics). The entire heart section was tiled at 40 x magnification and the 
area of the left ventricle was measured. Collagen and scar tissue were stained blue, 
muscle and cytoplasm were stained pink and nuclei were stained black thus 
providing clear delineation of infarcted and non-infarcted tissue (Harada, et al., 
2005). The infarcted area (blue, see Figure 4.5) was drawn around manually and 
expressed as a percentage of the total area of the left ventricle. Infarct thickness was 
determined by averaging scar thickness from five equally-spaced points along the 







Figure 2.5 Infarct size and thickness analysis 
Infarct size (a) was calculated by manually drawing round the infarcted area (red line) and 
expressing this as a percentage of the total area of the left ventricle. Infarct thickness (b) was 
calculated by averaging scar thickness (red lines) from five equally-spaced points along the 





2.5.1 Vessel density 
Vessel density was assessed using the method described by Meloni et al (2010). 
Isolectin B4 detects endothelial cells and α-SMA detects smooth muscle cells. 4 μm 
thick sections of paraffin wax-embedded heart were cut in the short axis using a 
microtome and transferred to glass slides. These sections were taken at the level of 
the papillary muscles in all hearts to ensure reproducibility. The sections were 
allowed to adhere to the slide overnight before being deparaffinised and rehydrated 
using xylene (2 x 5 min), 100 % EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH 
(3 min) and finally dH2O (30 s). Antigen retrieval was performed by submerging 
slides in 10 mM sodium citrate buffer, pH 6 and boiling in a microwave (3 x 4 min). 
After allowing the slides to cool to room temperature, they were washed in dH2O (3 
min) and PBS (3 min). A blocking step was performed using 10 % goat serum in 
PBS (1 h at room temperature). Slides were incubated overnight in a dark, 
humidified chamber at 4 
o
C with primary antibodies for isolectin B4 (1:100 
biotinylated isolectin B4 (Invitrogen)) and α-smooth muscle actin α-SMA (1:400 α-
SMA-Cy3 (Sigma)) diluted in 1 % goat serum in PBS. Slides were then washed in 
PBS (2 x 3 min) and incubated in a dark, humidified chamber with the secondary 
antibody for isolectin B4 (1:100 streptavidin-Alexa 488 diluted in PBS (Invitrogen)) 
for 1 h at room temperature. Slides were washed again in PBS (2 x 3 min) and 
counterstained with DAPI (1 min (Sigma)) diluted 1:1000 in PBS. After washing 
with PBS (4 x 3 min), slides were mounted using Fluoromount G (Southern Biotech) 
and coverslipped. 
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Five randomly selected regions of interest were visualised in the left ventricular free 
wall using a 40 x objective on a Nikon E800 Microscope. Adobe Photoshop CS5 










arterioles (4 – 200 μm diameter) and large arterioles (>200 μm diameter) present per 
mm
2
 in the left ventricular wall (see Figure. 3.11). 
 
2.5.1.1 Post-MI angiogenesis 
CD31, also known as PECAM-1, is a marker of endothelial cells and can be detected 
by immunohistochemistry to quantify peri-infarct angiogenesis in the heart after MI 
(Ismail, et al., 2003; McSweeney, et al., 2010). 
4 μm sections of paraffin wax-embedded heart were cut using a microtome and 
transferred to glass slides. These sections were allowed to adhere to the glass slides 
overnight before being deparaffinised and rehydrated using xylene (2 x 5 min), 100 
% EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH (3 min) and finally dH2O (30 
s). Antigen retrieval was performed by submerging slides in 10 mM sodium citrate 
buffer, pH 6 and boiling in a microwave (3 x 4 min). After allowing the slides to cool 
to room temperature, they were washed in dH2O (3 min) and PBS (3 min). 
Endogenous peroxidase activity was quenched by submerging the slides in 3 % H2O2 
for 10 min at room temperature. The slides were then washed in PBS (2 x 5 min) and 
a blocking step was performed using 10 % goat serum in 5 % BSA in PBS (30 min at 
room temperature). Two drops of Avidin Block (Vector) were added to each section 
and incubated for 15 min at room temperature, then the slides were washed in PBS (3 
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x 5 min). Two drops of Biotin Block (Vector) were added to each section and 
incubated for 15 min at room temperature, then the slides were again washed in PBS 
(3 x 5 min). Slides were incubated overnight in a humidified chamber at 4 
o
C with 
the primary antibody for CD31 (1:50 rabbit anti-mouse CD31 (Abcam) in PBS). 
Slides were then washed in PBS (2 x 3 min) and incubated in a dark, humidified 
chamber for 90 min at room temperature with the secondary antibody (1:200 
biotinylated goat anti-rabbit (Vector) in PBS). Two drops of RTU ABC Reagent 
(Vector) were added to each section and incubated for 30 min at room temperature 
before being washing in PBS (2 x 3 min). DAB solution (Vector) was made up 
immediately prior to using it. 80 μl of DAB solution was added to each section and 
the slides were observed for the development of brown staining. 
Once established, the reaction was stopped by washing the slides in PBS (3 x 3 min). 
Slides were then counterstained using tap water (10 s), Mayer’s haematoxylin (30 s), 
tap water (10 s), acid alcohol (5 s), tap water (10 s) and finally Scott’s tap water (20 
s). Slides were then dehydrated using 70 % EtOH (1 min), 90 % EtOH (1 min), 100 
% EtOH (2 x 1 min) and finally xylene (2 x 1 min) before being mounted in DPX 
(Sigma) and coverslipped. 
Quantification of peri-infarct angiogenesis was performed using Image Pro 6.2 and a 
Stereologer Analyser 6 (MediaCybernetics). Using a 40 x objective, 20 randomly 
assigned fields of view, which consisted of 50 % to 75 % infarct, were analysed. The 
number of CD31
+
 vessels were measured and categorised according to size; 
capillaries (<4 μm diameter), small arterioles (4 – 200 μm diameter) and large 
arterioles (>200 μm diameter). Each category was then expressed as number of peri-




2.5.2 Cardiomyocyte cross-sectional area 
Cardiomyocyte cross-sectional area can be calculated by immunohistochemical 
staining of heart sections with wheat germ agglutinin (Schultz, et al., 2002). 4 μm 
thick sections of paraffin wax-embedded heart were cut using a microtome and 
transferred to glass slides. These sections were taken at the level of the papillary 
muscles in all hearts to ensure reproducibility, and were allowed to adhere to the 
slide overnight before being deparaffinised and rehydrated using xylene (2 x 5 min), 
100 % EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH (3 min) and finally dH2O 
(30 s). Antigen retrieval was performed by submerging slides in 10 mM sodium 
citrate buffer, pH 6 and boiling in a microwave (3 x 4 min). After allowing the slides 
to cool to room temperature, they were washed in dH2O (3 min) and PBS (3 min). A 
blocking step was performed using 10 % goat serum in PBS (1 h at room 
temperature). Slides were incubated overnight in a humidified chamber at 4 
o
C with 
the primary antibody for isolectin B4 (1:100 biotinylated isolectin B4 (Invitrogen)) 
diluted in 1 % goat serum in PBS. Slides were then washed in PBS (2 x 3 min) and 
incubated in a dark, humidified chamber for 90 min at room temperature with the 
antibody for wheat germ agglutinin (1:75 wheat germ agglutinin-rhodamine 
(Vector)) and the secondary antibody for isolectin B4 (1:100 streptavidin-Alexa 488 
(Invitrogen)) diluted in PBS. Slides were washed again in PBS (2x3min) and 
counterstained with DAPI (1min (Sigma)) diluted 1:1000 in PBS. After washing with 
PBS (4 x 3 min), slides were mounted using Floromount G (Southern Biotech) and 
coverslipped. 
Five randomly selected regions of interest were visualised in the left ventricular free 
wall using a 40 x objective on a Nikon E800 Microscope. Adobe Photoshop CS5 
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Extended (Adobe) was used to calculate cardiomyocyte cross-sectional area in 
cardiomyocytes which a) appeared to be cut in the short axis, b) had a nucleus in the 
middle of the cell and, c) were surrounded by capillaries which were also cut in the 
short axis (see Figure 3.10). 
 
2.5.3 Macrophage quantification 
Mac2 (galectin-3) is expressed and secreted by activated macrophages and can be 
detected by immunohistochemistry to quantify macrophage infiltration into the heart 
after MI (MacKinnon, et al., 2008; McSweeney, et al., 2010). 
4 μm sections of paraffin wax-embedded heart were cut using a microtome and 
transferred to glass slides. These sections were allowed to adhere to the glass slides 
overnight before being deparaffinised and rehydrated using xylene (2 x 5 min), 100 
% EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH (3 min) and finally dH2O (30 
s). Antigen retrieval was performed by submerging slides in 10 mM sodium citrate 
buffer, pH 6 and boiling in a microwave (3 x 4 min). After allowing the slides to cool 
to room temperature, they were washed in dH2O (3 min) and PBS (3 min). 
Endogenous peroxidase activity was quenched by submerging the slides in 3 % H2O2 
for 10 min at room temperature. The slides were then washed in PBS (2 x 5 min) and 
a blocking step was performed using 10 % goat serum in 5 % BSA in PBS (30 min at 
room temperature). Two drops of Avidin Block (Vector) were added to each section 
and incubated for 15 min at room temperature, then the slides were washed in PBS (3 
x 5 min). Two drops of Biotin Block (Vector) were added to each section and 
incubated for 15 min at room temperature, then the slides were again washed in PBS 
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(3 x 5 min). Slides were incubated overnight in a humidified chamber at 4 
o
C with 
the primary antibody for mac2 (1:200 anti-mac2 FITC (Cedarlane) in PBS). 
Slides were then washed in PBS (2 x 3 min) and incubated in a dark, humidified 
chamber for 90 min at room temperature with the secondary antibody (1:4,000 rabbit 
anti-FITC (Vector) in PBS). Slides were washed again in PBS (2 x 3 min) and 
incubated with the biotinylated tertiary antibody (1:200 biotinylated goat anti-rabbit 
(Vector) in PBS) for 40 min at room temperature. Two drops of RTU ABC Reagent 
(Vector) were added to each section and incubated for 30 min at room temperature 
before being washed in PBS (2 x 3 min). DAB solution (Vector) was made up 
immediately prior to using it. 80 μl of DAB solution was added to each section and 
the slides were observed for the development of brown staining. 
Once established, the reaction was stopped by washing the slides in PBS (3 x 3 min). 
Slides were then counterstained using tap water (10 s), Mayer’s haematoxylin (30 s), 
tap water (10 s), acid alcohol (5 s), tap water (10 s) and finally Scott’s tap water (20 
s). Slides were then dehydrated using 70 % EtOH (1 min), 90 % EtOH (1 min), 100 
% EtOH (2 x 1 min) and finally xylene (2 x 1 min) before being mounted in DPX 
(Sigma) and coverslipped. Antibody concentrations were optimised by performing 
titration experiments. 
Quantification was performed using Image Pro 6.2 and a Stereologer Analyser 6 
(MediaCybernetics). The entire heart section was tiled at 40 x magnification and the 
area of the infarct was measured. A colour threshold was set manually so as to only 
select positive brown staining for Mac2 and the area of this positive staining within 
the infarct was calculated automatically. Total macrophage infiltration was then 
expressed as the percentage area of positive brown DAB staining within the infarct. 
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2.5.4 Alternatively-activated macrophage identification 
Ym1 is a marker of alternatively activated macrophages and can be detected by 
immunohistochemistry to quantify these macrophages in the heart after MI (Loke, et 
al., 2002; McSweeney, et al., 2010). 
4 μm sections of paraffin wax-embedded heart were cut using a microtome and 
transferred to glass slides. These sections were allowed to adhere to the glass slides 
overnight before being deparaffinised and rehydrated using xylene (2 x 5 min), 100 
% EtOH (2 x 5 min), 90 % EtOH (3 min), 70 % EtOH (3 min) and finally dH2O (30 
s). Antigen retrieval was performed by submerging slides in 10 mM sodium citrate 
buffer, pH 6 and boiling in a microwave (3 x 4 min). After allowing the slides to cool 
to room temperature, they were washed in dH2O (3 min) and PBS (3 min). 
Endogenous peroxidase activity was quenched by submerging the slides in 3 % H2O2 
for 10 min at room temperature. The slides were then washed in PBS (2 x 5 min) and 
a blocking step was performed using 10 % goat serum in 5 % BSA in PBS (30 min at 
room temperature). Two drops of Avidin Block (Vector) were added to each section 
and incubated for 15 min at room temperature, then the slides were washed in PBS (3 
x 5 min). Two drops of Biotin Block (Vector) were added to each section and 
incubated for 15 min at room temperature, then the slides were again washed in PBS 
(3 x 5 min). Slides were incubated overnight in a humidified chamber at 4 
o
C with 
the primary antibody for Ym1 (1:500 anti-Ym1 FITC (Stem Cell Technologies) in 
PBS). 
Slides were then washed in PBS (2 x 3 min) and incubated in a dark, humidified 
chamber for 90 min at room temperature with the secondary antibody (1:4,000 rabbit 
anti-FITC (Vector) in PBS). Slides were washed again in PBS (2 x 3 min) and 
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incubated with the biotinylated tertiary antibody (1:200 biotinylated goat anti-rabbit 
(Vector) in PBS) for 40 min at room temperature. Two drops of RTU ABC Reagent 
(Vector) were added to each section and incubated for 30 min at room temperature 
before being washed in PBS (2 x 3 min). DAB solution (Vector) was made up 
immediately prior to using it. 80 μl of DAB solution was added to each section and 
the slides were observed for the development of brown staining. 
Once established, the reaction was stopped by washing the slides in PBS (3 x 3 min). 
Slides were then counterstained using tap water (10 s), Mayer’s haematoxylin (30 s), 
tap water (10 s), acid alcohol (5 s), tap water (10 s) and finally Scott’s tap water (20 
s). Slides were then dehydrated using 70 % EtOH (1 min), 90 % EtOH (1 min), 100 
% EtOH (2 x 1 min) and finally xylene (2 x 1 min) before being mounted in DPX 
(Sigma) and coverslipped. 
Quantification was performed using Image Pro 6.2 and a Stereologer Analyser 6 
(MediaCybernetics). The entire heart section was tiled at 40 x magnification and the 
area of the infarct was measured. A colour threshold was set manually so as to only 
select positive brown staining for Ym1 and the area of this positive staining within 
the infarct was calculated automatically. Alternatively-activated macrophage 
infiltration was then expressed as the percentage area of positive brown DAB 
staining within the infarct. 
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2.6 Molecular techniques 
qRT-PCR is a technique used to amplify and determine the relative concentration of 
one target gene mRNA in one tissue compared to another. Essentially, mRNA is 
extracted from a tissue, reverse transcribed to complimentary DNA (cDNA) before 
primers specific to one gene amplify the gene of interest. The rate of amplification 
then allows the relative abundance of this gene to be determined, meaning 
differences in gene expression between mice of different genotypes/treatments can 
be investigated. 
 
2.6.1 RNA extraction 
Mice were killed by cervical dislocation and tissues were harvested, rinsed in ice 
cold sterile PBS, rapidly frozen on dry ice and stored at -80 
o
C until required for 
RNA extraction. RNA extraction and isolation was performed using a Trizol Plus 
RNA Purification Kit (Invitrogen). 
Approximately 30 – 40 mg of each left ventricular tissue sample and 400 µl Trizol 
(Invitrogen) were added to a 2 ml RNase-free tube and homogenised using a 
homogeniser. Another 100 µl of Trizol was added to give a final volume of 500 µl 
and the samples were left to incubate at room temperature for 5 min. The 
homogeniser was cleaned between samples using dH2O and 10 % H2O2. 200 µl 
chloroform was added to each tube and the samples were shaken vigorously by hand 
for 15 s before being incubated at room temperature for 2 min. They were then 
centrifuged at 12,000 G for 15 min at 4 
o
C. After centrifugation the mixture had 3 
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distinct layers; a colourless upper phase containing the RNA, an interphase 
containing protein, and a lower red-phenol phase. The colourless upper phase was 
transferred to a fresh RNase-free tube and an equal volume of 70 % EtOH was added 
before the tubes were vortexed. 
500 µl of this mixture was added to an RNA spin cartridge, which was centrifuged at 
12,000 G for 15 min. The flow-through was discarded and 700 µl Wash Buffer I was 
added before the spin cartridge was centrifuged at 12,000 G for 15 s. The collection 
tube was discarded and replaced then 500 µl Wash Buffer II was added before the 
spin cartridge was again centrifuged at 12,000 G for 15 s. The flow-through was 
discarded and the spin cartridge centrifuged at 12,000 G for 1 min to remove any 
remaining buffer. The RNA spin cartridge was then placed in a clean RNA recovery 
tube. 30 µl RNase-free water was added to the spin cartridge and incubated for 1 min 
at room temperature before being centrifuged at 12,000 G for 2 min to elute the 
RNA. 
RNA concentration and the A260/A280 ratio was determined for each sample using a 
Nanodrop 1000 Version 3.3 (Thermo Scientific). In order to remove genomic DNA, 
each sample was DNase I treated with a Deoxyribonuclease I Amplification Kit 
(Invitrogen). The sample volume which corresponded to 1 µg RNA was added to a 
0.2 µl RNase-free PCR tube along with 1 μl 10 x DNase I Reaction Buffer, 1 μl 
DNase I, and made up to a total volume of 10 μl with RNase-free H2O. The samples 
were incubated for 15 min at room temperature before 1 μl 25 mM EDTA was added 
to activate the DNase I. The samples were then heated to 65 
o
C for 10 min before 
being reverse transcribed to cDNA. 
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2.6.2 cDNA synthesis 
To reverse transcribe the RNA to cDNA, two mastermixes were prepared using a 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems); one for an 
internal control gene, and one for the gene of interest. Each reaction consisted of 2 μl 
10 X RT Buffer, 0.8 μl 25 X dNTP Mix (100 mM), 2 μl 10 X Random Primers, 1 μl 
Multiscribe RT, 1 μl RNase Inhibitor and 3.2 μl RNase free water and was scaled up 
as appropriate, depending on the number of samples being analysed. One sample was 
chosen at random to serve as the RT- control; this reaction consisted of 2 μl 10 X RT 
Buffer, 0.8 μl 25 X dNTP Mix (100 mM), 2 μl 10 X Random Primers, 1 μl RNase 
Inhibitor and 4.2 μl RNase free water. 10 μl of the mastermix was added to each 
sample RNA from above to give a final volume of 20 μl. cDNA synthesis was 
performed in a thermal cycler using the following conditions; 25 
o
C for 10 min, 48 
o
C for 40 min, 95 
o
C for 5 min, then cooled to 4 
o
C. Once cooled, the cDNA was 
stored at -20 
o
C until required for qRT-PCR. 
 
2.6.3 qRT-PCR 
11β-HSD1 mRNA levels were investigated using Taqman Gene Expression Assays. 
Taqman mastermixes (Applied Biosystems) were made for 11β-HSD1 and an 
internal control gene (β-actin or TBP) and consisted of 5 μl Taqman Fast Advanced 
MM, 0.5 μl Taqman Gene Expression Assay and 3.5 μl RNase-free water. This was 
scaled up as appropriate depending on the number of samples analysed. 9 μl of the 
mastermix was transferred to each well on a 384 well plate. Standards were made by 
pooling 2 μl from each cDNA sample and making serial dilutions of 1/5, 1/10, 1/20, 
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1/40, 1/80, 1/160 and 1/320 in RNase-free water. 1 μl of each standard was added to 
the plate in triplicate and 1 μl water was added to the end of the standard curve as a 
blank control. An aliquot of sample cDNA (at a dilution of 1/10 for liver samples, 
1/5 for heart and skeletal muscle samples and 1/2 for aorta samples) was made, and 1 
μl was added to the plate in triplicate. The plate was sealed using a plastic cover, 
turned upside down to mix the contents then centrifuged at 1,500 G for 2 min to 
ensure all the mixture was at the bottom of the wells. 
All other genes were investigated using the Universal Probe Library System (Roche). 
Roche Probe Mastermixes (Roche) were made for each gene and consisted of 2.7 μl 
Lightcycler H2O, 5 μl Roche Probe Mastermix, 0.1 μl forward primer (Invitrogen), 
0.1 μl reverse primer (Invitrogen) and 0.1 μl UPL Probe. This was scaled up as 
appropriate depending on the number of samples analysed. 8 μl of the mastermix was 
transferred to each well on a 384 well plate. Standards were made by pooling 2 μl 
from each cDNA sample and making serial dilutions of 1/5, 1/10, 1/20, 1/40, 1/80, 
1/160 and 1/320 in RNase-free water. 2 μl of each standard was added to the plate in 
triplicate and 2 μl water was added to the end of the standard curve as a blank 
control. An aliquot of sample cDNA (at a dilution of 1/5 for heart samples) was 
made, and 1 μl was added to the plate in triplicate. The plate was sealed using a 
plastic cover, turned upside down to mix the contents then centrifuged at 1,500 G for 
2 min to ensure all the mixture was at the bottom of the wells. 
qRT-PCR to assess mRNA levels of target genes and housekeeping genes was 
performed using a Lightcycler 480 System (Roche) and the Taqman Fast Advanced 
template or the Roche Fam Hydrolysis (Roche) template as appropriate. Standard 
curves were used to determine mRNA levels of the housekeeping genes and the 
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target genes. Target gene mRNA levels were normalised to housekeeping gene 
mRNA levels, which was similar in all samples. Triplicate values for qRT-PCR were 
averages and accepted providing the standard deviation of the crossing point (Cp) 
values were <0.5 cycles. Table 2.2 shows the Taqman Gene Expression Assays 
(Applied Biosystems) and Table 2.3 shows the custom primers (Invitrogen) used for 
the genes analysed.  
 114 
 
Gene (Protein) Taqman Gene Expression Assay Amplicon Length 
Hsd11b1 (11β-HSD1) Mm00476182_m1 67 
Actb (β-actin) Mm00525061_m1 118 
Tbp (TBP) Mm00446971_m1 93 
Table 2.2 Taqman Gene Expression Assay codes for qRT-PCR 
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 Primer Sequence 5’-3’  
Gene (Protein) Forward Reverse Design 
Nr3c1 (GR) caaagattgcaggtatcctatgaa cttggctcttcagaccttcc E R-Z 
Nr3c2 (MR) ccctaccatgtcctagaaaagc agaacgctccaaggtctgag E R-Z 
Fkbp5 (FKBP5) aaacgaaggagcaacggtaa tcaaatgtccttccaccaca E R-Z 
Tsc22d3 (GILZ) tccgttaaactggataacagtgc tggttcttcacgaggtccat E R-Z 
Ppargc1 (PGC1α) gaaagggccaaacagagaga gtaaatcacacggcgctctt E R-Z 
Sgk1 (SGK) tttccaaagggggatgct tgttggcatgattacattgttct E R-Z 
Tgfb1 (TGFβ) tggagcaacatgtggaactc cagcagccggttaccaag R R 
Col1α2 (Col1α2) gcaggttcacctactctgtcct cttgccccattcatttgtct R R 
Col3α1 (Col3α1) tcccctggaatctgtgaatc tgagtcgaattggggagaat R R 
Atp2a2 (SERCA) tcgaccagtcaattcttacagg cagggacagggtcagtatgc E R-Z 
Slc8a1 (NCX) gtcagccttcagagctggtc gacttccaactgctccaacc E R-Z 
Ryr2 (RyR) ttcaacacgctcacggagta tgccaggctctgctgatt E R-Z 
Cacna1c (CaV1.2) cctgcacaagggctctttc agatgagggacacgctaacc R R 
Myh6 (αMHC) cgcatcaaggagctcacc cctgcagccgcattaagt E R-Z 
Myh7 (βMHC) gcatctggaaattccgttagg ggctcgtcatccttattagacc E R-Z 
Nppa (ANP) cacagatctgatggatttcaaga cctcatcttctaccggcatc E R-Z 
Actb (β-actin) ctaaggccaaccgtgaaaag accagaggcatacagggaca E R-Z 
Table 2.3 Primer sequences for qRT-PCR 
Primer sequences for qRT-PCR. ‘E R-Z’ denotes primers designed by Eva Rog-Zielinska 
and ‘R R’ denotes primers designed by Rachel Richardson. 
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2.6.4 Western blotting 
Western blotting involves the extraction of proteins from a tissue sample and further 
separation on an agarose gel via gel electrophoresis before transferring these 
separated proteins onto a membrane. This membrane is then subjected to a primary 
antibody specific to a particular protein and, once further subjected to a fluorescent 
secondary antibody which amplifies the signal of the primary antibody, it is then 
developed onto x-ray film. Determination of protein density from each sample allows 
for differences in protein levels to be elucidated. 
11β-HSD1 protein expression was examined by Western blot in the heart and liver to 
check for appropriate deletion of the enzyme. 50 mg of tissue and 300 µl lysis buffer 
(5 ml stock solution consisting of 500 µl 10 X radio-immunoprecipitation assay 
(RIPA) buffer (Sigma), 50 µl Protease Inhibitor Cocktail (Sigma), 50 µl Phosphatase 
Inhibitor Cocktail P1 (Sigma), 50 µl Phosphatase Inhibitor Cocktail P2 (Sigma) and 
4350 µl water) were placed in a 1.5 ml Eppendorf and homogenised using a 
homogeniser. This was then centrifuged at 12,000 G for 15 min at 4 
o
C and the 
supernatant, containing the protein, was transferred to a fresh 1.5 ml tube. Protein 
concentration was determined using a Pierce BCA Protein Assay Kit (Thermo 
Scientific). Albumin (BSA) standards at concentrations of 25, 125, 250, 500, 750, 
1,000, 1,500 and 2,000 µg/ml were prepared and 20 µl of each was added to a 96 
well plate in replicate. Aliquots of protein lysate were diluted 1/10 with RIPA buffer 
and 20 µl of each were also added to the 96 well plate in replicate. The bicinchoninic 
acid (BCA) working reagent was prepared by mixing Reagent A with Reagent B at a 
ratio of 50:1. 200 µl was then added to each well of the 96 well plate. The plate was 
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incubated for 30 min in the dark at 37 
o
C, allowed to cool to room temperature and 
the optical density was read at 562 nm to determine protein concentration. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate the proteins in the lysate. The top 2 cm of the gel consisted of a 5 % SDS 
stacking gel (1.7 ml 30 % acrylamide, 2.5 ml 0.5 M Tris, 100 µl 10 % SDS, 100 µl 
10 % ammonium persulfate (APS), 30 µl tetramethylethylenediamine (TEMED) and 
5.6 ml water) and the remaining 8 cm consisted of an SDS running gel (12.7 % for 
11β-HSD1 (12.7 ml 30 % acrylamide, 7.5 ml 1.5 M Tris, 300 µl 10 % SDS, 300 µl 
10 % APS, 30 µl TEMED and 9.2 ml water), 9.2 % for SERCA (9.2 ml 30 % 
acrylamide, 7.5 ml 1.5 M Tris, 300 µl 10 % SDS, 300 µl 10 % APS, 30 µl TEMED 
and 12.7 ml water) and 13.1 % for phospholamban (PLN) (13.1 ml 30 % acrylamide, 
7.5 ml 1.5 M Tris, 300 µl 10 % SDS, 300 µl 10 % APS, 30 µl TEMED and 8.8 ml 
water)). TEMED was added last as this causes the gel to set. The protein lysates were 
aliquoted at a concentration of 2 µg/µl using RIPA buffer; 10 µl of this (20 µg 
protein) was added to a 1.5 ml Eppendorf, along with 1.67 µl 6 x sample buffer. 20 
µl ColorPlus Prestained Protein Marker Broad Range (7-175kDa) (New England 
Biolabs) was also added to a 1.5 ml Eppendorf and this, and the protein samples, 
were incubated at 95 
o
C for 5 min before being centrifuged at 12,000 G for 1 min. 10 
µl of the protein samples and 20 µl of the marker were loaded onto the gel and 10 µl 
RIPA buffer was added at the end as a blank control. The gel was run at 80 V for 15 
min then 120 V for 1 h in running buffer (12.11 g Tris, 57.65 g glycine and 2 g SDS 
in 2 L dH2O, stored at 4 
o
C). 
The gel was then placed in transfer buffer (2.93 g glycine, 5.81 g Tris, 0.375 g SDS, 
200 ml methanol and 800 ml water) and the stacking gel was carefully removed. 
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Amersham Hybond ECL nitrocellulose membrane (GE Healthcare) and extra thick 
blot paper (Bio-Rad) were trimmed to the same size as the gel and also placed in 
transfer buffer. These were then placed on a Trans-Blot Semi Dry Transfer Cell (Bio-
Rad) in the following order: blot paper, then nitrocellulose membrane, then the gel, 
and finally another sheet of blot paper. Bubbles between the layers were removed by 
gently pressing the top sheet of blot paper. The appropriate mA for transferring the 
proteins from the gel to the nitrocellulose membrane was calculated using the 
following equation: 
𝑚𝐴 = 𝐺𝑒𝑙 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎  𝑐𝑚2 𝑥 0.8 
 
As all the gels were 40 cm
2
, they were all transferred using 32 mA for 90 min. The 
nitrocellulose membrane was removed and placed in 0.1 % Tris-buffered 
saline/Tween 20 (TBST) (100 ml TBS 10 X, 900 ml water and 1 ml Tween 20) for 
10 min. The gel was then transferred to a 50 ml Falcon tube and 10 ml 5 % blocking 
buffer (100 ml TBST and 5 g powdered milk (Marvel)) was added. The tube was 
placed on a roller for 1 h at room temperature before the gel was washed in TBST for 
5 min. The primary antibody, diluted in 5 % BSA in water, was added to the tube and 
incubated on a roller overnight at 4 
o
C. 
The membrane was then washed with TBST (3 x 15 min) and the secondary 
antibody, diluted in 5 % BSA in water, was added. The tube was placed on the roller 
for 1 h at room temperature and again washed (3 x 15 min) with TBST. The 
membrane was blocked using blocking buffer and the primary internal control 
antibody, diluted in 5 % BSA in water, was added to the tube and incubated on the 
roller for 45 min at room temperature. The membrane was then washed with TBST 
(3 x 15 min) and the secondary internal control antibody, diluted in 5 % BSA in 
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water, was added. The tube was again placed on the roller and incubated for 45 min 
at room temperature, before being developed using an ECL Prime Western Blotting 
Detection Reagent (GE Healthcare). The membrane was wrapped in cling film and 
placed in a cassette. 1 ml of Reagent A was mixed with 1 ml of Reagent B in a 2 ml 
Eppendorf tube. This solution was then added to the membrane and incubated for 1 
min at room temperature. The membrane was the exposed to X-ray film before being 
developed. Target protein levels were then calculated by normalising the density of 
this band to that of the housekeeping protein. Table 2.4 lists all the primary and 
secondary antibodies used for western blotting in this project. 
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Protein Primary antibody Secondary antibody 
11β-HSD1 Anti- 11β-HSD1 (in-house (De 
Sousa Peixoto, et al., 2008)) 
Raised in sheep 
1/10,000 
Anti-sheep-HRP (Abcam) 
Raised in donkey 
1/5,000 
SERCA Anti-SERCA2A (Thermo 
Scientific) 
Raised in rabbit 
1/5,000 
Anti-rabbit-HRP (Abcam) 
Raised in goat 
1/5,000 
PLN Anti-PLN (Badrilla) 
Raised in mouse 
1/5,000 
Anti-mouse-HRP (Abcam) 







Raised in rabbit 
1/5,000 
Anti-rabbit-HRP (Abcam) 







Raised in rabbit 
1/5,000 
Anti-rabbit-HRP (Abcam) 
Raised in goat 
1/5,000 
β-actin Anti-β-actin (Sigma) 
Raised in mouse 
1/10,000 
Anti-mouse-HRP (Abcam) 
Raised in rabbit 
1/5,000 
α-tubulin Anti-α-tubulin (Sigma) 
Raised in mouse 
1/10,000 
Anti-mouse-HRP (Abcam) 
Raised in rabbit 
1/5,000 
Table 2.4 List of Western blot antibodies and dilutions 
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2.6.5 Cardiac troponin-I assay 
Cardiac Troponin-I (cTnI) is released by cardiomyocytes in response to injury and is 
used as a clinical tool for diagnosing acute MI (Gassenmaier, et al., 2012). Plasma 
levels of cardiac troponin-I were measured using a High Sensitivity Mouse Cardiac 
Troponin-I ELISA Kit (Life Diagnostics). Troponin standards were prepared at 
concentrations of 10, 5, 2.5, 1.25, 0.625, 0.312, 0.156 and 0 ng/ml. Sample plasma 
was diluted four fold with plasma diluent. 100 μl of cTnI HRP Conjugate and 100 μl 
of diluted plasma were added in replicate to the anti-cTnI coated wells on the 96 well 
plate. The plate was incubated on an orbital shaker at 100 G for 60 min at room 
temperature then the wells were emptied and washed six times with 1 X wash 
solution. The wells were again emptied ensuring no residual mixture remained before 
100 μl TMB Reagent was added to each well and incubated on an orbital shaker at 
100 G for 20 min at room temperature. 100 μl Stop Solution was added to each well 
and the plate was gently agitated ensuring all the blue colour in the wells changed to 
yellow. Absorbance was read at 450 nm to determine troponin-I concentration using 
the linear line standard curve constructed using the troponin standards detailed 
above. This assay was performed by Kieran McGregor. 
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2.7  Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5.00 (GraphPad Software) 
with data presented as the mean ± standard error of the mean. Statistical significance 
was reached with a p value of less than 0.05.  
Mortality data was compared using Fisher’s exact test and chi square test, and 
cardiomyocyte cross-sectional area distribution data was compared using a 
Kolmogorov-Smirnov test. 
Other statistical comparisons were performed using one way ANOVAs and two way 
ANOVAs, both with Bonferroni’s post-hoc test, and two-tailed unpaired Student’s t 




Rabbit anti-mouse-CD31 primary antibody, anti-sheep-HRP secondary antibody, 
anti-rabbit-HRP secondary antibody, anti-mouse-HRP secondary antibody 
 
AD Instruments 
22 gauge cannulae 
 
Adobe 
Adobe Photoshop CS5 Extended 
 
Agilent Technologies 
7T MRI Scanner 
 
Allergan 
Lacri-lube eye ointment 
 
Applied Biosystems 
High Capacity cDNA Reverse Transcription Kit, Taqman Mastermix, Taqman Gene 
Expression Assays (Mm00476182_m1, Mm00525061_m1, Mm00446971_m1) 
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Badrilla 
Anti-PLN primary antibody, anti-PLN-serine16 primary antibody, anti-PLN-
threonine17 primary antibody 
 
Bio-Rad 
















Drug Discovery Core, QMRI, University of Edinburgh 
Anti-11β-HSD1 primary antibody 
 
Ethicon 
6-0 prolene suture, 5-0 mersilk suture 
 




15ml Falcon tubes, 50ml Falcon tubes 
 
GE Healthcare 
Amersham Hybond ECL, ECL Prime Western Blot Detection Reagent 
 
GraphPad Software 
GraphPad Prism 5.00 
 
Harvard Apparatus 
HSE-Harvard MiniVent ventilator, 9mm autoclips 
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Invitrogen 
PCR primers (DelI and SMAC), qRT-PCR primers (GR, MR, FKBP5, SGK, GILZ, 
PGC1α, TGFβ, Col1α2, Col3α1, SERCA, NCX, RyR, CaV1.2, αMHC, βMHC, ANP 
and β-actin) Taq DNA Polymerase, biotinylated anti-isolectin B4 primary antibody, 
streptavidin-Alexa 488 secondary antibody, DAPI, Trizol Plus RNA Purification Kit, 
Trizol, Deoxyribonuclease I Amplification Kit 
 
Life Diagnostics 






Image Pro 6.2 
 
National Institutes of Health 
ImageJ Software 
 
New England Biolabs 












Lightcycler 480, Universal Probe Library System 
 
Sigma-Aldrich 
Sodium citrate tribasic dihydrate, hydrochloric acid, magnesium chloride, agarose, 
PBS tablets, formalin, ethanol, Krebs solution, protease type XIV, bovine serum 
albumin, anti-αSMA-Cy3 primary antibody, hydrogen peroxide, DPX mounting 
media, RIPA buffer, protease inhibitor cocktail, phosphatise inhibitor cocktail, Tris 
base, acrylamide, SDS, APS, TEMED, clear 96 well plates, glycine, TBS, Tween 20, 










Stem Cell Technologies 
Anti-Ym1-FITC primary antibody 
 
Thermo Scientific 




Goat serum, donkey serum, rabbit serum, WGA-Rhodamine primary antibody, 
avidin block, biotin block, rabbit anti-FITC secondary antibody, DAB solution, 
biotinylated goat anti-rabbit secondary antibody, RTU ABC Reagent 
 
Visulasonics 








Dissolve 6.95 g NaCl, 0.19 g KCl, 0.14 g NaH2PO4 (monobasic), 0.37 g 
CaCl2.2H2O, 0.26 g MgCl2.6H2O, 4.77 g HEPES and 1.98 g D-glucose in 1 L dH2O. 
 
PBS solution 
Dissolve 5 tablets in 1 L of dH2O. 
 
Sodium citrate buffer (10mM) 
Add 2.94 g sodium citrate tribasic dehydrate to 1 L dH2O and adjust to pH 6 using 
concentrated hydrochloric acid. 
 
TE buffer 
Make a 1 M Tris solution by dissolving 60.57 g Tris in 500 ml dH2O. Make a 0.5 M 
ethylenediamine tetraacetic acid (EDTA) solution by dissolving 18.6 g EDTA in 100 
ml dH2O and adjust to pH 8 using concentrated sodium hydroxide (NaOH). To make 
a 1 X TE buffer solution, dilute 5 ml 1 M Tris solution and 1 ml 0.5 M EDTA 





Make a 0.5 M EDTA solution by dissolving 93.05 g EDTA in 500 ml dH2O and 
adjust to pH 8 using concentrated NaOH. Make a TBE 5 X stock solution by adding 
54 g Tris base and 27.5 g boric acid in 980 ml dH2O and then add 20 ml of 0.5 M 
EDTA solution. To make a 0.5 X TBE solution, dilute 100 ml of 5 X TBE solution in 
900 ml dH2O. 
 
TBST solution 
Make a TBS 10 X stock solution by dissolving 24.2 g Tris base and 80 g NaCL in 1 




Basal Characterisation of Global and 
Cardiovascular-specific 11β-HSD1 Knock-out Mice 
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3.1 Introduction 
Intracellular pre-receptor metabolism by the two isozymes of the enzyme 11β-HSD 
controls the local bioavailability of glucocorticoids for binding to GR and MR 
(Zhang, et al., 2005). 11β-HSD type 1 regenerates glucocorticoids, converting 
inactive cortisone (11-dehydrocorticosterone in rodents) to its active form cortisol 
(corticosterone in rodents). 11β-HSD type 2 catalyses the reverse reaction, 
essentially inactivating glucocorticoids in the cytosol and preventing them from 
binding to GR or MR (Zhang, et al., 2005). 
In the cardiovascular system, glucocorticoids are involved in maintaining blood 
pressure and vascular tone (see Section 1.1.4.1) (Ullian, 1999; Hadoke, et al., 2006; 
Goodwin, et al., 2011). Glucocorticoids have been implicated in vascular 
remodelling using the 11β-HSD1 deficient mouse, which is unable to regenerate 
glucocorticoids intracellularly. 11β-HSD1 deficient mice show increased 
angiogenesis in vivo in response to implantation of subcutaneous sponges and in 
aortic ring preparations in vitro (Small, et al., 2005). Furthermore, 11β-HSD1 
deficiency results in increased angiogenesis in vivo in the peri-infarct region of the 
heart 7d after MI (Small, et al., 2005; McSweeney, et al., 2010). There is some 
debate as to whether 11β-HSD2 is present in the vasculature, however 11β-HSD2 
KO mice exhibit altered vascular function suggesting a functional role for 11β-HSD2 
in this tissue (Hadoke, et al., 2001). There is no evidence for 11β-HSD2 in 
cardiomyocytes. Approximately 50% of 11β-HSD2 KO mice die within 48h of birth, 
with survivors displaying renal hypertrophy, hypokalaemia and hypertension, in 
addition to the impaired vascular function mentioned above (Kotelevtsev, et al., 
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1999). Human mutations in the 11β-HSD2 gene can lead to the Syndrome of 
Apparent Mineralocorticoid Excess (SAME), characterised by high blood pressure 
(Draper & Stewart, 2005). 
11β-HSD1 deficient mice have reduced heart size and weight but the mechanism for 
this remains unknown (McSweeney, et al., 2010). Systolic function appears to be 
maintained but diastolic function and calcium regulation have not been studied. 
Moreover, a single nucleotide polymorphism in the Hsd11b1 gene, which encodes 
the 11β-HSD1 protein, has been associated with reduced left ventricular mass in a 
human population study (Rahman, et al., 2011). Further work using the GR knock-
out (KO) mouse has shown a crucial role for glucocorticoids in heart maturation. GR 
KO mice die at birth due to underdeveloped lungs (Cole, et al., 1995), however a 
number of these mice die prenatally prior to lung function being required. It is 
suggested that this is due to diastolic dysfunction, disorganised myofibrils within 
cardiomyocytes, and impaired calcium-induced calcium release (Rog-Zielinska, et 
al., 2013). GR overexpression studies have also shown the importance of 
glucocorticoids in maintaining cardiac homeostasis with tissue-specific myocardial 
overexpression of GR contributing to bradycardia, atrio-ventricular block, and 
altered calcium cycling (Sainte-Marie, et al., 2007). 
The importance of 11β-HSD1 in regulating cardiovascular function has led to the 
generation of a cardiovascular-specific 11β-HSD1 KO mouse in order to differentiate 





 (SMAC) mice have ‘floxed’ 11β-HSD1 alleles and a Cre 
recombinase transgene inserted into the Sm22α gene. Sm22α is a cytoskeletal protein 
expressed exclusively in cardiomyocytes during development and in smooth muscle 
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cells post-natally (Lees-Miller, et al., 1987; Li, et al., 1996). In tissues where Sm22α 
is expressed, Cre recombinase will also be expressed and will cut at the loxP sites 
flanking exon 3 on the ‘floxed’ 11β-HSD1 alleles. This excision removes exon three 
which contains the binding site for the co-factor NADPH, and thus renders the 
enzyme non-functional in these cells. However, to date there has been no 
characterisation of ‘cardiovascular’ 11β-HSD1 deletion in these mouse strains. 
Comparison of SMAC mice and their Cre
-
 controls with global 11β-HSD1 KO (DelI) 
mice and their controls (C57BL/6 mice) will allow the role of cardiovascular 11β-
HSD1 to be investigated. The aims of this chapter were to a) determine the 
distribution of 11β-HSD1 in the heart and vasculature, b) confirm global deletion in 
DelI mice and cardiovascular-specific deletion in SMAC mice, c) investigate the 
cardiovascular phenotype of mice with global and cardiovascular-specific 11β-HSD1 
deletion, and d) determine whether any phenotype could be reproduced by chronic 
pharmacological inhibition of 11β-HSD1. It was hypothesised that SMAC mice will 
show tissue specific deletion of 11β-HSD1 only in the heart and vasculature and that 
their basal cardiac phenotype will mimic that of the DelI mice; they will have 
reduced heart size and weight and their systolic function will be preserved. 
Considering the previous literature showing the importance of GR-mediated 
glucocorticoid action on subcellular cardiomyocyte structure and function, it is also 
hypothesised that these mice will have altered calcium regulation and impaired 
diastolic function. Furthermore, it was hypothesised that chronic pharmacological 





Three groups of male experimental mice, aged 6w-78w, were used; global 11β-





 mice; SMAC) and C57BL/6SJL mice which had UE2316, a 
selective 11β-HSD1 inhibitor, introduced in to their diet at 9 months of age, and 
delivered for a further 9 months. Each mouse received approximately 20mg of drug 
per kg of bodyweight. In livers collected, 11β-HSD1 activity was reduced to 44.2 ± 
13.7 % of control, as measured by thin layer chromatography (Liu, et al., 2008). 
These mice were part of an aging study being conducted by another group in the 
laboratory, whereby the end point was 78 weeks (18months). The opportunity arose 
to investigate their heart function, and thus they were included in this thesis. 
Treatment and 11β-HSD1 activity assay were performed by Karen Sooy. Controls 







) littermate mice and controls for the UE2316-treated 
mice were vehicle-treated C57BL/6SJL mice. 
Echocardiography (Section 2.2.2) was performed at time points detailed in Section 
3.2.6, and blood pressure was measured by tail plethysmography in DelI and SMAC 
mice, and their respective controls, at 10 weeks of age (Section 2.2.1). Mice were 
culled either by cervical dislocation or perfusion fixation (Section 2.3.1). Cervical 
dislocation was performed in order to harvest tissue for qRT-PCR and western 
blotting, for tissue gravimetrics, for myocardial interstitial fluid volume assessment 
(Section 2.2.3), for cardiomyocyte length measurement (Section 2.3.4) or after blood 
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volume measurement (Section 2.3.2). Perfusion fixation was performed in order to 
harvest tissue for immunohistochemistry and histology. 
 
3.2.2 Genotyping 
DNA was extracted from ear notches obtained at weaning, and PCR was performed 
to identify DelI mice and SMAC mice and their Cre
-




RNA was extracted from homogenised heart, aorta, liver and skeletal muscle tissue 
using TRIzol as described in Section 2.6.1. cDNA was synthesized as detailed in 
Section 2.6.2 and qRT-PCR was performed as described in Section 2.6.3 to assess 
mRNA levels of 11β-HSD1, GR, MR, FKBP5, GILZ, PGC1α, SGK, TGFβ, Col1α2, 
Col3α1, SERCA, NCX, RyR, CaV1.2, β-actin and TBP. 
 
3.2.4 Western blotting 
Protein was extracted from homogenised heart, aorta, liver, and skeletal muscle 
samples, ran on a gel and transferred to a nitrocellulose membrane as described in 
Section 2.6.4. The membranes were exposed to antibodies for 11β-HSD1, 
sarcoplasmic reticulum Ca
2+
 ATPase (SERCA), phospholamban (PLN), 
phosphorylation of PLN at serine 16 (Ser16) or threonine 17 (Thr17), and the 
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internal control proteins β-actin or α-tubulin before being developed on x-ray film as 
detailed in Section 2.6.4. 
 
3.2.5 Echocardiography 
High frequency echocardiography was performed on DelI and C57BL/6 control mice 
at 6, 10 and 78 weeks (18 months) of age, on SMAC and Cre- control mice at 6, 10, 
20 and 35 weeks of age and on UE2316-treated and vehicle-treated control mice at 
78 weeks (18 months) of age as described in Section 2.2.2. Scanning was performed 
by Adrian Thomson. 
 
3.2.6 Histology and immunohistochemistry 
Heart sections, 4μm thick, were used for histology and immunohistochemistry. 
Picrosirius Red staining was used to determine collagen content. Immunofluorescent 
staining with wheat germ agglutinin, isolectin B4 and DAPI and was used to measure 
cardiomyocyte cross-sectional area. Vessel density was determined by 
immunofluorescent staining with α-SMA, isolectin B4 and DAPI. Full details are 
given in Sections 2.4.2, 2.5.1 and 2.5.2. 
 
3.2.7 Statistical analysis 
All values are expressed as mean ± SEM. Statistical significance was reached with a 
p value of less than 0.05. Longitudinal echocardiography data was compared using a 
two way ANOVA with Bonferroni’s post-hoc test. Cardiomyocyte cross-sectional 
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area distribution data was compared using a Kolmogorov-Smirnov test. All other 
data were compared using two-tailed unpaired Student’s t tests. 
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3.3 Results 
3.3.1 Confirmation of global and cardiovascular-specific 11β-HSD1 deletion in 
DelI and SMAC mice, respectively 
11β-HSD1 mRNA was present in heart (Figure 3.1a and b), aorta (Figure 3.1c and 
d), liver (Figure 3.1e and f) and skeletal muscle (SkM; Figure 3.1g and h) tissue of 
C57BL/6 and Cre
-
 mice aged 12 weeks. Twelve week old DelI mice showed a 
reduction of 11β-HSD1 (Hsd11b1) mRNA compared to control in heart (p<0.001), 
aorta (p<0.001), liver (p<0.001) and SkM (p<0.001). Twelve week old SMAC mice 
exhibited a reduction of 11β-HSD1 mRNA in heart (p<0.01) and aorta (p<0.01) only. 
11β-HSD1 mRNA was normalised to internal control genes which were β-actin 
(Actb) for heart, aorta and liver tissue and TBP (Tbp) for SkM, which were similar in 
all groups (see Appendix 1). 
11β-HSD1 protein (Figure 3.2 and Figure 3.3) was detected at the expected sizes of 
32kDa and 34kDa, reflecting the non-glycosylated and glycosylated isoforms, 
respectively (Blum, et al., 2000; Gupta, et al., 2003). 11β-HSD1 protein expression 
was reduced in DelI heart (p<0.001), aorta (p<0.001), liver (p<0.001) and SkM 
(p<0.001) compared to C57BL/6 control mice. SMAC mice also displayed reduced 
11β-HSD1 protein expression in heart (p<0.001) and aorta (p<0.001) compared to 
Cre
-
 control mice, but expression in liver and SkM was comparable. 11β-HSD1 
protein was normalised to internal control proteins which were either β-actin for 
heart, aorta and liver tissue or α-tubulin for SkM, which were similar in all groups 
(see Appendix 2). 
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Figure 3.1 Confirmation of global 11β-HSD1 deletion in DelI mice and cardiovascular-
specific 11β-HSD1 deletion in SMAC mice by qRT-PCR 
mRNA levels of 11β-HSD1 were determined by qRT-PCR in DelI (left column) and SMAC 
(right column) mice and their respective controls at 12w of age. Heart (a & b), aorta (c & d), 
liver (e & f) and skeletal muscle (g & h) were investigated. 11β-HSD1 mRNA levels were 
normalised to β-actin, the internal control, which was similar in all groups (see Appendix 1). 
11β-HSD1 mRNA levels in the control groups were set to 100% and mRNA levels in DelI 
and SMAC mouse hearts were expressed as a percentage of this (Student’s t test *** = 


































































































































































































Figure 3.2 Sample 11β-HSD1 Western blots 
Sample 11β-HSD1 Western blots of (a) heart, (b) aorta, (c) liver and (d) skeletal muscle 
tissue from DelI, SMAC, C57BL/6 and Cre
-





























































































































Figure 3.3 11β-HSD1 Western blotting 
11β-HSD1 protein expression was assessed by Western blotting in DelI (left column) and 
SMAC (right column) mice and their respective controls at 12w of age. Heart (a & b), aorta 
(c & d), liver (e & f) and skeletal muscle (g & h) were investigated. 11β-HSD1 protein levels 
were normalised to the internal control (β-actin for heart, aorta and liver, or TBP for SkM) 
which was similar in all groups. 11β-HSD1 protein levels in the control groups were set to 
100% and protein levels in DelI and SMAC tissue were expressed as a percentage of this 



















































































































































































3.3.2 Expression of myocardial GR, MR and their target genes does not 
change with 11β-HSD1 deletion 
Myocardial GR (Nr3c1, Figure 3.4a and b), MR (Nr3c2, Figure 3.4c and d), FKBP5 
(Fkbp5, Figure 3.5a and b), GILZ (Tsc22d3, Figure 3.5c and d), PGC1α (Ppargc1a, 
Figure 3.5e and f) and SGK (Sgk1, Figure 3.5g and h) mRNA levels were similar in 
all genotypes. Target gene mRNA was normalised to β-actin (Actb), an internal 
control gene, which was similar in all groups (see Appendix 1). 
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Figure 3.4 11β-HSD1 deletion does not change levels of GR or MR mRNA 
mRNA levels of GR (a & b) and MR (c & d) were determined by qRT-PCR in hearts from 
DelI (left column) and SMAC (right column) mice and their respective controls at 12w of 
age. GR and MR mRNA levels were normalised to β-actin, the internal control, which was 
similar in all groups. GR and MR mRNA levels in the control groups were set to 100% and 
mRNA levels in DelI and SMAC mouse hearts were expressed as a percentage of this 


































































































Figure 3.5 11β-HSD1 deletion does not alter levels of GR or MR target gene mRNA 
mRNA levels of FKBP5 (a & b), GILZ (c & d), PGC1α (e & f) and SGK (g & h) were 
determined by qRT-PCR in hearts from DelI (left column) and SMAC (right column) mice 
and their respective controls at 12w of age. Target gene mRNA levels were normalised to β-
actin, the internal control, which was similar in all groups. Target gene mRNA levels in the 
control groups were set to 100% and mRNA levels in DelI and SMAC mouse hearts were 














































































































































































3.3.3 Systolic blood pressure is unaffected by global or cardiovascular-specific 
11β-HSD1 deletion 
Systolic blood pressure was similar between DelI and C57BL/6 control mice (Figure 
3.6a) and between SMAC and Cre
-
 control mice (Figure 3.6b). 
 
3.3.4 Ventricular growth is delayed in mice with global, but not 
cardiovascular-specific 11β-HSD1 deletion 
3.3.4.1 Echocardiography 
DelI mice had reduced left ventricular end diastolic area (LVEDA, p<0.05) and 
stroke volume (SV, p<0.001) compared to C57BL/6 control mice at 10 weeks of age, 
but not at 6 weeks or 78 weeks of age (Figure 3.7a and c). These observations were 
not seen in SMAC mice at any time point up to 35 weeks of age (Figure 3.7b and d). 
LVESA in DelI and SMAC mice was not different to their respective controls at any 
time point (Figure 3.7e and f). 
 
3.3.4.2 Gravimetrics 
Post-mortem data showed 12 week old DelI mice had reduced heart weights 
compared to C57BL/6 control mice (Figure 3.8a, p<0.01), despite both genotypes 
having similar body weights (Figure 3.8c). This resulted in a reduced heart weight to 
body weight ratio (Figure 3.8e, p<0.01). SMAC and Cre
-
 control mice had similar 
heart weights (Figure 3.8b) and body weights (Figure 3.8d) at 12 weeks of age, and 
















Figure 3.6 11β-HSD1 deletion does not affect systolic blood pressure 
Systolic blood pressure was measured by tail plethysmography and heart rate was measured 
by high frequency ultrasound in DelI (a and c) and SMAC (b and d) mice and their 
respective controls at 12w of age (Student’s t test; n=6/group). 


























































































































Figure 3.7 Global, but not cardiovascular-specific, 11β-HSD1 deletion delays left 
ventricular growth 
LVEDA (a & b), SV (c & d), and LVESA (e & f) were assessed by high frequency 
ultrasound in DelI mice (left column, dashed lines) and C57BL/6 controls (left column, solid 
lines), and SMAC mice (right column, dashed lines) and Cre
-
 controls (right column, solid 
lines) at 6, 10, 20, 35 and 78w of age (two way ANOVA *** = p<0.001, * = p<0.05; 

























































































































































Figure 3.8 Global, but not cardiovascular-specific, 11β-HSD1 deletion reduces heart 
weight 
Heart weight as measured by gravimetrics at post-mortem (a & b), body weight (c & d) and 
heart weight to body weight ratio (e & f) of DelI (left column) and SMAC (right column) 
mice and their respective controls at 12w of age (Student’s t test ** = p<0.01; n=8/group for 





































































































































3.3.4.3 Alteration in blood and interstitial fluid volume does not account for 
smaller, lighter left ventricles in mice with global 11β-HSD1 deletion 
Blood volume was similar in DelI and C57BL/6 mice (Figure 3.9a). Heart wet 
weight (Figure 3.9b, p<0.01) and dry weight (Figure 3.9c, p<0.01) were both reduced 
in DelI mice compared to C57BL/6 controls, giving both genotypes a similar heart 
wet weight to dry weight ratio (Figure 3.9d). 
 
3.3.4.4 Cardiomyocyte length, but not cross-sectional area, is reduced in hearts 
from mice with global 11β-HSD1 deletion 
Cardiomyocyte cross-sectional area in the left ventricular wall (Figure 3.10a) was 
similar in DelI and C57BL/6 mice (Figure 3.10b) and in SMAC and Cre
-
 mice 
(Figure 3.10c) at 12 weeks of age. Cardiomyocyte cross-sectional area distribution 
demonstrated a similar distribution pattern between DelI and C57BL/6 mice (Figure 
3.10d). 
Cardiomyocytes, freshly isolated from the hearts of DelI mice, were significantly 













Figure 3.9 Blood volume and interstitial fluid volume are unchanged in DelI mice 
Blood volume (a), heart wet weight (b), dry weight (c) and wet weight to dry weight ratio (d) 










































































































Figure 3.10 Cardiomyocyte cross-sectional area is unaltered in DelI mice, but 
cardiomyocyte length is reduced 
Cardiomyocyte cross sectional area was assessed by staining for isolectin B4, WGA and 
DAPI (a) in DelI mice (b) and SMAC mice (c) and their respective controls at 12w of age 
(Student’s t test; n=5/group). Isolectin B4 stains endothelial cells, WGA stains cell 
membranes and DAPI stains nuclei. This allowed cardiomyocyte cross-sectional area 
measurement by selecting cardiomyocytes which a) appeared to be cut in the short axis, b) 
had a nucleus in the middle of the cell and c) were surrounded by capillaries which were also 
cut in the short axis. The frequency of cross-sectional area distribution in DelI mice (red 
line) and C57BL/6 controls (black line) is shown in (d) (Kolmogorov-Smirnov test; 
n=5/group). The length of freshly isolated cardiomyocytes, using a Langendorff preparation, 
from hearts of DelI and control mice at 12w of age is shown in (e) (Student’s t test *** = 
p<0.001; n=3/group). Scale bar is 20μm. 
CM CSA Distribution





























































































































3.3.4.5 Myocardial vessel density is unchanged in mice with global and 
cardiovascular-specific 11β-HSD1 deletion 










arterioles (4-200μm diameter; Figure 3.11d and e) and large arterioles (>200μm 
diameter; Figure 3.11f and g) per 400μm
2
 in the left ventricular wall was similar in 
























Figure 3.11 Myocardial vessel density is not influenced by 11β-HSD1 deletion 
Myocardial vessel density was assessed by staining for isolectin B4, α-SMA and DAPI (a) in 
DelI mice (b, d & f) and SMAC mice (c, e & g) and their respective controls at 12w of age. 
Isolectin B4 stains endothelial cells, α-SMA stains smooth muscle cells and DAPI stains 









small (4-200μm diameter) and large arterioles (>200μm diameter) present per mm
2
 in 
the left ventricular wall was calculated. (Student’s t test; n=6/group for DelI & SMAC mice, 




















































































































































































Isolectin B4 α-SMA DAPI Merged
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3.3.4.6 Chronic pharmacological inhibition of 11βHSD1 tends to increase, 
rather than decrease, heart dimensions and weight in aged mice 
C57BL/6SJL mice which had UE2316, a selective 11β-HSD1 inhibitor, introduced 
into their diet for 9 months had a trend for increased left ventricular end diastolic 
areas (Figure 3.12a; p=0.18) and left ventricular systolic areas (Figure 3.12b; p=0.12) 
at 18 months of age. This was despite body weights being similar between the two 
groups (Figure 3.12c). Post-mortem gravimetrics revealed that mice treated with 
UE2316 had significantly heavier hearts (Figure 3.12d, p<0.01) and, therefore, an 
increased heart weight to body weight ratio (Figure 3.12e, p<0.05). Cardiomyocyte 
cross-sectional area was also similar between the two groups (Figure 3.13). 
Measurements of food intake showed each mouse received approximately 20mg of 
drug per kg of bodyweight. In livers collected, 11β-HSD1 activity was reduced to 
44.2 ± 13.7 % of control, as measured by thin layer chromatography. Treatment and 






















Figure 3.12 Chronic 11β-HSD1 inhibition increases heart weight 
LVEDA (a) and LVESA (b) were assessed by high frequency ultrasound in 18 month old 
mice treated with UE2316 (20mg/kg) in their diet for 9 months (chequered bars) and vehicle 
treated mice (filled bars) At post-mortem, body weight (c) and heart weight (d) were 
measured by gravimetrics, and heart weight to body weight ratio (e) was calculated 






















































































































Figure 3.13 Chronic 11β-HSD1 inhibition does not alter cardiomyocyte cross-sectional 
area 
Cardiomyocyte cross sectional area was assessed by staining for isolectin B4, WGA and 
DAPI in 18 month old mice treated with UE2316 (20mg/kg) in their diet for 9 months 
(chequered bars) and vehicle treated mice (filled bars). Isolectin B4 stains endothelial cells, 
WGA stains cell membranes and DAPI stains nuclei. This allowed cardiomyocyte cross-
sectional area measurement by selecting cardiomyocytes which a) appeared to be cut in the 
short axis, b) had a nucleus in the middle of the cell and c) were surrounded by capillaries 







































3.3.5 11β-HSD1 deletion and chronic inhibition influences diastolic, but not 
systolic, function 
3.3.5.1 Systolic function is unaffected by 11β-HSD1 deletion or inhibition 
Ejection fraction (Figure 3.14a and b) and fractional shortening (Figure 3.14c and d) 
were similar in DelI and C57BL/6 control mice and in SMAC and Cre
-
 control mice 
at all time points investigated. Reduced heart size and weight observed in DelI mice 
had a direct impact on stroke volume and therefore cardiac output, which was 
significantly reduced compared to C57BL/6 mice (Figure 3.14e, p<0.001). Cardiac 
output was similar in SMAC and Cre
-
 controls (Figure 3.14f). Heart rate was similar 
between all groups. 
UE2316-treated mice showed similar systolic function compared to vehicle-treated 
mice (Figure 3.15a-c). 
 
3.3.5.2 Mild diastolic dysfunction is evident in mice with global 11β-HSD1 
deletion and is reproduced in mice with cardiovascular-specific 11β-HSD1 
deletion, and following chronic 11β-HSD1 inhibition 
There was no change in E wave to A wave ratio in DelI mice or SMAC mice 
compared to their respective controls (Figure 3.16a and b). However, reduced E 
wave deceleration was seen in DelI mice (Figure 3.16c, p<0.05) and SMAC mice 
(Figure 3.16d, p<0.05, p<0.01 and p<0.001), and a corresponding increase in mitral 
valve deceleration time (MV DT) was observed in both DelI mice (Figure 3.16e, 
p<0.01 and p<0.001) and SMAC mice (Figure 3.16f, p<0.05, p<0.01 and p<0.001) 
compared to their respective controls.  
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A similar phenotype was observed in UE2316-treated mice, with these mice also 
displaying a similar E wave to A wave ratio to vehicle-treated control mice (Figure 
3.17a) but a reduced E wave deceleration (Figure 3.17b, p<0.05) and increased MV 
DT (Figure 3.17c, p<0.05). 
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Figure 3.14 Systolic function is unaltered after 11β-HSD1 deletion 
EF (a and b), FS (c and d) and CO (e and f) were assessed by high frequency ultrasound in 
DelI mice (left column, dashed lines) and SMAC mice (right column, dashed lines) and their 
respective controls (solid lines) at 6, 10, 20, 35 and 78 weeks of age (two way ANOVA, *** 





















































































































































































Figure 3.15 Chronic 11β-HSD1 inhibition does not influence systolic function 
EF (a), FS (b) and CO (c) were assessed by high frequency ultrasound in 18 month old mice 
treated with UE2316 (20mg/kg) in their diet for 9 months (chequered bars) and vehicle-



































































































Figure 3.16 Global and cardiovascular-specific 11β-HSD1 deletion leads to mild 
diastolic dysfunction 
E to A wave ratio (a and b), E wave deceleration (c and d) and MV DT (e and f) were 
assessed by Doppler ultrasound across the mitral valve in DelI (left column, dashed lines) 
and SMAC mice (right column, dashed lines) and their respective controls (solid lines) at 6, 
10, 20 and 35 weeks of age (two way ANOVA *** = p<0.001, ** = p<0.01, * = p<0.05; 































































































































































Figure 3.17 Chronic 11β-HSD1 inhibition leads to mild diastolic dysfunction 
E to A wave ratio (a), E wave deceleration (b) and MV DT (c) were assessed by Doppler 
ultrasound across the mitral valve in 18 month old mice treated with UE2316 (20mg/kg) in 
their diet for 9 months (chequered bars) and vehicle-treated controls (filled bars) (Student’s t 

































































3.3.5.3 Alteration in myocardial collagen content does not account for diastolic 
dysfunction in mice with 11β-HSD1 deletion or inhibition 
Collagen content (Figure 3.18a) was similar in DelI, SMAC and UE2316-treated 
mice compared to their respective controls (Figure 3.18b-d). 
Furthermore, myocardial mRNA levels of the alpha 2 subunit of type 1 collagen 
(Col1α2, Figure 3.19a and b), the alpha 1 subunit of type 3 collagen (Col3α1, Figure 
3.19c and d) and transforming growth factor β (Tgfb1, Figure 3.19e and f) were 
similar in 12w old DelI and C57BL/6 hearts, and in 12w old SMAC and Cre
-
 hearts. 
β-actin, the internal control, was similar in all groups (see Appendix 1). 
mRNA levels of Tgfb1, Col1α2 and Col3α1 in 18 month old UE2316-treated and 















Figure 3.18 Myocardial collagen content is unaltered by 11β-HSD1 deletion or chronic 
11β-HSD1 inhibition 
Myocardial collagen content was assessed by Picrosirius Red staining (a) of DelI (b), SMAC 
(c) and UE2316-treated heart sections (d) and their respective controls at 12w of age 























































































Figure 3.19 Fibrotic gene mRNA levels are unaltered by 11β-HSD1 deletion 
mRNA levels of Col1α2 (a & b), Col3α1(c & d) and TGFβ (e & f) were determined by qRT-
PCR in hearts from DelI (left column) and SMAC (right column) mice and their respective 
controls at 12w of age. Target gene mRNA levels were normalised to β-actin, the internal 
control, which was similar in all groups. Target gene mRNA levels in the control groups 
were set to 100% and mRNA levels in DelI and SMAC mouse hearts were expressed as a 








































































































































Figure 3.20 Fibrotic gene mRNA levels are unaltered after 11β-HSD1 inhibition 
mRNA levels of Col1α2 (a), Col3α1(b) and TGFβ (c) were determined by qRT-PCR in 
hearts from 18 month old mice treated with UE2316 (20mg/kg) in their diet for 9 months 
(chequered bars) and vehicle-treated controls (filled bars). Target gene mRNA levels were 
normalised to β-actin, the internal control, which was similar in all groups. Target gene 
mRNA levels in the vehicle-treated groups were set to 100% and mRNA levels in UE2316-































































3.3.5.4 Alteration in expression of calcium handling genes is evident in mice with 
global 11β-HSD1 deletion, and is reproduced in mice with cardiovascular-
specific 11β-HSD1 deletion and following chronic 11β-HSD1 inhibition 
NCX (Slc8a1, Figure 3.21c and d), RyR (Ryr2, Figure 3.21e and f) and CaV1.2 
(Cacna1c, Figure 3.21g and h) mRNA were similar in all groups at 12w of age, 
however SERCA mRNA levels (Atp2a2, Figure 3.21a and b) were reduced in DelI 
mice (p<0.01) and SMAC mice (p<0.001). This was also seen in 18 month old 
UE2316-treated mice (p<0.001) compared to their respective controls (Figure 3.22a-
d). 
SERCA protein expression was also reduced in 12w old DelI mice (Figure 3.23a, 
p<0.001), SMAC mice (Figure 3.23b, p<0.001) and 18 month old UE2316-treated 
mice (Figure 3.23c, p<0.001) compared to their respective controls. Sample blots are 
shown in Figure 3.23d. 
Further investigation into regulation of SERCA revealed no change in 
phospholamban (PLN) protein expression (Figure 3.24a-d), nor any changes in 
phospholamban phosphorylation at two key phosphorylation sites; serine 16 (Figure 
3.25a, c, e and g) and threonine 17 (Figure 3.25b, d, f and h). 
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Figure 3.21 11β-HSD1 deletion results in reduced SERCA mRNA levels in the heart 
mRNA levels of SERCA (a & b), NCX (c & d), RyR (e & f) and CaV1.2 (g & h) were 
determined by qRT-PCR in hearts from DelI (left column) and SMAC (right column) mice 
and their respective controls at 12w of age. Target gene mRNA levels were normalised to β-
actin, the internal control, which was similar in all groups. Target gene mRNA levels in the 
control groups were set to 100% and mRNA levels in DelI and SMAC mouse hearts were 
expressed as a percentage of this (Student’s t test; *** = p<0.001, ** = p<0.01; n=6/group 


















































































































































































Figure 3.22 Chronic 11β-HSD1 inhibition reduces SERCA mRNA levels in the heart 
mRNA levels of SERCA (a), NCX (b), RyR (c) and CaV1.2 (d) were determined by qRT-
PCR in hearts from from 18 month old mice treated with UE2316 (20mg/kg) in their diet for 
9 months (chequered bars) and vehicle-treated controls (filled bars). Target gene mRNA 
levels were normalised to β-actin, the internal control, which was similar in all groups. 
Target gene mRNA levels in the vehicle-treated groups were set to 100% and mRNA levels 
in UE2316-treated mouse hearts were expressed as a percentage of this (Student’s t test; *** 






































































































Figure 3.23 11β-HSD1 deletion or chronic inhibition results in reduced SERCA protein 
levels in the heart 
SERCA protein levels were assessed by Western blotting in ventricular tissue from 12w old 
DelI (a) and SMAC mice (b), and 18 month old mice treated with UE2316 (20mg/kg) in 
their diet for 9 months (c) and their respective controls. SERCA protein levels were 
normalised to the internal control, β-actin, which was similar in all groups. SERCA protein 
levels in the control groups were set to 100% and protein levels in DelI, SMAC and 
UE2316-treated tissue were expressed as a percentage of this. Sample Western blots are 
shown in (d). (Student’s t test *** = p<0.001; n=6/group for DelI & SMAC mice, n=4/group 
for controls). 
























































































Figure 3.24 11β-HSD1 deletion or chronic inhibition does not affect phospholamban 
protein levels in the heart 
Phospholamban (PLN) protein levels were assessed by Western blotting in ventricular tissue 
from 12w old DelI (a) and SMAC mice (b), and 18 month old mice treated with UE2316 
(20mg/kg) in their diet for 9 months (c) and their respective controls. PLN protein levels 
were normalised to the internal control, β-actin, which was similar in all groups. PLN protein 
levels in the control groups were set to 100% and protein levels in DelI, SMAC and 
UE2316-treated tissue were expressed as a percentage of this. A sample Western blot is 

















































































Figure 3.25 Phospholamban phosphorylation is not influenced by 11β-HSD1 deletion or 
chronic inhibition 
Phosphorylation of phospholamban (PLN) at serine 16 (Ser16, a, c & e) and threonine 17 
(Thr17, b, d & f) was assessed by Western blotting in ventricular tissue from 12w old DelI, 
SMAC and UE2316-treated mice and their respective controls. Example DelI Western blots 
are shown for Ser16 (g) and Thr7 (h) (Student’s t test; n=4/group). Phosphorylated PLN 
protein levels were normalised to the internal control, β-actin, which was similar in all 
groups. Phosphorylated PLN protein levels in the control groups were set to 100% and 
protein levels in DelI, SMAC and UE2316-treated tissue were expressed as a percentage of 






























































































































GR-mediated action of glucocorticoids has previously been shown to regulate heart 
maturation (Rog-Zielinska, et al., 2013), vascular tone (Ullian, 1999; Hadoke, et al., 
2006; Goodwin, et al., 2011) and calcium handling within cardiomyocytes (Sainte-
Marie, et al., 2007). Furthermore, local glucocorticoid regeneration by the enzyme 
11β-HSD1 has been shown to be involved in regulating both heart size  
(McSweeney, et al., 2010; Rahman, et al., 2011) and angiogenesis (Small, et al., 
2005). However, expression of 11β-HSD1 in the heart and its specific roles in 
regulating heart growth and function are incompletely understood. The aim of this 
study was to investigate the impact of global and cardiovascular-specific 11β-HSD1 
deletion on heart size and function, and determine whether this could be reproduced 
by chronic pharmacological inhibition of 11β-HSD1. 
The data presented in this chapter shows that global 11β-HSD1 deletion (DelI mice) 
results in smaller, lighter hearts at 12 weeks of age which may be due to shorter 
cardiomyocytes. However, this phenotype appears to be transient because by 18 
months of age, heart size in DelI and C67BL/6 mice is similar. This does not seem to 
be a result of 11β-HSD1 deficiency in cardiomyocytes or VSMCs themselves, 
because this phenotype is not reproduced in mice with cardiovascular-specific 
deletion (SMAC mice). There is a clear role for 11β-HSD1 in cardiomyocytes and 
VSMCs, however, in regulating genes associated with calcium cycling and 
maintaining normal diastolic function, as deletion of the enzyme in these cells leads 
to mild diastolic dysfunction and reduced SERCA expression; a phenotype also seen 
in the global KO. Moreover, this diastolic phenotype occurred following 
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pharmacological inhibition of 11β-HSD1, by administration of UE2316, a selective 
11β-HSD1 inhibitor. 
This data therefore suggests that 11β-HSD1 in cardiomyocytes and VSMCs 
influences physiological cardiac function, possibly by regulating calcium handling 
within cardiomyocytes. However, 11β-HSD1 in another cell type influences 
cardiomyocyte length, resulting in smaller hearts in its absence. 
 
3.4.1 Expression of 11β-HSD1 and corticosteroid-related genes 
Myocardial 11β-HSD1 is present in cardiomyocytes, vascular smooth muscle cells 
and cardiac fibroblasts (Christy, et al., 2003; Klusonova, et al., 2009; McSweeney, 
2010) as well as in the vascular wall (Hadoke, et al., 2001). Outside the 
cardiovascular system, 11β-HSD1 expression is highest in liver (Tannin, et al., 1991) 
with lower levels present in skeletal muscle (Morgan, et al., 2009). GR are expressed 
almost ubiquitously in all cell types (Hadoke, et al., 2009) whereas MR are restricted 
to aldosterone target organs such as the kidneys, the colon and the salivary glands, 
but are also present in cardiomyocytes and the vascular endothelium (Walker, 2007a; 
Fraccarollo, et al., 2011).  
Consistent with these findings, 11β-HSD1 mRNA and protein was found in heart, 
aorta, liver and skeletal muscle tissue of C57BL/6 and Cre
-
 control mice. DelI mice 
showed deletion of 11β-HSD1 in each of these tissues whereas SMAC mice only 
showed deletion in heart and aortic tissue. Expression in liver and skeletal muscle 
was unaffected, demonstrating the strategy of selectively targeting 11β-HSD1 
expression in the cardiovascular system using SM22α-Cre
+
 was a successful one. 
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However, 11β-HSD1 activity in these tissues was not investigated and should be 
performed in future studies. The low levels of 11β-HSD1 mRNA and protein 
detected in hearts and aortas from SMAC mice may be due to cardiac and adventitial 
fibroblasts, which known to express 11β-HSD1 (Brereton, et al., 2001; McSweeney, 
2010). These cells may therefore account for this expression. Furthermore, although 
the connective and adipose tissue surrounding the aorta was removed as extensively 
as possible, some cells may have remained. Adipose cells also express 11β-HSD1 
and may therefore have contributed to the small levels of 11β-HSD1 mRNA and 
protein detected in SMAC mice (Walker & Seckl, 2003; Tomlinson & Stewart, 
2005). 
Levels of GR and MR mRNA in heart tissue were unaffected, as were myocardial 
mRNA levels of genes affected by glucocorticoid signalling; FKBP5, GILZ, PGC1α 
and SGK. FKBP5 is an immunophilin which binds to GR, along with HSP90, and 
regulates GR affinity for glucocorticoids (Wochnik, et al., 2005). GILZ is a leucine 
zipper which regulates several GR-mediated processes including apoptosis, cell 
proliferation and the immune response where it elicits and anti-inflammatory action 
(Ayroldi & Riccardi, 2009). PGC1α is a nuclear receptor co-activator which co-
activates HNF-4α and GR (Herzig, et al., 2001). SGK is induced by glucocorticoids 
and aldosterone via both GR and MR and can be phosphorylated by the 
phosphoinositide 3-kinase, a kinase which is involved in cardiomyocyte hypertrophy 
(Sheppard & Autelitano, 2002). The data presented here suggest that basal GR- and 
MR-mediated signalling in the heart was unaffected despite DelI and SMAC mice 
being unable to locally regenerate glucocorticoids globally or in cardiomyocytes and 
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VSMCs, respectively. Therefore, systemic glucocorticoid release from the adrenal 
glands must be sufficient to overcome this deficiency, at least in the healthy mouse. 
Although 11β-HSD1 mRNA levels and protein expression was measured in the 
current study, 11β-HSD1 activity was not and this should be investigated in future 
studies. Furthermore, since tissue homogenate was used to assess expression, 
localisation of 11β-HSD1 was not examined, and so it remains unclear as to whether 
11β-HSD1 is absent in cardiac fibroblasts of SMAC mice. It has been shown that 
Sm22α is not present in isolated fibroblasts from chronic obstructive pulmonary 
disease (COPD) patients, and is only present in myofibroblasts and VSMCs, not 
fibroblasts in rabbit bladder (Chiavegato, et al., 1999; Hallgren, et al., 2010). 
However, investigation of this by immunohistochemistry and in isolated fibroblasts 
warrants further study. 
 
3.4.2 Heart dimensions 
11β-HSD1 deficient mice have previously been observed to have smaller hearts at 
10-12w of age (McSweeney, et al., 2010), although the reason for this was not 
completely understood. In the present study, global deletion of 11β-HSD1 resulted in 
the same phenotype with smaller, lighter hearts in 12 week old DelI mice compared 
to C57BL/6 control mice, but without changes in blood pressure, cardiomyocyte 
cross sectional-area, blood volume and myocardial interstitial volume.  
Preload is a term used to describe the pressure exerted on the left ventricle at the end 
of diastole and can be affected by several physiological parameters, primarily blood 
pressure and blood volume. A reduced blood volume decreases the end diastolic 
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filling pressure and results in a smaller left ventricular end diastolic volume (De 
Simone, 2003). This is because the pressure experienced by the cardiomyocytes in 
the left ventricular wall is reduced and so cardiomyocyte diastolic length is reduced 
(Hanft, et al., 2008). The effect of glucocorticoids on elevating blood pressure are 
well established (Connell, et al., 1987; Fraser, et al., 1999; Masuzaki, et al., 2003; 
Van Raalte, et al., 2013), however lack of 11β-HSD1 in DelI mice did not lower 
blood pressure or modify blood volume, suggesting these parameters are not 
responsible for reducing heart size and weight in these mice.  
Further investigation of DelI hearts revealed these mice had shorter cardiomyocytes 
which may account for them having smaller hearts. Having said that, cardiomyocyte 
length was only reduced approximately 10% whereas heart weight was reduced by 
approximately 30% suggesting further changes take place in DelI mice which 
contribute to the reduction in heart size and this needs further investigation. Deletion 
of 11β-HSD1 in cardiomyocytes and VSMCs did not reproduce this ‘small heart’ 
phenotype suggesting lack of 11β-HSD1 in another cell type is responsible. This 
phenotype was not seen in adult mice treated with UE2316, suggesting that it may be 
due to the developmental or early post-natal action of 11β-HSD1. Furthermore, this 
phenotype appeared to be transient, as a similar heart size was observed in DelI and 
C57BL/6 control mice at 78w (18 months) of age.  
Cardiac fibroblasts secrete a number of factors crucial for cardiomyocytes growth, 
and loss of 11β-HSD1 in these cells may alter growth factor secretion. For example, 
fibroblasts express fibroblast growth factor-2 (FGF-2) (Jiang, et al., 2007), and 
deletion of this has been shown to attenuate eccentric hypertrophy after pressure 
overload, whereby cardiomyocyte length increases, but cross-sectional area does not 
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(Schultz, et al., 1999). Furthermore, leukaemia inhibitory factor (LIF) and 
cardiotrophin-1 (CT-1) are members of the IL-6 family which are both secreted by 
fibroblasts and involved in cardiomyocytes growth (Matsui, et al., 1996; Wollert, et 
al., 1996; Wang, et al., 2002). IL-33 is a fibroblast-derived cytokine which exerts an 
antihypertrophic effect after phenylephrine or angiotensin II stimulation (Sanada, et 
al., 2007). Indeed, administration of IL-33 in vivo has been shown to attenuate 
hypertrophy after pressure overload (Sanada, et al., 2007). Fibroblast-cardiomyocyte 
cell-cell interactions appear to be mediated by connexin 43 and connexin 45 
(Oyamada, et al., 1994; Zhang, et al., 2008), and may also contribute to 
cardiomyocytes entering a ‘hibernation state’ which is characterised, among other 
things, by a loss of sarcomeres, and thus cell shortening (Dispersyn, et al., 2001). 
Investigation into the secretion of growth factors by fibroblasts in DelI mice, 
including those described above, may provide further insight into why these mice 
have shorter cardiomyocytes. 
A direct effect of glucocorticoids on cardiomyocyte structure and maturation has 
recently been elucidated. GR-mediated glucocorticoid action is necessary for lung 
development in utero, and GR KO mice die at birth due to underdeveloped lungs 
(Cole, et al., 1995). However, a proportion of these mice die prenatally and it is 
suggested that this is due to diastolic dysfunction, disorganised cardiomyocyte 
myofibrils, and impaired calcium-induced calcium release (Rog-Zielinska, et al., 
2013). Furthermore, administration of the synthetic GR-specific glucocorticoid 
cortivasol to neonatal rat cardiomyocytes has been shown to upregulate hypertrophic 
gene expression (Yoshikawa, et al., 2009). Hypercortisolaemia in patients with 
Cushing’s syndrome and chronic administration of glucocorticoids in animal models 
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has been shown to result in left ventricular hypertrophy (Walker, 2007a; De, et al., 
2011), possibly in an angiotensin II-dependent manner (Ghose Roy, et al., 2009). It 
may therefore be hypothesised that DelI mice have reduced expression of pro-
hypertrophic genes, such as B-type natriuretic peptide (BNP), skeletal muscle α-actin 
(SKA), atrial natriuretic peptide (ANP) and β-myosin heavy chain (β-MHC) (Ren, et 
al., 2012; Katoh, et al., 2014) because they are unable to regenerate glucocorticoids 
intracellularly, which results in them having shorter cardiomyocytes and smaller, 
lighter hearts. Cardiomyocyte length increases rapidly in the first 4 weeks after birth, 
with the rate of growth decreasing from 4 weeks onwards (Leu, et al., 2001). Heart 
growth in DelI mice at early postnatal time points should therefore be investigated. 
11β-HSD1 deletion in cardiac fibroblasts or resident macrophages may be key to 
modifying growth factor secretion or hypertrophic gene induction and thus warrants 
further study. In addition to the growth factors secreted by fibroblasts, above, 
macrophages also secrete factors involved in cardiomyocytes growth. For example, 
insulin-like growth factor-1 (IGF-1) is expressed by macrophages (Gow, et al., 2010) 
and transgenic cardiac overexpression of IGF-1 or its receptor (IGF-1R) results in 
increased cardiomyocytes growth and cell hypertrophy (McMullen, et al., 2004; 
Torella, et al., 2004). 
One further interesting observation was that, at 18 months of age and after 9 months 
of pharmacological 11β-HSD1 inhibition, relative to vehicle-treated age-matched 
mice, UE2316-treated mice showed a trend for larger hearts as measured by 
echocardiography, and significantly heavier hearts as weighed at post-mortem. 
However, the level of 11β-HSD1 inhibition in the heart was not measured, and 
should be performed. 
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Blood pressure and circulating cortisol are both known to increase with age, and both 
have been shown to enhance the development of cardiac hypertrophy (Landahl, et 
al., 1986; Van Cauter, et al., 1996; Walker, 2007a; De, et al., 2011; Drazner, 2011). 
In aged mice, such as those treated with UE2316, blood pressure and cortisol levels 
may be further increased as a result of impaired GR-mediated negative feedback by 
glucocorticoids, due to reduced intracellular glucocorticoid bioavailability. However, 
this must be properly investigated to determine the cause behind the heavier hearts in 
these mice. 
It has also been shown previously that allowing aldosterone access to MR in 
cardiomyocytes, by overexpressing 11β-HSD2 in these cells, leads to cardiac 
hypertrophy (Qin, et al., 2003). As such, it may hypothesised that aldosterone is able 
to occupy MR in cardiomyocytes in mice in which 11β-HSD1 is inhibited in these 
cells, and therefore lead to larger hearts. Having said that, 11β-HSD2 is expressed at 
very low levels in the heart and so this hypothesis may be incorrect. Furthermore, 
this phenotype is not seen in DelI mice at 18 months of age, suggesting that this 
phenotype may be a result of unknown off-target effects of UE2316, or that partial 
11β-HSD1 inhibition gives a different phenotype to complete KO. Further 
investigation into off-target drug effects, heart weight, blood pressure and 
corticosterone levels in 11β-HSD1 deficient mice at 18 months of age is therefore 
required. Moreover, further studies should attempt to elucidate the mechanism of this 
phenotype in UE2316-treated mice; for example, assessment of blood pressure, 
blood volume and myocardial interstitial fluid. 
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3.4.3 Cardiac function 
High-resolution echocardiography showed ejection fraction and fractional shortening 
in DelI, SMAC and UE2316-treated mice was similar to their respective controls. 
This agrees with the previous finding that 11β-HSD1 deficiency does not influence 
cardiac function (McSweeney, et al., 2010). However, additional investigation by 
pulsed-wave Doppler ultrasound revealed that DelI, SMAC and UE2316-treated 
mice all exhibited mild diastolic dysfunction compared to their respective controls. 
In each case, E wave deceleration was reduced and mitral valve deceleration time 
was accordingly increased, suggesting either reduced compliance or relaxation 
deficit.  
Collagen accumulation is associated with reduced compliance and can lead to cardiac 
pathology (Pauschinger, et al., 1999). Collagen types I and III are the most abundant 
in the heart with type I being significantly stiffer than the more elastic type III 
(Sharma, et al., 2004). DelI, SMAC and UE2316-treated mice have similar overall 
myocardial collagen content, and similar mRNA levels of Col1α2, Col3α1 and 
TGFβ, suggesting similar fibrosis in these mice to their respective controls. 
Calcium handling in cardiomyocytes, and particularly calcium removal from the 
cytosol following excitation-contraction coupling, is essential to maintain normal 
muscle relaxation. SERCA is involved in reuptake of calcium back into the 
sarcoplasmic reticulum (SR) while the sodium-calcium exchanger (NCX) extrudes 
calcium from the cell following contraction (Reeves & Hale, 1984; Periasamy & 
Kalyanasundaram, 2007). Therefore these two transporters are heavily involved in 
regulating cardiomyocyte relaxation (see Figure 1.1) (Bers, 2001; Louch, et al., 
2012). In the SERCA KO mouse, expression of NCX is increased to provide an 
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alternative means of removing calcium from the cytosol at the end of contraction (Li, 
et al., 2011). However, in the present study, reduction of SERCA was not 
accompanied by any change in NCX. This may indicate that a reduction in SERCA 
expression is already compensated for in a different way in mice with 11β-HSD1 
deletion or inhibition. 
Glucocorticoids have been shown to play a role in SERCA expression 
developmentally, in adulthood, and after an ischaemic insult. In late gestation an 
increase in SERCA mRNA is normally seen, however this is attenuated in GR KO 
mice (Rog-Zielinska, et al., 2013). Skeletal muscle cells from adult rat diaphragm 
have decreased SERCA mRNA levels after treatment with triamcinolone, a synthetic 
corticosteroid (Gayan-Ramirez, et al., 2000). In a setting of myocardial ischaemia in 
piglets, methylprednisolone treatment after cardio-pulmonary graft prevents loss of 
SERCA protein and maintains the calcium transient in cardiomyocytes (Pearl, et al., 
2011). Furthermore, experiments using hexose-6-phosphate dehydrogenase (H6PD) 
KO mice have also revealed a role for glucocorticoids in regulating SERCA 
expression, whereby these mice have reduced SERCA protein expression in skeletal 
muscle (Lavery, et al., 2008). H6PD is responsible for converting glucose-6-
phosphate to 6-phosphogluconolactonate which also results in the generation of 
NADPH, the cofactor required by 11β-HSD1 in order for it to function as an 
oxoreductase enzyme (Bujalska, et al., 2005; Morton, 2010). In the absence of 
NADPH, 11β-HSD1 functions as a dehydrogenase, inactivating glucocorticoids and 
converting them to their inert 11-keto metabolites (Lavery, et al., 2006). 
The data presented in this chapter suggest a role for the local glucocorticoid 
regenerating enzyme 11β-HSD1 in regulating calcium homeostasis, as lack of 11β-
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HSD1 in cardiomyocytes and VSMCs, or pharmacological inhibition of 11β-HSD1 
in adults, results in reduced myocardial SERCA mRNA and protein expression, 
leading to mild diastolic dysfunction. 
Regulation of SERCA by phospholamban (PLN) is also an important interaction with 
regard to myocardial calcium handling (MacLennan, et al., 2003). PLN can be 
thought of as a reverse inhibitor of SERCA; when it is not phosphorylated it inhibits 
the action of SERCA and therefore reduces the transport of calcium from the cytosol 
into the SR (MacLennan, et al., 2003). When PLN is phosphorylated this inhibition 
is lost and SERCA activity increases (MacLennan, et al., 2003). Previous studies 
investigating cardiomyocytes from rats which had been adrenalectomised, and rats 
which had been treated with dexamethasone, revealed no change in cardiomyocyte 
PLN protein expression or PLN phosphorylation state at two key phosphorylation 
sites, serine 16 and threonine 17, which are phosphorylated by PKA and CamKII, 
respectively (Rao, et al., 2001).  
There was no change in PLN protein expression or PLN phosphorylation in DelI, 
SMAC or UE2316-treated mice compared to their respective controls, suggesting 
loss of 11β-HSD1 in cardiomyocytes and VSMCs directly regulates myocardial 
SERCA expression. Together these observations suggest PLN expression and 
phosphorylation is not glucocorticoid dependent. Therefore, although a reduction in 
SERCA protein has been demonstrated in DelI, SMAC and UE2316-treated mice, 
assessment of SERCA activity and intracellular calcium flux merits further 
investigation in order to fully understand whether cytosolic calcium availability is 
modified in these mice. If it is indeed reduced then contractile filament sensitivity 
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should also be studied as perhaps that increased sensitivity prevents the loss of 
contractile function in these mice. 
The data presented in this chapter demonstrate that global 11β-HSD1 deletion results 
in shorter cardiomyocytes, and thus smaller hearts. However, this phenotype is not 
due to loss of 11β-HSD1 in cardiomyocytes themselves, as this phenotype is not 
present in SMAC mice, meaning other cell types are responsible. Loss of 11β-HSD1 
in cardiomyocytes and VSMCs leads to mild diastolic dysfunction, possibly as a 
result of alteration in cardiomyocyte calcium handling gene expression. Furthermore, 
this phenotype can be induced by pharmacological inhibition of 11β-HSD1 by 
UE2316, a selective 11β-HSD1 inhibitor. These unexpected phenotypes should be 
kept in mind when analysing the acute and chronic remodelling and functional 




The Acute Response of Cardiovascular-specific 





In the heart, immunoreactive 11β-HSD1 is present in cardiomyocytes, vascular 
smooth muscle cells, cardiac fibroblasts (Christy, et al., 2003, Klusonova, et al., 
2009; McSweeney, 2010) as well as in the vascular wall (Hadoke, et al., 2001). 
Global deletion of this enzyme (in DelI mice) results in smaller, lighter hearts with 
shorter cardiomyocytes (Chapter 3). However, cardiovascular-specific 11β-HSD1 
deletion (SMAC mice) does not reproduce this finding (Chapter 3), suggesting it is 
the action of 11β-HSD1 out with the cardiovascular system that is responsible for 
this phenotype. In contrast, both DelI and SMAC mice showed diastolic 
abnormalities and reduced SERCA expression, although systolic function and 
cardiac vessel density appeared normal (Chapter 3). After infarction, mice globally 
deficient in 11β-HSD1 have an augmented inflammatory response, associated with 
increased representation of pro-reparative alternatively-activated macrophages, 
enhanced peri-infarct angiogenesis and improved cardiac function (McSweeney, et 
al., 2010). However, whether this is due to ‘cardiovascular’ 11β-HSD1 is unknown 
and is the focus of this chapter. 
The aim of this chapter was to determine whether the beneficial acute outcomes seen 
previously in 11β-HSD1 deficient mice after MI could be reproduced by selective 
cardiovascular deletion of the enzyme. Considering previous work from our 
laboratory describing the anti-angiogenic role of 11β-HSD1 in the vessel wall 
(Small, et al., 2005), it was hypothesised that SMAC mice would reproduce the 
beneficial phenotype previously seen in mice globally deficient in 11β-HSD1. It was 
hypothesised that, following MI, SMAC mice would exhibit enhanced angiogenesis, 
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a modified inflammatory response, reduced scar size, attenuated left ventricular 
dilatation and maintained cardiac function. 
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4.2 Methods 
Male cardiovascular-specific 11β-HSD1 KO (SMAC) mice, and Cre
-
 control mice, 
aged 10-12 weeks underwent coronary artery ligation or sham surgery (Section 
2.2.3). Tail blood was collected 24h after surgery (Section 2.2.4) to determine the 
extent of initial cardiac injury, by measurement of cardiac troponin-I (Section 2.6.5). 
High frequency echocardiography was performed 7d after surgery to assess cardiac 
size and function (Section 2.2.2). Mice were killed by perfusion fixation (Section 
2.3.1) immediately following echocardiography and hearts were harvested, 
processed, embedded in paraffin wax and microtomed into 4μm thick sections. 
Histology and immunohistochemical analysis allowed determination of infarct size, 
peri-infarct angiogenesis, total macrophage recruitment and alternatively-activated 
macrophage recruitment. 
 
4.2.1 Histology and immunohistochemistry 
Masson’s Trichrome staining was used to determine infarct size as detailed in 
Section 2.4.3. CD31 staining was used to measure peri-infarct angiogenesis, Mac2 
staining was used to quantify macrophage infiltration into the heart, and Ym1 
staining was used to identify alternatively-activated macrophages. Full details are 





4.2.2 Statistical analysis 
All values are expressed as mean ± SEM. Statistical significance was reached with a 
p value of less than 0.05. Mortality data was compared using Fisher’s exact test and 
chi square test. Echocardiography and cardiac troponin-I data were compared using 
two way ANOVA with Bonferroni’s post-hoc test. Masson’s Trichrome staining, 
peri-infarct angiogenesis, total macrophage and alternatively activated macrophage 
data were compared using two-tailed unpaired Student’s t tests. 
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4.3 Results 
4.3.1 Cardiovascular 11β-HSD1 deletion does not influence mortality after MI 
Mortality was similar in SMAC and Cre
-
 control mice after surgery, with 65% of 
SMAC mice and 76% of control mice surviving until 7d post-MI (Figure 4.1). Post 
mortem investigation of deaths revealed they were all a result of cardiac rupture, as 
determined by the presence of blood in the chest cavity and a rupture of the left 
ventricular wall. All sham-operated mice (100%, n=6/group) survived until 7 days 
post surgery. 
 
4.3.2 Cardiovascular 11β-HSD1 deletion does not influence initial ischaemic 
injury 
24h after ligation surgery, plasma levels of cardiac troponin-I were elevated to a 
similar extent in SMAC and Cre
-
 control mice (Con), compared to sham-operated 
mice (Figure 4.2), suggesting a similar extent of initial cardiac injury in both 

















Figure 4.1 Cardiovascular 11β-HSD1 deletion does not affect mortality after coronary 
artery ligation 
Mortality after coronary artery ligation surgery in Cre
- 
control mice (solid line, n=20 at day 0 
and n=13 at day 7) and SMAC mice (dashed line, n=17 at day 0 and n=13 at day 7) (no 
significant difference; Fisher’s exact test, chi square p=0.49). 
Mortality





















Figure 4.2 Cardiovascular 11β-HSD1 deletion does not affect the extent of initial injury 
after coronary artery ligation 
Plasma cardiac troponin-I levels, measured by ELISA, in 10-12w old SMAC and Cre
-
 
control mice, and sham-operated mice 24hr after surgery (two way ANOVA *** = p<0.001; 
n=8/group for SMAC & Cre
-
 mice, n=6/group for shams). 
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4.3.3 Ventricular dilatation and systolic function 7d after MI are not changed 
in mice with cardiovascular 11β-HSD1 deletion  
4.3.3.1 Heart size 
SMAC mice and their Cre
-
 controls (Con) had increased left ventricular end diastolic 
areas (LVEDA, Figure 4.3a) and left ventricular end systolic areas (LVESA, Figure 
4.3b) following MI compared to sham-operated mice, indicating similar levels of left 
ventricular dilatation in both genotypes. 
 
4.3.3.2 Systolic function 
Ejection fraction (EF, Figure 4.4a) and fractional shortening (FS, Figure 4.4b), were 
similar in sham-operated SMAC and Cre
-
 control mice, and similarly reduced in both 
genotypes following MI. 
 
4.3.4 Infarct size 7d after MI is not influenced by cardiovascular 11β-HSD1 
deletion 
Quantification of scar tissue showed SMAC (Figure 4.5a) and control mice (Figure 





















Figure 4.3 Heart size 7d post-MI is not influenced by cardiovascular 11β-HSD1 deletion 
Left ventricular end diastolic area (LVEDA, a) and left ventricular end systolic area 
(LVESA, b) of SMAC and Cre
-
 mice 7d post-MI, and sham-operated control mice 7d after 
sham surgery, was assessed using high frequency ultrasound (two way ANOVA *** = 
p<0.001, ** = p<0.01; n=8/group for SMAC & Cre- mice, n=6/group for shams). 
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Figure 4.4 Systolic function 7d post-MI is not influenced by cardiovascular 11β-HSD1 
deletion 
Ejection fraction (a) and fractional shortening (b) of 10-12w old SMAC and Cre
-
 mice 7d 
post-MI, and sham-operated control mice 7d after sham surgery, was assessed using high 
frequency ultrasound (two way ANOVA *** = p<0.001; n=8/group for SMAC & Cre- mice, 






































































Figure 4.5 Cardiovascular 11β-HSD1 deletion does not affect infarct size 7d post-MI 
Representative Masson’s Trichrome stained heart sections from 10-12w old (a) SMAC and 
(b) Cre
-
 mice 7d post-MI. Quantification of infarct size is shown in (c) (Student’s t test; 


























4.3.5 Macrophage recruitment 7d after MI is unaffected by cardiovascular 
11β-HSD1 deletion 
Mac2 staining of macrophages amounted to approximately 1.2% of the left ventricle 
in sham-operated SMAC and Cre
-
 control mice (Con). Macrophage content (Mac2 
staining, Figure 4.6 a and b) of the left ventricle 7d post-MI was elevated to a similar 
extent in both SMAC and Cre
-
 mice (Figure 4.6c) compared to their sham-operated 
controls. 
Recruitment of alternatively-activated macrophages, identified by Ym1 staining, to 
the left ventricle was elevated to a similar extent in SMAC and Cre
-
 mice 7d after 
MI, compared to their sham-operated controls (Con) (Figure 4.7). 
 
4.3.6 Peri-infarct angiogenesis 7d after MI is not influenced by cardiovascular 
11β-HSD1 deletion 




 in the peri-infarct region was similar for 
each of the three vessel diameter categories (<4μm, 4-200μm, and >200μm) in 
SMAC and Cre
-






















Figure 4.6 Macrophage recruitment to the heart 7d post-MI is unaffected by 
cardiovascular 11β-HSD1 deletion 
Representative Mac2 stained heart sections from 10-12w old (a) SMAC and (b) Cre
-
 mice 7d 
post-MI. Some cardiomyocytes in hearts from both SMAC and Cre
-
 mice show very light 
staining, which appears to be non-specific staining. Quantification of Mac2 staining in hearts 
from SMAC and Cre
-
 mice 7d post-MI and sham-operated controls 7d after sham surgery is 
shown in (c) (two way ANOVA *** = p<0.001; n=8/group for SMAC & Cre- mice, 
n=6/group for shams). Scale bar is 20μm. 
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Figure 4.7 Alternatively-activated macrophage recruitment to the heart 7d post-MI is 
unaffected by cardiovascular 11β-HSD1 deletion 
Representative Ym1 stained heart sections from 10-12w old (a) SMAC and (b) Cre
-
 mice 7d 
post-MI. Quantification of Ym1 staining in hearts from SMAC mice and Cre
-
 mice 7d post-
MI and sham-operated controls 7d after sham surgery is shown in (c) (two way ANOVA *** 
= p<0.001; n=8/group for SMAC & Cre- mice, n=6/group for shams). Scale bar is 25μm. 
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Figure 4.8 Cardiovascular 11β-HSD1 deletion does not alter peri-infarct angiogenesis 
7d post-MI 
Representative CD31 stained heart sections from 10-12w old (a) SMAC and (b) Cre
-
 mice 7d 
post-MI. Quantification of peri-infarct angiogenesis in hearts from SMAC and Cre
-
 mice 7d 



























11β-HSD1 deletion has previously been shown to result in increased angiogenesis in 
subcutaneous sponge implants (Small, et al., 2005). Moreover, mice globally 
deficient in 11β-HSD1 have an augmented inflammatory response 7d post-MI, with 
increased representation of pro-reparative alternatively-activated macrophages, 
enhanced peri-infarct angiogenesis and improved cardiac function (McSweeney, et 
al., 2010). The data presented in this chapter shows that selective ‘cardiovascular 
deletion’ of 11β-HSD1 in cardiomyocytes and VSMCs (SMAC mice) does not 
reproduce this phenotype. Seven days after MI, SMAC and control mice had similar 
peri-infarct angiogenesis, total macrophage and alternatively-activated macrophage 
infiltration, infarct size, ventricular dilatation and systolic function. Thus, lack of 
11β-HSD1 in one or more cell types, other than cardiomyocytes and VSMCs, must 
underlie this beneficial phenotype. 
 
4.4.1 Mortality and initial ischaemic damage 
Despite the inability of SMAC mice to locally regenerate glucocorticoids in 
cardiomyocytes and VSMCs, there was no difference in primary cause or rate of 
mortality, or initial ischaemic injury, in SMAC mice compared to Cre
-
 control. This 
suggests that systemic corticosterone release in these mice is sufficient to overcome 
any lack of intracellular glucocorticoid regeneration in cardiomyocytes, and protect 
these hearts from initial ischaemic damage in a similar fashion to control mice. 
Several studies, going back to the 1970s, have investigated the therapeutic capacity 
of administering glucocorticoids after MI (Libby, et al., 1973; Hoffstein, et al., 
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1976). Glucocorticoids given immediately after infarction are initially protective, by 
reducing ischaemic cell death, and therefore limiting infarct size (Libby, et al., 
1973), possibly by preserving the integrity of lysosomal membranes and thus 
preventing the spillage of lysozymes into the cytosol (Hoffstein, et al., 1976). 
However, longer term glucocorticoid administration increases the likelihood of left 
ventricular rupture (Hammerman, et al., 1983). Nevertheless, glucocorticoids are 
critical to early post-MI survival (Reynolds, et al., 2010b). 
Plasma corticosterone levels are similar in mice globally deficient in 11β-HSD1 and 
control mice 24h after infarction (McSweeney, et al., 2010). Levels were not 
measured in the current study, and should be investigated to confirm a similar 
systemic HPA axis response to infarction in SMAC mice. It is hypothesised that 
SMAC mice would have similar plasma corticosterone levels to control mice, given 
that global deletion of the enzyme had no effect. 
Cardiac troponin-I is one of three subunits which comprise the actin filament found 
in cardiac muscle (Wu, 2006). It has been known as a highly sensitive marker of 
cardiac injury for over 20 years (Adams III, et al., 1993) as it is normally present in 
the bloodstream only at very low levels, and is currently used clinically to diagnose 
acute myocardial infarction (Gassenmaier, et al., 2012). The degree of elevation of 
plasma cardiac troponin-I correlates with the extent of myocardial injury, and can 
thus be used to determine initial ischaemic damage (Selvanayagam, et al., 2005). As 
such, it was crucial to investigate the initial response of SMAC mice to coronary 
artery ligation surgery by measuring plasma cardiac troponin-I levels 24hr after 
infarction. A differential release of cardiac troponin-I immediately following 
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occlusion may modify the inflammatory response and thus modify longer term 
infarct healing. 
The data presented in this study show that SMAC mice had similar plasma levels of 
cardiac troponin-I compared to control, and therefore had a similar extent of initial 
cardiac injury 24hr after coronary artery ligation surgery. This suggests that 11β-
HSD1 deletion in the heart and vasculature does not impact upon initial injury.  
 
4.4.2 Peri-infarct angiogenesis 
After MI, 11β-HSD1 deficient mice have increased angiogenesis in the peri-infarct 
region (Small, et al., 2005; McSweeney, et al., 2010). However, SMAC mice have a 
similar angiogenic response to Cre
-
 control mice after MI, with no difference in the 
density of CD31
+
 capillaries, in any size category, in the peri-infarct region. This is 
consistent with the finding that these mice have similar levels of macrophage 
infiltration, and particularly similar levels of alternatively-activated macrophage 
infiltration (Sections 4.3.6 and 4.3.7), as these cells play a key role in the induction 
of post-MI angiogenesis; they release pro-angiogenic factors such as basic FGF, 
IGF-1 and VEGF (Berse, et al., 1992; Henke, et al., 1993; Nahrendorf, et al., 2007; 
Dobrucki, et al., 2010). These data suggest that deletion of 11β-HSD1 in 
cardiomyocytes and VSMCs is not sufficient to alter the inflammatory response and 
reproduce the enhanced angiogenesis observed in globally 11β-HSD1 deficient mice 
after MI.  
Global deficiency of 11β-HSD1 results in upregulation of myocardial expression of 
the pro-angiogenic cytokine IL-8 after MI, but not VEGF (McSweeney, et al., 2010). 
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The increase in IL-8 is suggested to be due to increased macrophage infiltration, as 
macrophages are known to secrete IL-8 and promote angiogenesis (Koch, et al., 
1992). As such, it could contribute to the increased peri-infarct angiogenesis present 
in these mice (McSweeney, et al., 2010). Neither basic FGF, VEGF, IGF-1 nor IL-8 
expression was measured in the hearts of SMAC mice and should be investigated in 
future studies. 11β-HSD1 in infiltrating macrophages is a possible candidate for 
modifying the post-MI phenotype and is therefore the most obvious focus for future 
studies, particularly considering the altered expression of IL-8 in globally 11β-HSD1 
deficient mice compared to control mice. Additionally, cardiac fibroblasts express 
11β-HSD1, and their role in regulating angiogenesis is now well recognised, with 
several fibroblast-derived proteins, such as collagen I, procollagen C endopeptidase 
enhancer, osteonectin, TGF β-induced protein ig-h3 and IGF-binding protein 7, 
having been shown to be critical for lumen formation (Newman, et al., 2011) and 
VEGF having been shown to play a key role in endothelial cell sprouting in tumour 
angiogenesis (Ito, et al., 2007). Inserting a Cre recombinase transgene into the 
Sm22α gene may have an effect on expression of 11β-HSD1 in myofibroblasts, as 
Sm22α has been found to be expressed in isolated myofibroblasts from rabbit bladder 
(Chiavegato, et al., 1999). However, Sm22α does not appear to be express in isolated 
human fibroblasts from COPD patients (Hallgren, et al., 2010). As such, 11β-HSD1 
expression in cardiac fibroblasts and myofibroblasts, and its role in a post-MI setting 





4.4.3 Post-infarct inflammation 
Mice which are globally deficient in 11β-HSD1 have increased neutrophil infiltration 
into the heart after MI (McSweeney, et al., 2010). Recently, 11β-HSD1 deficiency in 
bone marrow-derived cells has been shown to be atheroprotective, pointing to a 
beneficial phenotype in a different inflammatory setting as a result of modified 
glucocorticoid regeneration in inflammatory cells (Garcia, et al., 2013; Kipari, et al., 
2013). However, in the present study, neutrophil infiltration was not examined, and 
should be considered for further studies. 
After clearing dead tissue from the infarcted myocardium, neutrophils undergo 
apoptosis and are recognised and subsequently phagocytosed by classically-activated 
macrophages (Meszaros, et al., 1999). Macrophage infiltration was investigated to 
determine if SMAC mice could reproduce the phenotype found previously in global 
globally 11β-HSD1 deficient mice, whereby these mice had increased Mac2
+
 
macrophage infiltration, and an increase in the proportion of alternatively-activated 
Ym1
+
 macrophages (McSweeney, et al., 2010). However, SMAC mice had similar 
levels of Mac2
+
 macrophages and Ym1
+
 alternatively-activated macrophages in the 
heart, compared to control, seven days after infarction. This suggests 11β-HSD1 
deletion out with cardiomyocytes and VSMCs is responsible for the phenotype 
observed in globally 11β-HSD1 deficient mice and points to a role for 11β-HSD1 in 
neutrophils or macrophages in modifying the inflammatory response after MI. 
Alternatively, resident fibroblasts, which also express 11β-HSD1, may underlie this 
phenotype and therefore warrant further investigation. 
To test this hypothesis, it would necessary to generate genetically modified mice 






been generated in our centre and their post-MI phenotype has been found to be 
similar to that of SMAC mice. Additionally, bone marrow transplant experiments 
have also been conducted in our laboratory whereby DelI mice received wild-type 
bone marrow, and wild-type mice received DelI bone marrow, prior to induction of 
MI. Preliminary data suggest that 11β-HSD1 deficiency in the host mouse is key to 
an improved post-MI outcome and so current studies are focussing on inhibiting 11β-
HSD1 in fibroblasts to determine the role of 11β-HSD1 in this cell type after MI 
(Mylonas, et al., unpublished). 
 
4.4.4 Cardiac size and function 
The role of ‘cardiovascular’ 11β-HSD1 in maintaining systolic function was 
investigated in the current study. As might have been expected from the previous 
data (Sections 4.3.7 and 4.3.8), which showed SMAC mice have similar levels of 
angiogenesis and alternatively-activated macrophage recruitment to the heart after 
MI, cardiac function was similar to control 7d after MI. SMAC and Cre
-
 control mice 
both showed a reduction in ejection fraction and fractional shortening which is in 
agreement with previous studies showing a reduction in function in animal and 
human models of MI (Pfeffer & Braunwald, 1990; Yang, et al., 2002a; Numaguchi, 
et al., 2006). Moreover, ‘cardiovascular deletion’ of 11β-HSD1 does not impact upon 
infarct size, with SMAC mice having similar infarct sizes to control 7 days after MI. 
The similar cardiac size and function seen in SMAC mice and control mice 
highlights the importance of increased peri-infarct angiogenesis and the altered 
inflammatory response seen in globally 11β-HSD1 deficient mice; reduced scar size 
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and, ultimately, maintained ejection fraction would not have resulted without 
modification of these pathways. 
The data in this chapter suggest SMAC mice do not recapitulate the beneficial post-
MI phenotype previously observed in globally 11β-HSD1 deficient mice, which is in 
contrast to earlier research showing 11β-HSD1 deficiency in the vessel wall is key to 
the enhanced angiogenesis seen in sponge implants (Small, et al., 2005). However, it 
is clear that ‘cardiovascular’ 11β-HSD1 contributes to appropriate calcium handling 
gene expression and normal diastolic function (Chapter 3), parameters which are 
altered in the post-MI progression to heart failure. As such, the phenotype of 
cardiovascular-specific 11β-HSD1 KO mice, and global 11β-HSD1 deficient mice, 
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MI is a major contributor to heart failure (Jhund & McMurray, 2008). 11β-HSD1 
deficient mice show enhanced angiogenesis, shorter infarcts and preserved ejection 
fraction 28d after MI (see Section 1.2.6) (Small, et al., 2005; McSweeney, et al., 
2010), but the effects on the development of heart failure are unknown. 
Cardiovascular 11β-HSD1 plays a role in calcium handling gene expression, as 
deletion specifically in cardiomyocytes and VSMCs (SMAC mice) leads to diastolic 
dysfunction and reduced SERCA mRNA and protein expression (Chapter 3). Infarct 
healing in the short term, up to seven days post-MI, is unaffected in these mice 
(Chapter 4), however it is unclear how 11β-HSD1 deficient mice and SMAC mice 
will respond to MI in the long term. 11β-HSD1 deficient mice may be in a position 
to better adapt, given the they have increased angiogenesis after MI, and therefore 
show an improved outcome. On the other hand, they may exhibit an exaggerated 
detrimental phenotype compared to control, considering the ubiquitous reduction in 
myocardial SERCA. SMAC mice may show more severe heart failure compared to 
controls, since these mice do not exhibit enhanced angiogenesis, yet do have reduced 
myocardial SERCA. 
It is therefore hypothesised that 11β-HSD1 deficient mice will still show a beneficial 
phenotype, and resist heart failure, eight weeks after infarction; they will have 
smaller infarcts, preserved cardiac function and attenuated chamber dilatation. It is 
hypothesised that the basal reduction in SERCA mRNA levels and protein 
expression limits the scope for further SERCA reduction and therefore this will not 
impact on the favourable outcomes previously found (McSweeney, et al., 2010). 
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However, SMAC mice do not show a beneficial response seven days post-MI 
(Chapter 4), and so it is hypothesised that SMAC mice will show similar left 
ventricular dilatation, infarct size and reduction in systolic function to controls eight 
weeks after MI. 
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5.2 Methods 
Male 11β-HSD1 deficient mice and their C57BL/6 controls, and cardiovascular-
specific 11β-HSD1 KO (SMAC) mice, and their Cre
-
 littermate controls, underwent 
coronary artery ligation surgery aged 10-12 weeks (Section 2.2.3). Initially, global 
11β-HSD1 KO mice (DelI mice) initially underwent coronary artery ligation. 
However, all mice (n=16) died between d3 and d5 after surgery from cardiac rupture. 
This may be due to a greatly enhanced inflammatory response, which has been 
previously shown to result in cardiac rupture (Nian, et al., 2004), and this is currently 
being investigated. Because of the lack of survival of DelI mice beyond d5, 11β-
HSD1 deficient mice, which are hypomorphic for 11β-HSD1, were used. 
Tail blood was collected 24h after surgery (Section 2.2.4) to determine the extent of 
initial cardiac injury, by measurement of cardiac troponin-I (Section 2.6.5). CINE 
MRI was performed 8w after surgery (Section 2.2.5) to assess cardiac size and 
function. Mice were killed by cervical dislocation immediately following CINE MRI 
and hearts and lungs were harvested. Lungs were weighed to assess pulmonary 
oedema. Hearts were weighed and either frozen at -80
o
C for qRT-PCR and western 
blotting, or processed, embedded in paraffin wax and microtomed into 4μm thick 
sections for histology and immunohistochemical analysis. This allowed 






5.2.1 Histology and immunohistochemistry 
Masson’s Trichrome staining was used to determine infarct size and thickness 
(Section 2.4.3). Immunofluorescent staining with wheat germ agglutinin, isolectin B4 




RNA was extracted from homogenised heart tissue using TRIzol as described in 
Section 2.6.1. cDNA was synthesized as detailed in Section 2.6.2 and qRT-PCR was 
performed as described in Section 2.6.3 to assess mRNA levels of SERCA (Atp2a2), 
NCX (Slc8a1), RyR (Ryr2), CaV1.2 (Cacna1c), ANP (Nppa), Col1α2 (Col1a2), 
Col3α1 (Col3a1), TGFβ (Tgfb1), α-MHC (Myh6), and β-MHC (Myh7). The internal 
control for all qRT-PCR experiments was β-actin (Actb) which was similar in all 
groups (See Appendix 1). 
 
5.2.3 Western blotting 
Protein was extracted from homogenised heart samples, electrophoresed on a 
polyacrilamide gel and transferred onto a nitrocellulose membrane as described in 
Section 2.6.4. The membranes were exposed to antibodies against SERCA and the 




5.2.4 Statistical analysis 
All values are expressed as mean ± SEM. A p value of less than 0.05 indicated 
statistical significance. Mortality data were compared using Fisher’s exact test and 




5.3.1 Global 11β-HSD1 deficiency and cardiovascular 11β-HSD1 deletion do 
not influence mortality 
After coronary artery ligation, mortality was similar in 11β-HSD1 deficient mice and 
C57BL/6 control mice (Figure 5.1a) and in SMAC and their Cre
-
 control mice 
(Figure 5.1b), with 73%, 75%, 80% and 86% of mice, respectively, surviving until 
8w post-MI. Post mortem investigation of deaths revealed they were all a result of 
cardiac rupture, as determined by the presence of blood in the chest cavity and a 
rupture of the left ventricular wall. 
 
5.3.2 Initial ischaemic injury is unaffected by global 11β-HSD1 deficiency and 
cardiovascular 11β-HSD1 deletion 
24hr after ligation surgery, plasma levels of cardiac troponin-I were elevated to a 
similar extent in 11β-HSD1 deficient mice and C57BL/6 control mice (Figure 5.2a), 
and in SMAC and Cre
-
 control mice (Figure 5.2b), suggesting a similar extent of 
initial cardiac injury in all genotypes. 
 
5.3.3 Global 11β-HSD1 deficiency, but not cardiovascular 11β-HSD1 deletion, 
attenuates left ventricular dilatation 8w after MI 
5.3.3.1 CINE MRI 
11β-HSD1 deficient mice had reduced left ventricular dilatation compared to 
C57BL/6 control mice, with smaller left ventricular end systolic volumes (LVESV, 
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Figure 5.3a, p<0.05) and left ventricular end diastolic volumes (LVEDV, Figure 
5.3c, p<0.05). This reduced dilatation was not seen in SMAC mice, as they had 
similar LVESV and LVEDV to Cre
-
 controls, 8w post-MI (Figure 5.3b and d). 
Having said that, a direct comparison between 11β-HSD1 deficient mice and SMAC 
mice was not made. 
 
5.3.3.2 Gravimetrics 
The difference in left ventricular volume between 11β-HSD1 deficient mice and 
control mice was supported by post-mortem data showing that 11β-HSD1 deficient 
mice had reduced heart weights compared to control (Figure 5.4a, p<0.001), despite 
both genotypes having similar body weights (Figure 5.4b). This resulted in a reduced 
heart weight to body weight ratio (Figure 5.4c, p<0.001). In contrast, heart weight to 
body weight ratio was similar between SMAC and Cre
-
 control mice. 
 
5.3.3.3 Cardiomyocyte cross-sectional area 









Figure 5.1 Global 11β-HSD1 deficiency, or cardiovascular 11β-HSD1 deletion does not 
affect mortality after coronary artery ligation 
Mortality after coronary artery ligation surgery in 10-12w old (a) 11β-HSD1 deficient mice 
(dashed line, n=10) and C57BL/6 mice (solid line, n=8) (no significant difference; Fisher’s 
exact test, chi square p=0.71) and in (b) SMAC mice (dashed line, n=10) and Cre- control 
mice (solid line, n=8) (no significant difference; Fisher’s exact test, chi square p=0.88). 
SMAC mortality
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Figure 5.2 Global 11β-HSD1 deficiency, or cardiovascular 11β-HSD1 deletion, does not 
affect the extent of initial injury after coronary artery ligation 
Plasma cardiac troponin-I levels were measured by ELISA in 10-12w old (a) 11β-HSD1 
deficient mice and C57BL/6 control mice and (b) SMAC and Cre
-
 control mice 24h post-MI 



























































Figure 5.3 Global, but not cardiovascular, 11β-HSD1 deficiency attenuates left 
ventricular dilatation 8w post-MI 
LVESV and LVEDV of 18-20w old 11β-HSD1 deficient mice and C57BL/6 control mice (a 
and c) and SMAC and Cre
-
 control mice (b and d) were measured by CINE MRI 8w post-MI 






























































































































Figure 5.4 Global, but not cardiovascular, 11β-HSD1 deficiency reduces heart weight 
8w post-MI 
Heart weight (a and b), body weight (c and d) and heart weight to body weight ratio (e and f) 
in 18-20w old 11β-HSD1 deficient mice and C57BL/6 control mice, and SMAC mice and 
Cre
-
 control mice 8w post-MI (Student’s t test *** = p<0.001; n=8/group for SMAC & 11β-




































































































































































Figure 5.5 Cardiomyocyte cross-sectional area is not influenced by 11β-HSD1 
deficiency 8w post-MI 
Cardiomyocyte cross sectional area (a) in 18-20w old 11β-HSD1 deficient mice and 
C57BL/6 control mice (b), and SMAC and Cre
-
 control mice (c) 8w post-MI (Student’s t 
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5.3.4 Global 11β-HSD1 deficiency, but not cardiovascular 11β-HSD1 deletion, 
reduces foetal gene expression and pulmonary oedema 8w after MI 
5.3.4.1 ANP and β-MHC expression 
ANP mRNA levels were significantly reduced in 11β-HSD1 deficient mice 8w post-
MI compared to C57BL/6 control mice (Figure 5.6a, p<0.01). 11β-HSD1 deficient 
mice also exhibited an increased α-MHC to β-MHC mRNA ratio compared to 
control mice (Figure 5.6c, p<0.05). ANP mRNA levels and α-MHC to β-MHC ratio 
were similar in SMAC mice and Cre
-
 control mice (Figure 5.6b and d). 
 
5.3.4.2 Pulmonary Oedema 
Lung wet weight was measured immediately following cull by cervical dislocation. 
11β-HSD1 deficient mice had significantly lighter lungs compared to their C57BL/6 
control mice (Figure 5.7a, p<0.05), whereas SMAC and their respective control mice 
had similar lung weights (Figure 5.7b). 
 
5.3.5 Systolic function is preserved in mice with global 11β-HSD1 deficiency, 
but not in mice with cardiovascular 11β-HSD1 deletion 8w after MI 
Ejection fraction (EF), assessed by CINE MRI, was increased in 11β-HSD1 deficient 
mice compared to their C57BL/6 control mice (Figure 5.8a, p<0.05). SMAC and 
their Cre
-















Figure 5.6 Global, but not cardiovascular, 11β-HSD1 deficiency reduces ANP and β-
MHC mRNA levels in the heart 8w post-MI 
ANP mRNA levels and α-MHC:β-MHC ratio, as measured by qRT-PCR, in 18-20w old 
11β-HSD1 deficient mice and C57BL/6 control mice (a and c) and SMAC and Cre
-
 control 
mice (b and d) 8w post-MI (Student’s t test ** = p<0.01, * = p<0.05; n=8/group for SMAC 











































































Figure 5.7 Global, but not cardiovascular, 11β-HSD1 deficiency reduces pulmonary 
oedema 8w post-MI 
Lung weight, measured immediately following cull, in 18-20w old (a) 11β-HSD1 deficient 
mice and C57BL/6 control mice, and (b) SMAC and Cre
-
 control mice 8w post-MI 




















































Figure 5.8 Global, but not cardiovascular, 11β-HSD1 deficiency preserves systolic 
function 8w post-MI 
Ejection fraction of 18-20w old 11β-HSD1 deficient mice and C57BL/6 control mice (a), 
and SMAC and Cre
-
 control mice (b) was measured by CINE MRI 8w post-MI (Student’s t 


















































5.3.6 Infarct length is reduced and infarct thickness is increased in global 11β-
HSD1 deficient mice, but not in mice with cardiovascular-specific 11β-HSD1 
deletion, 8w after MI 
5.3.6.1 Magnetic resonance imaging 
Analysis of CINE MRI images revealed 11β-HSD1 deficient mice had shorter 
infarcts compared to their C57BL/6 controls (Figure 5.9a, p<0.05), whereas SMAC 
mice and their Cre
-
 controls had similar infarct lengths (Figure 5.9b). 
 
5.3.6.2 Masson’s Trichrome staining 
Figure 5.10 shows example images of Masson’s Trichrome staining of C57BL/6 
(Figure 5.10a) and 11β-HSD1 deficient (Figure 5.10b) hearts, and Cre
-
 (Figure 5.10c) 
and SMAC (Figure 5.10d) hearts. 
11β-HSD1 deficient mice had significantly shorter infarcts compared to their 
C57BL/6 control mice (Figure 5.10e, p<0.01), whereas SMAC mice and their Cre
-
 
control mice had infarcts of similar length (Figure 5.10f).  
11β-HSD1 deficient mice had significantly thicker infarcts compared to their 
C57BL/6 control mice (Figure 5.10g, p<0.001), whereas SMAC and their Cre
-
 









Figure 5.9 Global, but not cardiovascular, 11β-HSD1 deficiency reduces infarct length 
8w post-MI 
Infarct length, as measured by CINE MRI (see Section 2.2.6), of 18-20w old (a) 11β-HSD1 
deficient mice and C57BL/6 control mice, and (b) SMAC mice and Cre
-
 control mice 8w 
post-MI (Student’s t test * = p<0.05; n=8/group for SMAC & 11β-HSD1 deficient mice, 






































































Figure 5.10 Global 11β-HSD1 deficiency reduces infarct length and increases infarct 
thickness 8w post-MI, but cardiovascular 11β-HSD1 deletion does not 
Representative images of Masson’s Trichrome stained heart sections from 18-20w old (a) 
C57BL/6 mice, (b) 11β-HSD1 deficient mice (c) Cre
-
 mice and (d) SMAC mice 8w post-MI. 
Infarct length and thickness in 11β-HSD1 deficient mice and C57BL/6 control mice (e and 
g), and SMAC mice and Cre
-
 control mice (f and h) were measured as detailed in Section 
2.4.2 (Student’s t test *** = p<0.001, ** = p<0.01; n=8/group for SMAC & 11β-HSD1 
deficient mice, n=6/group for controls). Scale bar is 25μm. 
































































































5.3.7 Myocardial collagen gene expression, 8w after MI, is not influenced by 
global 11β-HSD1 deficiency or cardiovascular 11β-HSD1 deletion 
mRNA levels of the alpha 2 subunit of type 1 collagen (Col1a2, Figure 5.11a and b), 
the alpha 1 subunit of type 3 collagen (Col3a1, Figure 5.11c and d) and TGFβ 
(Tgfb1, Figure 5.11e and f) in the heart were similar in all groups, as was β-actin 
(Actb), the internal control (see Appendix 1). 
 
5.3.8 Calcium handling genes are not influenced by global 11β-HSD1 
deficiency or cardiovascular 11β-HSD1 deletion 8w after MI 
SERCA (Atp2a2, Figure 5.12a and b) and NCX (Slc8a1, Figure 5.12c and d) mRNA 
levels were similar in all groups. SERCA protein (Figure 5.12e) was also similar in 





















Figure 5.11 Fibrotic gene mRNA levels in the heart are not influenced by 11β-HSD1 
deficiency 8w post-MI 
Myocardial Col1α2 (a and b), Col3α1 (c and d) and TGFβ (e and f) mRNA levels in 18-20w 
old 11β-HSD1 deficient mice and C57BL/6 control mice, and SMAC and Cre
-
 control mice 












































































































































Figure 5.12 11β-HSD1 deficiency does not alter mRNA levels of calcium handling genes 
in the heart 8w post-MI 
Myocardial SERCA (a and b) and NCX (c and d) mRNA levels, as measured by qRT-PCR, 
and SERCA protein expression (e – g), as measured by Western blotting, in 18-20w old 11β-
HSD1 deficient mice and C57BL/6 control mice, and SMAC Cre
-
 control mice 8w post-MI 



















































































































































The data presented in this chapter shows that the beneficial phenotype seen in global 
11β-HSD1 deficient mice at 28d post-MI is maintained up to 8w after MI. These 
mice have smaller, lighter hearts, reduced left ventricular dilatation, preserved 
systolic function, attenuated expression of ANP and β-MHC, attenuated pulmonary 
oedema and smaller infarcts than controls. SMAC mice did not recapitulate the 
phenotype of 11β-HSD1 deficient mice and were similar to Cre
-
 control mice for all 
parameters. Despite SMAC mice displaying mild diastolic dysfunction basally, 
possibly due to altered calcium handling as a result of reduced SERCA expression 
(Chapter 3), they did not appear to have abnormally impaired calcium handling gene 
expression eight weeks after infarction; SERCA mRNA levels and protein 
expression and NCX protein expression in these mice were similar to levels in 
control mice. 
 
5.4.1 Initial ischaemic injury and mortality 
The data presented in this study show that 11β-HSD1 deficient mice and SMAC 
mice had similar plasma cardiac troponin-I levels compared to their respective 
controls, and therefore had a similar extent of initial cardiac injury 24h after coronary 
artery ligation. This suggests that 11β-HSD1 deletion in the heart and vasculature 
does not impact upon initial injury and any differences in left ventricular dilatation, 
systolic function, infarct size, collagen deposition or gene expression 8w after MI, 
are not due to differences in initial injury. However, sham-operated mice were not 
used in this study, and so a comparison of 24h plasma cardiac troponin-I levels, or 
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any other parameters 8w post-MI, to sham-operated animals cannot be made. 
Nevertheless, previous studies have shown cardiac troponin-I is present at very low 
levels in sham-operated C57BL/6 mice but is significantly elevated 24h after MI 
(Montecucco, et al., 2012) to a similar level to that seen in the mice used in this 
study. Sham-operated Cre
-
 mice (Chapter 4) also show significantly reduced plasma 
cardiac troponin-I levels compared to Cre
-
 mice which had ligation surgery. As such, 
plasma cardiac troponin-I levels observed in 11β-HSD1 deficient mice and SMAC 
mice, and their respective controls, 24h after MI in this study reflect published levels. 
The primary cause and rate of mortality was similar in all groups, demonstrating that 
11β-HSD1 deficiency, either globally or specifically in cardiovascular cells, does not 
result in grossly adverse cardiac remodelling.  
The ability of glucocorticoids to protect ischaemic cardiomyocytes immediately 
following occlusion is well established (Libby, et al., 1973; Hoffstein, et al., 1976). 
HPA axis activation after MI leads to increased circulating corticosterone levels 
(McSweeney, 2010). The degree of elevation of plasma corticosterone immediately 
after MI can modify the extent of initial injury (Xu, et al., 2011), demonstrating the 
cardioprotective effect of corticosteroids in this setting. The extent of remodelling 
which occurs after MI is largely dependent on initial injury and infarct size, with 
infarct size negatively correlating with morbidity and mortality in the long term 
(Yang, et al., 2002a; Numaguchi, et al., 2006). Given that 11β-HSD1 deficient mice 
and SMAC mice are unable to locally regenerate glucocorticoids in cardiomyocytes, 
systemic corticosterone release from the adrenal glands must therefore be sufficient 
to protect cardiomyocytes from initial ischaemic damage, in a similar manner to 
control mice.  
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Global 11β-HSD1 deficiency on the C57BL/6 background has been shown to alter 
basal HPA axis function, with these mice exhibiting increased plasma corticosterone 
levels (Harris, et al., 2001; Carter, et al., 2009). This may impact upon the data 
presented in this thesis, as increased basal plasma corticosterone levels may lead to 
an exaggerated HPA axis response after infarction. Indeed, 11β-HSD1 deficiency has 
been shown to result in an augmented HPA axis response after restraint stress 
(Harris, et al., 2001). However, these mice have been shown to have similar 
circulating plasma corticosterone levels 24h after infarction (McSweeney, et al., 
2010), although this was not measured in the current study. Effects of 11β-HSD1 
deficiency on HPA axis regulation is strain specific as 11β-HSD1 deletion on the 
129/MF1 background causes hypersecretion of glucocorticoids under basal 
conditions (Harris, et al., 2001; Carter, et al., 2009). It is hypothesised that 11β-
HSD1 deficient mice and SMAC mice would have similar plasma corticosterone 
levels compared to their respective controls since all are on the C57BL/6 
background. However, this should be confirmed in future studies. 
 
5.4.2 Markers of heart failure 
The inadequacy of the heart to efficiently eject blood following infarction can result 
in cardiogenic pulmonary oedema. This occurs because of a build up of back 
pressure in the pulmonary circulation which, in turn, causes fluid to extravasate from 
the capillary bed out into the alveoli (Vital, et al., 2013). This can lead to impaired 
gas exchange at the alveolar-capillary interface and, therefore, breathing difficulties 
(Vital, et al., 2013). Pulmonary oedema is thus a key indicator of heart failure (Lu, et 
al., 2010; Thorneloe, et al., 2012; Clark & Cleland, 2013) and is associated with 
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reduced left ventricular ejection fraction after infarction (Schiffrin & Taillefer, 1986; 
Jones, et al., 2003). Therefore, it can be used as a marker to assess the extent of heart 
failure. Although lung weights in mice 8w post-MI cannot be directly compared to 
sham-operated mice, due to an absence of sham-operated mice in this study, the lung 
weight in the mice which underwent ligation surgery are similar to published data 
(Adachi, et al., 2003; Lu, et al., 2010), suggesting these animals show signs of 
pulmonary oedema. 
Cardiac dysfunction and hypertrophy is also characterised by an increase in atrial 
natriuretic peptide (ANP) levels and increased expression of β-myosin heavy chain 
(β-MHC) (Jones, et al., 1996; Harada, et al., 1999), which indicates a reversion of 
cardiomyocytes back to a foetal phenotype (Rog-Zielinska, et al., 2013). ANP is a 
hormone released from cardiomyocytes in a stretch-dependent fashion (De Bold, et 
al., 1981). Increased cytosolic calcium concentration, which is seen in a setting of 
hypertrophy, activates the phosphoinositide pathway leading to ANP secretion 
(Sonnenberg, 1986). Upon secretion, this peptide binds to its receptor, guanylyl 
cyclase-A (GC-A), and through a cGMP-mediated pathway it affects a number of 
physiological parameters (Holtwick, et al., 2002). It performs compensatory 
functions in an attempt to attenuate the progression of heart failure. It causes diuresis 
and natriuresis, it is hypotensive, anti-hypertrophic, anti-fibrotic and anti-
proliferative, and it contributes to angiogenesis (reviewed in Saito, 2010). Indeed, 
ANP KO mice have salt-sensitive hypertension (John, et al., 1995) and GC-A KO 
mice have salt-insensitive hypertension (Lopez, et al., 1995). The mechanism of 
hypertension in the GC-A KO mouse is hypothesised to be due to inhibition of the 
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extravasation of blood from the intravascular space to the extravascular space 
(Holtwick, et al., 2002; Sabrane, et al., 2009). 
After infarction, ANP has been shown to be vital for survival within the first seven 
days following occlusion, and that its action via the GC-A receptor attenuates fibrotic 
and hypertrophic responses (Nakanishi, et al., 2005). Myocardial and plasma ANP 
levels have been shown to increase after MI, and that increasing levels correlate with 
the extent of left ventricular dysfunction (Lu, et al., 2010; Vaz Perez, et al., 2010). 
As such, it can be used as a marker to help ascertain the degree of heart failure in an 
experimental model of MI. Since this study lacks sham-operated mice, myocardial 
ANP mRNA levels in mice 8w post-MI cannot be directly compared to levels after 
sham operations. However, ANP mRNA in the hearts from mice which underwent 
ligation surgery was detectable at a very low cDNA dilution (1/2) during qRT-PCR. 
This suggests ANP mRNA was abundant and, considering ANP has been shown to 
be present at very low levels in sham-operated hearts in other studies  (Drexler, et al., 
1989; Hama, et al., 1995), it can be hypothesised that the levels detected in the mice 
which underwent coronary artery ligation are markedly increased compared to 
baseline. 
Another gene which is upregulated in heart failure is β-MHC (Buttrick, et al., 1991; 
Takahashi, et al., 1992). Cardiac muscle myosin is a hexameric protein which 
consists of two heavy chain subunits, two light chain subunits and two regulatory 
subunits. The heavy chain exists as two isoforms, α and β. In the myocardium of 
small mammals, such as mice, expression of the α isoform predominates (Lompre, et 
al., 1979) whereas this is reversed in humans, with the β isoform accounting for over 
90% of the MHC subunits (Gorza, et al., 1984). The role of α-MHC in regulating 
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cardiac contractility has been shown by genetic manipulation in an experimental 
model of familial hypertrophic cardiomyopathy, with disruption of this gene 
resulting in cardiac dysfunction (Geisterfer-Lowrance, et al., 1996). A role for 
glucocorticoids has also been implicated, as glucocorticoids increase cardiac α-MHC 
expression and reduce β-MHC expression in rats (Sheer & Morkin, 1984). 
Transgenic mice which constitutively express β-MHC instead of α-MHC also 
showed a detrimental phenotype in response to chronic isoproterenol administration 
and in response to an MI model of heart failure (Krenz & Robbins, 2004). The ratio 
of α-MHC:β-MHC has been shown to directly correlate with cardiac function in both 
animals and humans (Miyata, et al., 2000; Abraham, et al., 2002; Herron & 
McDonald, 2002) and can thus be used to help determine the extent of heart failure 
in a model of infarction.  
11β-HSD1 deficient mice showed a reduced lung weight, a reduction in myocardial 
ANP mRNA levels and an increased α-MHC:β-MHC ratio compared to C57BL/6 
control mice. This indicates these mice have reduced remodelling 8w post-MI 
compared to control, and that global deficiency of 11β-HSD1 may attenuate the 
progression to heart failure 8w after infarction, which agrees with previous data 
(McSweeney, et al., 2010). In support of this conclusion, 11β-HSD1 deficient mice 
also have reduced dilatation and maintained systolic function, as well as shorter, 
thicker infarcts, which is discussed below. 
SMAC mice, on the other hand, had no difference in any of these parameters 
compared to their Cre
-
 controls 8w post-MI. This agrees with the data in Chapter 4 
which shows no change in any parameter in these mice after MI in the short term 
(<7d) compared to control. This suggests beneficial long term outcomes are 
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dependent on limiting early infarct expansion and that 11β-HSD1 in cardiomyocytes 
has no protective role in later remodelling. Further work to confirm this is necessary, 
possibly by using other models of heart failure, such as transaortic constriction or 
doxorubicin-induced heart failure. 
 
5.4.3 Fibrosis and infarct size 
The data presented here shows that the attenuated infarct thinning present in 11β-
HSD1 deficient mice 28 days after infarction, is maintained through to eight weeks 
after infarction. Furthermore, 11β-HSD1 deficient mice also exhibited a reduced total 
infarct size as measured by both CINE MRI and Masson’s Trichrome staining. This 
may be due to the enhanced angiogenesis previously reported in global 11β-HSD1 
deficient mice (Small, et al., 2005; McSweeney, et al., 2010), which may help to 
limit early infarct expansion, thus maintaining function and attenuating dilatation in 
the longer term. This beneficial outcome is seen despite similar initial injury as 
measured by plasma cardiac troponin-I. The inability of SMAC mice to reproduce 
the favourable phenotype seen in 11β-HSD1 deficient mice after MI suggests 11β-
HSD1 out with cardiomyocytes and VSMCs is responsible.  
Following the inflammatory phase of infarct healing, a collagen-rich scar is formed 
which is necessary to maintain the structural integrity of the left ventricular wall, and 
to prevent cardiac rupture (Porter & Turner, 2009). Deposition of collagen type I and 
type III, and other molecules necessary for appropriate ECM remodelling, is 
primarily performed by myofibroblasts; cells which have differentiated from cardiac 
fibroblasts and assume phenotypic characteristics similar to smooth muscle cells 
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(Gabbiani, 1998). Expression of pro-inflammatory and pro-fibrotic cytokines, such 
as IL-1β, IL-6, TNFα and TGFβ are all increased in patients following infarction 
(Nian, et al., 2004). Fibroblast migration into tissues occurs as a result of the pro-
inflammatory milieu of the infarcted heart, with TNFα and IL-1β being important 
chemoattractants (Nian, et al., 2004). IL-6, along with TNFα, has been shown to 
enhance fibroblast proliferation (Siwik, et al., 2000; Hellkvist, et al., 2002), with 
TGFβ known to stimulate fibroblast differentiation into myofibroblasts (Hao, et al., 
2008). IL-1β and IL-6 have been shown to degrade the ECM, primarily through 
expression of MMPs, such as MMP-2, MMP-9, and MMP-13 (Siwik, et al., 2000). 
TGFβ also plays a crucial role in stimulating collagen, fibronectin and proteoglycan 
deposition from myofibroblasts (Eghbali, et al., 1991; Heimer, et al., 1995; 
Villarreal, et al., 1996). ANP, which is released from cardiomyocytes in heart failure, 
performs a contrasting role; it inhibits fibroblast proliferation, differentiation into 
myofibroblasts, and collagen synthesis (Li, et al., 2008). Myocardial levels of 
Col1α2, Col3α1 and TGFβ mRNA were similar in 11β-HSD1 deficient mice and 
control mice, suggesting similar myofibroblast activation. As such, it may be 
concluded that this is not the mechanism which results in 11β-HSD1 deficient mice 
having smaller infarcts. 
Angiogenesis begins almost immediately after MI with endothelial cell sprouting and 
the formation of a primitive vessel network, which upon resolution of the 
inflammatory phase, is pruned and organised into an efficient network (Bergers & 
Song, 2005). Upon pericyte coating, these vessels mature and provide a long term 
blood supply to the surrounding tissue (Bergers & Song, 2005). Enhancing 
angiogenesis after infarction is key to salvaging affected ischaemic cardiomyocytes 
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in the peri-infarct region, and previous studies have shown augmenting this 
mechanism reduces infarct size and preserves cardiac function (Sasaki, et al., 2007). 
Moreover, maintenance of peri-infarct angiogenesis is crucial to prevent infarct 
expansion (Liu, et al., 2007). For example, in humans, capillary density in infarcted 
hearts correlates with reduced infarct size (Prech, et al., 2006). 
Glucocorticoids have long been known to have anti-angiogenic effects, with 11β-
HSD1 deficiency resulting in enhanced angiogenesis in subcutaneous sponge 
implants (Small, et al., 2005). Furthermore, 11β-HSD1 deficient mice fed a high fat 
diet have increased angiogenesis in adipose tissue which is hypothesised to protect 
this tissue from hypoxia, detrimental inflammation, metabolic abnormalities and 
fibrosis (Michailidou, et al., 2012). It may be hypothesised that increased peri-infarct 
angiogenesis in 11β-HSD1 deficient mice limits infarct expansion, leading to 
reduced remodelling. However, this still needs to be fully investigated. Since SMAC 
mice show a similar response to infarction, both acutely and in the long term, to 
control mice, it can be concluded that any possible change in peri-infarct 
angiogenesis is not a result of 11β-HSD1 deletion in cardiomyocytes or VSMCs. 
Key cell types involved in promoting and regulating angiogenesis include fibroblasts 
and alternatively-activated macrophages. As such, these cells are currently under 
investigation in the laboratory in a post-MI setting. 
 
5.4.4 Cardiac size and function 
Scar expansion and thinning, following resolution of the inflammatory phase, both 
contribute to adverse ventricular remodelling, and initial infarct size has been shown 
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to negatively correlate with morbidity and mortality (Pfeffer & Braunwald, 1990; 
Yang, et al., 2002a; Numaguchi, et al., 2006). Development of heart failure is 
characterised by several factors, including left ventricular dilatation and an increase 
in heart weight (Millar, et al., 2000; Gray & Sherry, 2002). Reduced cardiac function 
is also seen after MI, and has been reported in both human and animal studies 
(Pfeffer & Braunwald, 1990; Yang, et al., 2002a; Numaguchi, et al., 2006). 
C57BL/6 mice and Cre
-
 control mice both showed similar left ventricular size to 
published values in other mouse models of hearts failure (Yang, et al., 2002b; Protti, 
et al., 2012), as well as heavier hearts compared to naїve mice (Chapter 3). 
Furthermore, they exhibited very low ejection fractions, in line with published data 
(Yang, et al., 2002b; Protti, et al., 2012), suggesting loss of systolic function. This 
suggests these mice did indeed show left ventricular dilatation. Coupled with the rest 
of the data in this chapter showing these mice had increased lung weight, increased 
ANP mRNA and reduced α-MHC:β-MHC ratio, it can be concluded this coronary 
artery ligation model does indeed lead to heart failure after eight weeks. 
This study shows that global 11β-HSD1 deficiency results in attenuated left 
ventricular dilatation, as measured in vivo by MRI, as well as reduced heart weight as 
measured ex vivo by gravimetrics 8w after MI. The shorter, thicker infarcts present in 
11β-HSD1 deficient mice may contribute to this phenotype, as reduced infarct 
thinning enhances the structural integrity of the heart. Correspondingly, ejection 
fraction is preserved in 11β-HSD1 deficient mice. However, this phenotype is not 
reproduced by ‘cardiovascular’ 11β-HSD1 deletion, with SMAC mice showing 
similar dilatation and ejection fraction to Cre
-
 controls. Taken together, the MRI and 
gravimetrics data suggests cardiovascular 11β-HSD1 deletion does not attenuate left 
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ventricular dilatation or maintain cardiac function 8w after MI and 11β-HSD1 out 
with the cardiovascular system appears to be responsible for the beneficial outcome 
seen in globally 11β-HSD1 deficient mice. 
Recent clinical trials into blockade of MR in the Randomised Aldactone Evaluation 
Study (RALES) and the Eplerenone Post Acute Myocardial Infarction Heart Failure 
Efficacy and Survival Study (EPHESUS) have demonstrated the beneficial effects of 
selectively blocking these receptors in patients with heart failure, whereby these 
patients showed reduced remodelling and reduced myocardial fibrosis (Pitt, et al., 
1999; Pitt, et al., 2003). In experimental models, eplerenone has been shown to 
accelerate macrophage infiltration, enhance peri-infarct angiogenesis and maintain 
left ventricular function in rats when administered immediately after coronary artery 
ligation (Fraccarollo, et al., 2008). Allowing aldosterone access to MR in 
cardiomyocytes, by overexpressing 11β-HSD2 in these cells, and thus reducing 
intracellular availability of glucocorticoids, leads to cardiac hypertrophy (Qin, et al., 
2003). It may be hypothesised that a similar situation is seen with 11β-HSD1 
deletion in cardiomyocytes (SMAC mice). Deletion of 11β-HSD1 specifically in 
these cells may also allow aldosterone access to MR, and thus result in a post-MI 
response similar to control, particularly since aldosterone has been shown to increase 
after infarction (Ceremuzynski, 1981). In globally 11β-HSD1 deficient mice, this 
adverse, or similar, response may be overcome by deletion of the enzyme in another 
cell type. For example, 11β-HSD1 deletion in fibroblasts, alternatively-activated 
macrophages or another cell type may be key to the differences observed in 
remodelling in 11β-HSD1 deficient mice versus SMAC mice, and they thus warrant 
further investigation. Attenuation of heart failure in a non-MI model by 
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administration of an 11β-HSD1 inhibitor further suggests that alterations of 
mechanisms over and above manipulating infarct size contribute to this beneficial 
outcome (Gordon, et al., 2014). 
Electrophysiological changes also occur in heart failure, with several clinical studies 
in the 1990s reporting reduced SERCA mRNA levels and protein expression 
(Mercadier, et al., 1990; Takahashi, et al., 1992) and a subsequent increase in NCX 
mRNA and protein expression (Studer, et al., 1994; Flesch, et al., 1996) in this 
disease setting. Considering that naїve SMAC mice have lower SERCA mRNA 
levels and protein expression under basal conditions (Chapter 3), it was hypothesised 
that these mice may have had an exaggerated response to heart failure. However, 
mRNA levels and protein expression of SERCA and protein expression of NCX was 
similar across all groups suggesting this is not the case. The degree of SERCA 
expression relative to sham was not investigated, due to a lack of sham-operated 
mice in this study, and should be included in future studies, as should the regulation 
of SERCA by phospholamban. Phospholamban is a key regulator of SERCA activity 
and changes in protein expression, or its phosphorylation state, which regulates its 
inhibitory influence on SERCA, may provide further insights into calcium regulation 
during heart failure in these mice. 
In conclusion, the data presented in this chapter suggests that the beneficial outcome 
seen 8 weeks after MI in mice globally deficient in 11β-HSD1, is not due to deletion 
of the enzyme in cardiomyocytes or VSMCs. As such, deletion of 11β-HSD1 out 
with these cell types appears to be responsible for maintaining scar thickness, 
attenuating infarct thinning and left ventricular dilatation and preserving systolic 
function through to 8w post-MI. Along with the data presented in Chapter 4, this 
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may suggest a key role for 11β-HSD1 deficiency in neutrophils, macrophages, or 
fibroblasts in modifying initial inflammatory and angiogenic pathways, leading to 
beneficial outcomes acutely and chronically after infarction. 
This data therefore suggests that it is not lack of 11β-HSD1 in myocardial cells 
which maintains the beneficial phenotype seen in global 11β-HSD1 deficient mice at 
28d post-MI, but rather loss of 11β-HSD1 in another cell type. Considering the data 
in this chapter, and the data in Chapter 4, recruited neutrophils, macrophages, or 






11β-HSD1 is found in numerous cells in the heart, including cardiomyocytes, 
VSMCs, fibroblasts, and the vascular wall (Hadoke, et al., 2001; Christy, et al., 
2003; Klusonova, et al., 2009; McSweeney, et al., 2010). This thesis aimed to 
determine the relative role of 11β-HSD1 in cardiomyocytes and VSMCs. 
The first hypothesis investigated in this thesis was that deletion of 11β-HSD1 in 
cardiomyocytes and VSMCs would result in smaller, lighter hearts, but would not 
influence cardiac function. The second hypothesis was deletion of 11β-HSD1 in 
these cells would reproduce the beneficial post-MI phenotype previously seen in 
global 11β-HSD1 deficient mice. 
 
6.1 11β-HSD1 in cardiomyocytes and VSMCs influences the 
physiological function of the heart 
11β-HSD1 expression in the heart is relatively modest compared to other tissues, 
such as the liver, and expression is primarily found in fibroblasts (Brereton, et al., 
2001). As such, 11β-HSD1 expression in cardiomyocytes and VSMCs contributes a 
small proportion to the overall 11β-HSD1 protein levels in the heart. Despite this low 
level, 11β-HSD1 expression in the heart is critical to normal cardiac structure and 
function. For example, investigation of the basal cardiac phenotype of mice globally 
deficient in 11β-HSD1 revealed these mice had reduced heart size and weight 
(McSweeney, 2010), however, the reason for this was unknown. 11β-HSD1 has also 
been shown to regulate heart size in a human population study, with a single 
nucleotide polymorphism in the Hsd11b1 gene associating with reduced left 
ventricular mass in a human population study (Rahman, et al., 2011). The data in this 
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thesis (Chapter 3) show that global 11β-HSD1 deletion has no influence on 
cardiomyocytes cross-sectional area, but rather results in shorter cardiomyocytes in 
young adult males. This does not appear to be due to loss of the enzyme in 
cardiomyocytes (or VSMCs) themselves, as this phenotype is not reproduced in 
SMAC mice. As such, the mechanism behind this phenotype may lie with other cells 
present in the heart which express 11β-HSD1, such as cardiac fibroblasts (Brereton, 
et al., 2001) or macrophages, which are known to express 11β-HSD1 in other tissues 
(Gilmour, et al., 2006). 
The work in this thesis shows that global 11β-HSD1 deletion results in mild diastolic 
dysfunction, a phenotype reproduced by cardiovascular-specific deletion and chronic 
11β-HSD1 inhibition (Chapter 3). Further investigation into this diastolic phenotype 
revealed that this may be due to reduced expression of SERCA, a transporter which 
is crucial for reuptake of calcium back into the sarcoplasmic reticulum after cellular 
contraction (Periasamy & Kalyanasundaram, 2007). A reduction in SERCA, either in 
genetic KO animals or in a pathological setting such as heart failure, is normally 
compensated for by an increase in NCX, so as to sustain calcium removal from the 
cytosol and maintain normal cardiomyocyte relaxation (Limas, et al., 1987; Dash, et 
al., 2001; Li, et al., 2011). However, NCX mRNA levels are not increased in DelI, 
SMAC or UE2316-treated mice, suggesting this reduction in SERCA may be 
compensated for in some other way in these mice. For example, reduced SERCA has 
been shown to lead to increased intracellular calcium concentration during diastole, 
which in itself enhances SERCA activity (Stokke, et al., 2010; Li, et al., 2011). 
In terms of regulation of SERCA activity, a reduction in overall SERCA protein 
expression was not compensated for by reduced expression of its key regulator 
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phospholamban, or by increased phospholamban phosphorylation at Serine 16 or 
Threonine 17, which would have resulted in reduced inhibition of SERCA function. 
The ratio of phospholamban to SERCA is a key regulator of contractility as 
experiments using murine atrial and ventricular tissue, which express differential 
levels of phospholamban, have shown (Koss, et al., 1997). Indeed, studies using 
phospholamban KO mice demonstrated these hearts have increased left ventricular 
contractility, thus reinforcing the importance of the phosopholamban:SERCA ratio 
(Koss, et al., 1997). 
Assessment of SERCA activity and intracellular calcium flux merits further 
investigation in isolated cardiomyocytes, and in isolated hearts using a Langendorff 
preparation, in order to fully understand whether cytosolic calcium availability is 
modified in these mice. If this is the case, and considering systolic function is 
unaltered in these mice, it may be hypothesised that contractile filament sensitivity 
may therefore be increased to account for unaltered contractile function, although 
further functional studies in isolated cardiomyocytes are required to investigate this. 
In a pathophysiological setting, such as heart failure, a reduction in SERCA mRNA 
levels and protein expression are commonly seen (Mercadier, et al., 1990; Takahashi, 
et al., 1992). However, 8w after MI, SERCA expression was not altered in 11β-
HSD1 deficient mice or SMAC mice, and there was no compensatory increase in 
NCX mRNA levels, relative to their respective controls. The unaltered expression of 
NCX may help to prevent sodium accumulation, which is seen in the SERCA KO 
mouse, and contributes to diastolic dysfunction (Louch, et al., 2010; Li, et al., 2012). 
However, the degree of SERCA expression relative to sham was not investigated, 
due to a lack of sham-operated mice in this study, and should be included in future 
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studies, as should the regulation of SERCA by phospholamban, by determining 
phospholamban protein expression and phosphorylation levels. 
The data presented in this thesis suggest that, despite a reduction in basal SERCA 
expression, loss of 11β-HSD1 is overall beneficial in terms of preventing heart 
failure. Therefore, it remains an area of potential therapeutic benefit. 
 
6.2 11β-HSD1 in locations distinct from cardiomyocytes and 
VSMCs influences cardiac growth and the response to MI 
Loss of 11β-HSD1 only in cardiomyocytes and VSMCs does not impact upon heart 
size, but loss elsewhere results in a reduced heart weight and shorter cardiomyocytes. 
Therefore, the mechanism behind this phenotype may lie with other cells present in 
the heart which express 11β-HSD1, such as cardiac fibroblasts (Brereton, et al., 
2001) or macrophages (Gilmour, et al., 2006), or perhaps in another tissue 
completely. For example, male mice have high levels of 11β-HSD1 mRNA in the 
kidney (Rajan, et al., 1995), an organ heavily involved with blood volume and blood 
pressure regulation; factors which directly influence cardiomyocyte length (De 
Simone, 2003; Hanft, et al., 2008). These parameters were unaltered in the present 
study, however other factors secreted from the kidney may play a role. Peroxisome 
proliferator-activator receptor-γ (PPAR-γ), which is present on cardiomyocytes 
(Saris, et al., 2001) and renin, which is secreted by the kidney, have also been shown 
to regulate cardiomyocyte length (Hinrichs, et al., 2011). Blood volume and blood 
pressure are unaffected by global 11β-HSD1 deletion, but levels of PPAR-γ and 
renin were not investigated and should be considered for further studies. This is 
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despite the well known effect of glucocorticoids on elevating blood pressure 
(Connell, et al., 1987; Fraser, et al., 1999; Masuzaki, et al., 2003; Van Raalte, et al., 
2013). Therefore, 11β-HSD1 deletion in another cell type, or types, must be 
responsible. 
Cardiac fibroblasts secrete a number of growth factors crucial for cardiomyocytes 
growth, such as FGF-2, IL-33, LIF and CT-1 (Matsui, et al., 1996; Wollert, et al., 
1996; Wang, et al., 2002; Jiang, et al., 2007). Resident macrophages also secrete 
growth factors, with IGF-1 being particularly prominent with regards to stimulating 
cardiomyocyte growth (Gow, et al., 2010). Glucocorticoids are known to upregulate 
expression of hypertrophic genes (Yoshikawa, et al., 2009) and so loss of 11β-HSD1 
in one or both of these cell types may alter the expression and secretion of growth 
factors. However, these growth factors are primarily known for regulating 
cardiomyocyte cross-sectional area and their influence on cardiomyocytes length has 
not been explored. Isolation of these cell types from DelI hearts, and investigation 
into their growth factor profile, may help to elucidate why global 11β-HSD1 deletion 
results in shorter cardiomyocytes. 
The expression of 11β-HSD1 in the cardiac fibroblasts of SMAC mice should also be 
investigated. Previous work has shown that inserting a Cre recombinase transgene 
into the Sm22α gene may have an effect on gene expression in myofibroblasts, as 
Sm22α has been found to be expressed in isolated myofibroblasts from rabbit bladder 
(Chiavegato, et al., 1999). However, Sm22α does not appear to be expressed in 
isolated human fibroblasts from COPD patients (Hallgren, et al., 2010). This 
suggests 11β-HSD1 expression may not be altered in cardiac fibroblasts in SMAC 
mice but nevertheless, this should be confirmed by immunohistochemical staining. 
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The transient nature of this phenotype is also an area of interest. DelI mice show 
reduced heart size at 10 weeks of age but heart size and cardiomyocyte cross-
sectional area (Appendix 3) is similar to C57BL/6 at 18 months of age, suggesting 
normal cardiomyocyte lengthening may be delayed rather than completely abrogated. 
It would be of interest to investigate cardiomyocyte length in neonate mice, or at 
other early post-natal stages in order to determine whether the trajectory of growth is 
delayed at other stages. GR-mediated glucocorticoid signalling has been shown to be 
critical for normal heart maturation during development (Rog-Zielinska, et al., 
2013), showing a role for glucocorticoids in regulating cardiac size and function. It 
may, therefore, be hypothesised that glucocorticoid amplification by 11β-HSD1 is 
necessary for appropriate heart growth during early post-natal development and the 
progression to adulthood. 
Administration of a selective 11β-HSD1 inhibitor, UE2316, for 9 months to adult 
C57BL/6SJL mice resulted in these mice showing a trend for larger, rather than 
smaller, hearts as assessed by high frequency ultrasound, and heavier, rather than 
lighter, hearts as weighed at post-mortem, however this was not due to a change in 
cardiomyocyte cross-sectional area. This suggests that inhibition of 11β-HSD1 in 
adults may have a separate effect to that seen in younger mice. Blood pressure and 
circulating cortisol are both known to increase with age, and both have been shown 
to enhance the development of cardiac hypertrophy (Landahl, et al., 1986; Van 
Cauter, et al., 1996; Walker, 2007a; De, et al., 2011; Drazner, 2011). As such, it may 
be hypothesised that global 11β-HSD1 deletion or chronic 11β-HSD1 inhibition may 
result in impaired GR-mediated negative feedback by glucocorticoids, due to reduced 
intracellular glucocorticoid bioavailability. In addition, the phenotype in UE2316-
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treated mice may be a result of unknown off-target effects of UE2316, or that partial 
11β-HSD1 inhibition gives a different phenotype to complete KO. Further 
investigation into off-target drug effects, heart weight, blood pressure and 
corticosterone levels in 11β-HSD1 deficient mice at 18 months of age is therefore 
required. Moreover, further studies should attempt to elucidate the mechanism of this 
phenotype in UE2316-treated mice; for example, assessment of blood pressure, 
blood volume and myocardial interstitial fluid. 
Loss of 11β-HSD1 in cardiomyocytes and VSMCs does not reproduce the beneficial 
outcome seen previously with global 11β-HSD1 deficiency after MI, suggesting a 
key role for another cell type(s). This agrees with bone marrow experiments 
conducted in our laboratory using irradiated DelI mice. These mice received 
transplantation of wild-type bone marrow prior to coronary artery ligation surgery 
and demonstrated a beneficial phenotype after MI, suggesting that 11β-HSD1 
deficiency in the host mouse is key to an improved post-MI outcome (Mylonas, et 
al., unpublished). As such, current studies are focussing on inhibiting 11β-HSD1 in 
fibroblasts to determine the role of 11β-HSD1 in this cell type in this setting. This 
may uncover a mechanism behind the enhanced inflammatory response seen 
previously in 11β-HSD1 deficient mice.  
It has previously been reported that 11β-HSD1 deficient mice have enhanced peri-
infarct angiogenesis 4w after MI (McSweeney, et al., 2010), after the pruning phase 
of excess vessels by endothelial cell apoptosis has passed (Patan, 2000; Conway, et 
al., 2001; Grass, et al., 2006), which attenuates the development of heart failure. The 
data in this thesis demonstrates that the beneficial phenotype observed in global 11β-
HSD1 deficient mice 4w after MI is maintained through to 8w after MI when mice 
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have developed heart failure. It has been shown that sustained enhanced angiogenesis 
limits infarct expansion and thinning, and contributes to the maintenance of cardiac 
function (Orlic, et al., 2001; Kido, et al., 2005; Engel, et al., 2006; Liu, et al., 2007; 
Payne, et al., 2007; Sasaki, et al., 2007). This was not assessed in the current study 
and should be investigated by immunohistochemical staining, however the thicker 
infarcts and preserved systolic function seen in 11β-HSD1 deficient mice indicate 
that this enhanced angiogenesis may be sustained through to 8w after MI.  
 
6.2.1 Why does 11β-HSD1 deletion lead to ventricular rupture, but 11β-HSD1 
deficiency does not? 
It has previously been shown that 11β-HSD1 deficient mice have a beneficial 
phenotype 7d and 4w after MI (Small, et al., 2005; McSweeney, et al., 2010). These 
mice, originally generated by Koteletsev et al (1997), have an augmented 
inflammatory response, with increased representation of pro-reparative alternatively-
activated macrophages, enhanced peri-infarct angiogenesis, thicker infarcts and 
improved cardiac function (McSweeney, et al., 2010). However, as has been 
discussed above, there are profound basal effects of 11β-HSD1 deletion in cells other 
than cardiomyocytes and VSMCs, such as regulation of cardiomyocyte length. The 
beneficial outcome outlined above was not reproduced with tissue specific 11β-
HSD1 deletion in cardiomyocytes and VSMCs, suggesting 11β-HSD1 deletion in 
other cells types may be responsible for this phenotype. Current studies in our 
laboratory have shown definitively that 11β-HSD1 deletion in myeloid cells does not 
give rise to this beneficial phenotype (Mylonas, et al., unpublished), however the 
role of 11β-HSD1 in fibroblasts after MI warrants further investigation. 11β-HSD1 
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has been shown to modify fibroblast inflammatory mediatory secretion (Mylonas, et 
al., unpublished), and, as such, could be the case here.  
Since the creation of the original 11β-HSD1 ‘KO’ mouse (Kotelevtsev, et al., 1997), 
it has been found to be deficient, rather than null, for 11β-HSD1, and has therefore 
been referred to as such throughout this thesis. This is the key difference between 
this mouse and the DelI mouse, which is a complete KO. After MI, all DelI mice 
died from cardiac rupture between d3 and d5. Recent work in our lab has started to 
uncover the mechanism behind the 100% rate of rupture in DelI mice after coronary 
artery ligation. As discussed above, 11β-HSD1 in cardiac fibroblasts may be key in 
regulating the improved outcome in mice deficient in 11β-HSD1, through regulation 
of macrophage phenotype in the proliferative phase of infarct healing. However, the 
differences in propensity to rupture in the earlier phase of infarct healing suggests 
11β-HSD1 is also important in regulating early inflammatory cell recruitment to the 
infarct (Mylonas, et al., unpublished). Neutrophil recruitment is enhanced in 11β-
HSD1 deficient mice (McSweeney, 2010; McSweeney, et al., 2010) but not to the 
extent that it is in mice with complete deletion of 11β-HSD1 (DelI mice). Expression 
of MCP-1 and monocyte recruitment are also both significantly increased in DelI 
mice (Mylonas, et al., unpublished) and this is associated with the increased rate of 
rupture, in agreement with other studies linking monocyte recruitment to rupture 
(Nian, et al., 2004). This shows, firstly, the importance of 11β-HSD1 as a regulator 
of the inflammatory response and, furthermore, suggests that targeting 11β-HSD1 in 
cardiac myofibroblasts may be key to improving outcomes post-MI. 
With respect to the administration of potential drug treatments, it may by 
hypothesised that delaying 11β-HSD1 inhibition, so as not to detrimentally enhance 
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early inflammatory cell recruitment, may lead to a beneficial acute, and long term, 
outcome. Indeed one method of inducing heart failure is chronic isoproterenol 
treatment (Gordon, et al., 2014). After 3w of treatment, cardiac dysfunction and 
hypertrophy are observed, but this is completely reversed by administration of a 
selective 11β-HSD1 inhibitor (Gordon, et al., 2014). This is promising, as it shows 
that delayed 11β-HSD1 inhibition can still lead to a beneficial outcome. This may 
circumvent the fatal phenotype seen with complete global 11β-HSD1 deletion; 
overly-enhanced inflammatory cell recruitment. As such, pharmacological 11β-
HSD1 inhibition should therefore continue to be explored as a potential area of 
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Appendix 1 
mRNA levels of β-actin, the internal control gene for heart (a), aorta (b) and liver (c) 
qRT-PCR was similar in all groups. mRNA levels of TBP, the internal control gene 













Appendix 1. qRT-PCR internal control genes 
β-actin was used as the internal control for heart (a), aorta (b) and liver(c). TBP was used as 
the internal control for skeletal muscle (d). mRNA levels of these genes were similar in all 
groups in all tissues investigated (two way ANOVA). 
-actin in heart





















































































TBP in skeletal muscle
































Protein expression of β-actin, the internal control gene for heart (a), aorta (b) and 
liver (c) western blotting was similar in all groups. Protein expression of α-tubulin, 
the internal control gene for skeletal muscle western blotting, was also similar in all 
groups (d). An example heart blot (e) shows β-actin protein at approximately 42kDa 


















Appendix 2. Western blot internal control genes 
 β-actin was used as the internal control for heart (a), aorta (b) and liver (c). α-tubulin was 
used as the internal control for skeletal muscle (d). Protein expression was similar in all 
groups in all tissues investigated (two way ANOVA). An example heart western blot (e) 
shows β-actin at approximately 42kDa in all samples and 11β-HSD1 at approximately 























































































































-tubulin in skeletal muscle































Cardiomyocyte cross-sectional area in the left ventricular wall was similar in DelI 







Appendix 3. Cardiomyocyte cross-sectional area is unaltered in DelI mice at 18 months 
of age 
Cardiomyocyte cross sectional area was assessed by staining for isolectin B4, WGA and 
DAPI in DelI and C57BL/6 mice at 18 months of age (Student’s t test; n=5/group). Isolectin 
B4 stains endothelial cells, WGA stains cell membranes and DAPI stains nuclei. This 
allowed cardiomyocyte cross-sectional area measurement by selecting cardiomyocytes 
which a) appeared to be cut in the short axis, b) had a nucleus in the middle of the cell and c) 









































Means plus standard error of the mean for all results in Chapter 3. 





Heart 1.02 ± 1.01 100 ± 6.3 8.4 ± 2.1 100 ± 17.8 
 Aorta 1.05 ± 1 100 ± 11 5.3 ± 2.3 100 ± 14.8 
 Liver 1.03 ± 0.5 100 ± 4 88.4 ± 3.1 100 ± 3.4 
 Skeletal 
Muscle 
0.55 ± 1.01 100 ± 2 9.2 ± 1 100 ± 4.7 
11β-HSD1 
protein (%) 
Heart 2.05 ± 1.2 100 ± 4.3 9.04 ± 1.1 100 ± 5.3 
 Aorta 2.1 ± 0.5 100 ± 5.2 10.4 ± 1.2 100 ± 5.8 
 Liver 2 ± 1.1 100 ± 2.2 93 ± 4.7 100 ± 5.7 
 Skeletal 
Muscle 
3 ± 1.1 100 ± 4.5 96 ± 6.4 100 ± 4.3 
Nr3c1 
mRNA (%) 
 94 ± 10 100 ± 11.4 99 ± 11.3 100 ±10.1 
Nrc32 
mRNA (%) 
 105 ± 17.3 100 ± 11.7 99 ± 12.1 100 ± 10.2 
Fkbp5 
mRNA (%) 
 81 ± 7.8 100 ± 5.8 86 ± 4.6 100 ± 4.6 
Tsc22d3 
mRNA (%) 
 78 ± 16.4 100 ± 14.8 87 ± 10.9 100 ± 12.4 
Ppargc1a 
mRNA (%) 
 113 ± 5.6 100 ± 4.3 105 ± 8.4 100 ± 6.6 
Sgk1 mRNA 
(%) 
 103 ± 7.1 100 ± 5.4 93 ± 5 100 ± 5.8 
Systolic BP 
(mmHg) 
 99 ± 2 97 ± 3.1 90 ± 2 92 ± 2.1 





6w 22 ± 1.4 23 ± 1 20 ± 1.2 20 ± 1.7 
 10w 21 ± 0.5 28 ± 2.1 21 ± 1.2 22 ± 1.4 
 20w   24 ± 1.6 24 ± 1.6 
 35w   23 ± 4.1 23 ± 1.2 
 78w 28 ± 1 28 ± 2   
SV (μl) 6w 35 ± 2.1 37 ± 2.3 28 ± 1.2 28 ± 1.6 
 10w 32 ± 1 49 ± 4 39 ± 2.3 41 ± 2.8 
 20w   39 ± 2 39 ± 3.8 
 35w   38 ± 2.1 38 ± 2.2 





6w 13 ± 3.5 14 ± 2.1 12 ± 2.3 12 ± 3 
 10w 14 ± 2.7 14 ± 3.5 14 ± 2.1 15 ± 2 
 20w   16 ± 2.2 16 ± 2.1 
 35w   14 ± 3 12 ±3.5 
 78w 15 ± 2 13 ± 4.8   
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 135.4 ± 8.1 178.2 ± 18.3 173.1 ± 10 181.6 ± 20.7 
Body weight 
(g) 




 4.2 ± 0.2 6.8 ± 0.5 7.8 ± 0.6 7.9 ± 1.1 
Blood 
volume (ml) 
 1.85  ± 0.09 1.96  ± 0.06   
Heart wet 
weight (mg) 
 158.3  ± 5.4 231.4  ± 6.8   
Heart dry 
weight (mg) 
 32  ± 1.2 49.2  ± 3.7   
Heart wet to 
dry weight 
ratio 















<4μm 3294 ± 83 3260 ± 121 3267 ± 58 3217 ± 101 
 4-200μm 3184 ± 106 3216 ± 78 3309 ± 43 3203 ± 61 
 >200μm 145 ± 4 133 ± 9 141 ± 5 135 ± 9 
Ejection 
fraction (%) 
6w 62.2 ± 4.1 64.3 ± 3.5 59.7 ± 4.2 56.6 ± 6.8 
 10w 61 ± 3.5 72.4 ± 3.6 57.3 ± 5.8 54 ± 4.7 
 20w   61.4 ± 3.2 61.5 ± 3.8 
 35w   61.8 ± 3.1 62.9 ± 4.5 




6w 37 ± 3.2 37.1 ± 2.8 39.6 ± 4.5 39 ± 4.2 
 10w 36.3 ± 2.2 33.5 ± 2.6 38.4 ± 4.2 37.1 ± 3 
 20w   36.5 ± 2.4 36.3 ± 2.7 
 35w   45.8 ± 4 41.1 ± 6.3 




6w 16.4 ± 2.1 16.3 ± 2.2 12.6 ± 3.8 13.4 ± 2.2 
 10w 15 ± 1.1 24.6 ± 1 11.3 ± 2.6 13.4 ± 2.5 
 20w   14.5 ± 2.5 16.3 ± 2 
 35w   18 ± 1.3 18.3 ± 1.1 









6w 1.9 ± 0.2 1.75 ± 0.2 1.75 ± 0.2 1.75 ± 0.1 
 10w 1.45 ± 0.05 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 
 20w   1.55 ± 0.1 1.7 ± 0.25 










27381 ± 9316 43107 ± 
22096 
 10w 28384 ± 837 38862 ± 7302 26322 ± 966 45063 ± 
12359 
 20w   29934 ± 4019 41987 ± 
8219 
 35w   25966 ± 473 38137 ± 
13341 
MV DT (ms) 6w 35.2 ± 1.1 21.5 ± 2.2 31.6 ± 3.5 21.4 ± 2.9 
 10w 29.1  ± 0.5 20.5 ± 0.5 30.5 ± 2.5 21.5 ± 1 
 20w   29.5 ± 1 21 ± 0.5 
 35w   34.5 ± 1.5 21 ± 0.5 
Collagen 
content (%) 
 4.5 ± 0.4 4.4  ± 0.3 4.7 ± 0.6 4.6 ± 0.3 
Col1a2 (%) mRNA  98.1 ± 12.4 100 ± 9.2 101.1 ± 10.3 100 ± 11.5 
Col3a1 (%) mRNA 106.4 ± 14.3 100 ± 20.6 103.3 ± 13.4 100 ± 10 
Tgfb1 (%) mRNA 113.2 ± 12.4 100 ± 24.4 104 ± 14.8 100 ± 12.1 
Atp2a2 (%) mRNA 76.4 ± 4.1 100 ± 3.3 69 ± 4.5 100 ± 6.5 
Slc8a1 (%) mRNA 94.6 ± 6.5 100 ± 5.1 96 ± 4.1 100 ± 2.2 
Ryr2 (%) mRNA 99 ± 12.1 100 ± 7.9 101 ± 13.6 100 ± 11.4 
Cacna1c (%) mRNA 102 ± 17.8 100 ± 21.4 101 ± 8 100 ± 9.9 
SERCA (%) Protein 49.2 ± 3.3 100 ± 3.6 42.8 ± 5.1 100 ± 3.8 
PLN (%) Protein 98.4 ± 3.7 100 ± 2.1 101 ± 3.2 100 ± 3.4 
Ser16 (%) Protein 107 ± 4.2 100 ± 5.2 96.3 ± 3.5 100 ± 4.7 




  UE2316 Veh 
LVEDA (mm
2
)  27.4 ± 1.1 23.5 ± 2.3 
LVESA (mm
2
)  16.5 ± 3.3 12.5 ± 3.2 
Body weight (g)  44.1 ± 1.2 39.3 ± 2.4 
Heart weight (mg)  277 ± 12.1 201.4 ± 11.6 
Heart weight to body 
weight ratio 
 6.4 ± 0.4 5.1 ± 0.4 
CM CSA (μm
2
)  231.4 ± 5.6 224 ± 12.8 
Ejection fraction (%)  58.4 ± 5.1 68.6 ± 4.2 
Fractional shortening 
(%) 
 42 ± 6.3 43.2 ± 6.8 
Cardiac output 
(ml/min) 
 22.4 ± 2.5 20.5 ± 3.5 
E/A wave ratio  1.4 ± 0.1 1.4 ± 0.2 




 35362 ± 
1221 
23389 ± 3821 
MV DT (ms)  23.5 ± 0.8 21.5 ± 2.1 
Collagen content (%)  6.5 ± 0.3 6.1 ± 0.3 
Col1a2 (%) mRNA 105.1 ± 7.2 100 ± 6.3 
Col3a1 (%) mRNA 116.1 ± 9.1 100 ± 11.8 
Tgfb1 (%) mRNA 111.3 ± 14.3 100 ± 15.6 
Atp2a2 (%) mRNA 74 ± 2.2 100 ± 2.4 
Slc8a1 (%) mRNA 102.5 ± 5.1 100 ± 3.8 
Ryr2 (%) mRNA 98.2 ± 4.4 100 ± 5.7 
Cacna1c (%) mRNA 91.6 ± 6.4 100 ± 6.7 
SERCA (%) Protein 52.4 ± 2.9 100 ± 3.6 
PLN (%) Protein 98 ± 3.5 100 ± 2 
Ser16 (%) Protein 102 ± 3.4 100 ± 4.7 
Thr17 (%) Protein 102 ± 5.8 100 ± 4.6 
 




Means plus standard error of the mean for all results in Chapter 4. 
  SMAC Cre
-
 














 34.9 ± 3.7 11.6 ± 2.7 28.5 ± 4 10.5 ± 1.3 
Ejection 
fraction (%) 
 27.3 ± 2.2 64.5 ± 5.6 31.2 ± 4.3 70.1 ± 3 
Fractional 
shortening 
 11.5 ± 2.8 43.6 ± 4.9 13.2 ± 3.3 39 ± 6.8 
Infarct Size  34.2 ± 4.1  37.6 ± 5.9  
Mac2 (%)  10.5 ± 2.5 2.2 ± 0.4 11.6 ± 2.8 2 ± 0.5 
Ym1 (%)  0.11 ± 0.02 0.05 ± 0.01 0.11 ± 0.02 0.05 ± 0.01 
Peri-infarct 
angiogenesis 
<4μm 7.4 ± 0.4  8.3 ± 0.5  
 4-200μm 8.2 ± 0.5  9.5 ± 0.8  
 >200μm 0.1 ± 0.01  0.1 ± 0.01  
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Appendix 6 
Means plus standard error of the mean for all results in Chapter 5. 






 53.2 ± 7.1 50.5 ± 6.6 49 ± 6.3 54.1 ± 5.2 
LVEDV 
(ml) 
 0.17 ± 0.01  0.22 ± 0.01 0.19 ± 0.03 0.2 ± 0.02 
LVESV (ml)  0.11 ± 0.01 0.15 ± 0.1 0.13 ± 0.03 0.15 ± 0.01 
Heart weight 
(mg) 
 201.3 ± 7.6 286.5 ± 19.4 256.7 ± 12 248 ± 8.9 
Body weight 
(g) 









 221.2 ± 6.3 230.5 ± 7.5 232.1 ± 4 233.5 ± 8.7 
ANP (%) mRNA 49.5 ± 9.5 100 ± 10.1 98.3 ± 12.4 100 ± 8.3 
αMHC to 
βMHC ratio 
 1.15 ± 0.01 1 ± 0.03 10.5 ± 0.4 1 ± 0.05 
Lung weight 
(mg) 
 136.5 ± 12.2 174 ± 15.3 178.1 ± 10.9 169 ± 8.6 
Ejection 
fraction (%) 
 33.5 ± 3.5 25.6 ± 2.4 24.1 ± 2.6 26.6 ± 2 
Infarct 
length (%) 









mRNA 642.9 ± 31.3 395.6 ± 24 401.6 ± 41.2 417.2 ± 37.4 
Col1a2 mRNA 106.3 ± 18 100 ± 12.2 94.2 ± 19.3 100 ± 17.1 
Col3a1 mRNA 108.9 ± 13.1 100 ± 15 98.2 ± 23.1 100 ± 18.2 
Tgfb1 mRNA 94.8 ± 17.6 100 ± 13.5 113.2 ± 21.1 100 ± 18.6 
Atp2a2 mRNA 99.6 ± 13.4 100 ± 7 89.7 ± 13 100 ± 6.9 
Slc8a1 mRNA 99.2 ± 7.3 100 ± 11.4 103.6 ± 6.3 100 ± 9.1 
SERCA Protein 102.3 ± 8.4 100 ± 6 98.2 ± 5.3 100 ± 9.5 
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